CanSinoBIO

2024

Environmental, Social and Governance (ESG) & Sustainability Report

CanSinoBIO

Contents

About the Report

Following the principle of objectivity, normativity, transparency, and comprehensiveness, the Environmental, Social and Governance (ESG) & Substainability Report provides a detailed disclosure of CanSinoBIO's social responsibility practices and performances in ESG and sustainability across various areas, including operations and development, environment, labor and community, and value chain.

Basis of Preparation

The Report is prepared in accordance with the *Environmental, Social and Governance Reporting Code* set out in Appendix C2 to the *Rules Governing the Listing of Securities* (the *Listing Rules*) on HKEX and the *SSE Environmental Information Disclosure Guidelines for Listed Companies* by Shanghai Stock Exchange, with reference to the *Guidelines No.14 of Shanghai Stock Exchange for Self-Regulation of Listed Companies-Sustainability Report(Trial)*, as well as the requirements of the GRI Standards issued by the Global Sustainability Standards Boards (GSSB).

Scope of Report

The Report involves the major research and development ("R&D") and manufacturing sites, workplaces and subsidiaries of CanSino Biologics Inc. It covers the period from January 1, 2024, to December 31, 2024, with some reviews over previous years and the forecast of 2025 when necessary. Notes will be found in the text when the data scope is inconsistent with the Report.

Source of Information

The information and cases herein were extracted mainly from the Company's statistical reports, internal communications, and other relevant documents. The financial data involved are sourced from the annual financial statement of CanSino Biologics Inc. unless otherwise specified. Other data comes from internal statistics and manual collation within the Company.

Reporting Principle

Materiality: To prepare this Report, the Company follows the materiality assessment procedure to determine what and to which extent these contents should be disclosed in the Report. The results of the materiality analysis in 2024 are available in the chapter "Stakeholder Communication".

Quantitative: The Report discloses the quantitative information on environmental and social a spects to present our performance in main ESG KPIs.

Balance: The Report objectively discloses both positive and negative information to ensure balanced disclosures.

Consistency: Data disclosed herein are for 2024 unless otherwise specified. We will prepare the future ESG report with consistent statistical methodologies according to the actual management, and disclose the comparative data for consecutive years as far as possible to help readers better understand how indicators change over time. Unless otherwise stated, the data disclosed in the Report are counted according to the unified information collection process and mechanism established by the Company to ensure comparability.

References

To facilitate presentation and reading, in the Report, "CanSino Biologics Inc." is also referred to as "CanSinoBIO", "the Company", or "we". CanSino Biologics Inc. and its subsidiaries are referred to as "the Group". The monetary unit adopted in the Report is RMB (yuan) unless otherwise specified.

About CanSinoBIO

Company Profile

Incorporated in Tianjin Economic-Technological Development Area (TEDA) West District, Tianjin in 2009, CanSino Biologics Inc. is a high-tech company dedicated to the R&D, production, and commercialization of high-quality innovative vaccines (stock code in H-share: CanSinoBIO 06185.HK, stock code in A-share: CanSino 688185.SH).

CanSinoBIO has gathered a galaxy of senior vaccine scientists and technical experts who once worked for renowned pharmaceutical companies in China and abroad. Harnessing excellent management skills and strong R&D capabilities, CanSinoBIO has rapidly promoted the R&D, production, and commercialization of innovative vaccines. As a leading company in innovative vaccine R&D, we are committed to promoting global public health, fulfilling social and international responsibilities by unswervingly developing and providing high-quality vaccines and making contributions to global public health.

Technology platforms

CanSinoBIO has established five core technology platforms: adenovirus-based viral vector technology, synthetic biotechnology, protein structure design and VLP assembly, mRNA and LNP technology, formulation, and drug delivery technology.

Vaccine R&D

The R&D pipeline covers multiple innovative vaccines in more than 10 disease fields such as meningitis, pneumonia, DPT, novel coronavirus (COVID-19), Ebola virus disease, herpes zoster, tuberculosis, etc.

Vaccine manufacturing

CanSinoBIO has established large-scale modern vaccine industrial bases in Tianjin and Shanghai, China, and has contributed to multiple local production lines in countries and regions such as Mexico, Pakistan, and Malaysia to supply innovative vaccines in multiple locations.

Collaborations

The Company has established partnerships with Barinthus Biotherapeutics (formerly Vaccitech) and Ocugen, etc.

Under the mission of “To Provide Innovative, High-Quality and Affordable Vaccines”, CanSinoBIO proactively fulfills the vision of “Innovation for a Safer World”. We pursue the value of “Respect, Agility, Innovation, Superior in Quality and Engagement” to treasure the reverence and protection of life.

Culture and Value

Mission

To Provide Innovative, High-Quality and Affordable Vaccines

Vision

Innovation for a Safer World

Value

Respect

Agility

Innovation

Superior in quality

Engagement

Milestones in 2024

January

CanSinoBIO initiated a Phase I clinical trial in Australia for its self-developed Recombinant Poliomyelitis Vaccine and successfully enrolled the first participant. This vaccine utilizes virus-like particle (VLP) technology with no live viruses, thereby enhancing safety. The World Health Organization (WHO) has identified it as a key strategy for the future eradication of polio.

February

CanSinoBIO's PCV13*i* completed its Phase III clinical trial, demonstrating good safety and immunogenicity, and achieving the predefined clinical endpoints. Based on these results, the Company submitted a domestic drug registration application for market approval, which has obtained the *Notice of Acceptance* issued by the National Medical Products Administration (NMPA). The PCV13*i* vaccine features dual-carrier technology to enhance immune response and utilizes an animal-origin-free culture medium to improve production safety.

March

CanSinoBIO initiated a Phase III clinical trial for its self-developed Tetanus Vaccine and successfully enrolled the first participant. The vaccine is fermented using an animal-origin-free medium, ensuring stable production and improved safety. It is primarily intended for tetanus prevention in non-neonatal populations.

April

CanSinoBIO has received approval from NMPA and officially initiated Phase I clinical trials of its self-developed Hib vaccine. The vaccine is a covalent combination of purified Hib capsular polysaccharide and tetanus toxoid protein in a freeze-dried dosage, which is expected to induce humoral immunity against Hib after vaccination and provide protection to the vaccinees.

May

At the Fourth China Association for Vaccines Forum, CanSinoBIO shared updates on DTcP, Ad5-nCoV, and MCV4. The DTcP Infant is in Phase III clinical trials, while the Tdcp Adolescent and Adult (aged 6 and above) has completed full participant enrollment in its Phase I clinical trial.

June

A WHO expert team visited CanSinoBIO and discussed international collaboration on the Recombinant Poliomyelitis Vaccine. This vaccine, which does not require live viruses in production and demonstrates a superior safety profile, has received funding from the Bill & Melinda Gates Foundation and is undergoing a Phase I clinical trial in Australia.

July

CanSinoBIO signed a collaboration agreement with Malaysia's National Institutes of Biotechnology (NIBM) regarding mRNA multivalent influenza vaccine for R&D, manufacturing and potential technology transfer. The partnership will also focus on talent exchange, supporting Malaysia's goal of achieving domestic vaccine production by 2030.

August

CanSinoBIO, in collaboration with the Red Cross Society of Hainan Branch, successfully hosted a charitable donation ceremony in Haikou, donating medical equipment worth approximately RMB 850,000 to enhance primary healthcare infrastructure and improve medical service capabilities.

September

CanSinoBIO successfully hosted the SAB 2024 Academic Conference on September 24, bringing together international experts to discuss vaccine innovation, technology platforms, and core products. Key discussions included Recombinant Poliomyelitis Vaccine, PBPV, inhalation drug delivery technologies, and new mRNA solutions, providing strategic and commercialization insights for the Company.



October

CanSinoBIO signed an agreement with the Bill & Melinda Gates Foundation, securing a total of over USD17 million in project funding. This funding will support further development of its VLP-based poliomyelitis vaccine, including clinical research, process development, and production scale-up. Additionally, the grant will facilitate the development of combination vaccines incorporating the Recombinant Poliomyelitis Vaccine, driving diversified and innovative vaccine R&D.

November

CanSinoBIO received *the Notice of Acceptance* from NMPA for its supplemental drug application for MCV4, expanding the approved age range from 3 months to 3 years (47 months) to 3 months to 6 years (83 months).

December

CanSinoBIO initiated a Phase II/III clinical trial for its Tdcp Adolescent and Adult and successfully enrolled the first participant of Phase II. Designed for individuals aged 6 and above as a booster immunization for diphtheria, tetanus, and pertussis, this vaccine is expected to fill the market gap in China upon approval.

Accolades in 2024

2024 China Best ESG Employer

Aon Group

Golden Grid Award· Outstanding IR Team of the Year

Gelonghui

HRA “Best Practice in Human Resource Management” Award

Human Resource Association for Chinese & Foreign Enterprises, Beijing (HRA)

National Intellectual Property Advantage Enterprise

China National Intellectual Property Administration

2024 Tianjin Intelligent Factory

Tianjin Industrial and Information Technology Bureau

Tianjin Advanced Intelligent Factory

Tianjin Industrial and Information Technology Bureau

Tianjin Manufacturing Industry Single Field Champion

Tianjin Industrial and Information Technology Bureau



Chairman's Statement

Over the past year, remaining true to the original aspiration of "Health, Hope, and Promises", CanSinoBIO has forged ahead in vaccine R&D, production, and global health initiatives while achieving remarkable milestones. We are aware that robust corporate growth is crucially correlated to the emphasis on environmental, social, and governance (ESG). Therefore, we have embedded ESG into our strategic planning and daily operations, striving to create economic value while contributing positively to the sustainable development of society.

We advance innovation to safeguard lifelong health. Health is a timeless pursuit for us and the unwavering goal that drives CanSinoBIO forward. For years, we have remained dedicated to vaccine R&D, exploring core proprietary technologies, expanding into new fields, and developing innovative vaccine candidates that offer healthier choices to people worldwide. In 2024, we have made significant progress in multiple innovative vaccines, securing recognition and approvals from esteemed international institutions while overcoming industry bottlenecks. Looking ahead, we will continue to launch a diverse portfolio of vaccines targeting a broad spectrum of diseases, addressing health needs across all ages and scenarios. As science progresses and the pursuit of well-being grow, there is vast potential for vaccine innovation. CanSinoBIO is committed to pushing these boundaries and delivering more satisfactory solutions for global customers.

We promote standardized governance to ensure compliance development. CanSinoBIO operates with an unwavering commitment to compliance and transparency and upholds the highest ethical standards. In 2024, our ISO 37301-certified compliance management system successfully passed rigorous external audits. Leveraging risk-aware strategies and process controls, we ensure every business activity aligns with regulatory frameworks, reinforcing trust with stakeholders. Throughout this process, we applied rigorous risk assessment methodologies and scientific management practices to ensure that all business activities operate within a robust compliance framework.

We pursue a greener path to protect the health of our planet. We recognize that vaccine production depends on the responsible use of natural resources. Committed to a path of green and sustainable development, CanSinoBIO actively drives the green transformation of the entire industry value chain. We staunchly strive to achieve national carbon peaking and carbon neutrality goals, proactively addressing climate change while implementing resource conservation initiatives to reduce our carbon footprint. Moving forward, we will intensify our efforts, working alongside upstream and downstream industry partners and consumers to foster a more sustainable pharmaceutical production and consumption model and safeguard a healthy planet.

Looking ahead, we will navigate our course with scientific pursuit as our compass and sustainable development as our guiding principle. We will continue to break new ground in vaccine R&D through innovation, fortify corporate governance through standardization, and reshape the industry landscape through greener development. By uniting efforts across the upstream and downstream of the value chain, we strive to build a more resilient ecosystem of life and health for mankind.

ESG Governance System

As an innovation-driven vaccine company, CanSinoBIO integrates the ESG philosophy into its core development strategy. Regarding the environmental aspect, CanSinoBIO upholds the philosophy of green and low-carbon practices. The Company consistently optimizes production processes, aiming to reduce energy consumption and emissions. All of these efforts are in pursuit of harmonious coexistence with the environment while ensuring product quality and safety. As for the social responsibility, CanSinoBIO is deeply committed to the R&D and innovation of vaccines, actively responds to the UN's Sustainable Development Goals (SDGs), and is dedicated to providing solutions to the prevention of infectious diseases worldwide. As for the governance aspect, CanSinoBIO adheres to standardized and transparent management principles, establishes and improves a sound corporate governance structure and internal control system, and ensures scientific and effective decisions. Looking ahead, we will continue to improve vaccine accessibility with innovative technologies, and strive to achieve coordinated development between the economy, society, and environment, contributing to the global healthcare cause.

Board Statement

The Board of CanSinoBIO has always been committed to deeply integrating the ESG philosophy into the Company's development strategies. We have been keeping track of ESG performance in every aspect of our daily operation to optimize the ESG management system. We have proactively responded to the expectations of various stakeholders while ensuring the realization of operational goals, willingly assuming social responsibilities and continuously creating long-term values for society to lay a solid foundation for the sustainable and high-quality development of the Company.

ESG Management Policy and Strategy: The Board of Directors of CanSinoBIO strictly complies with the *Code of Corporate Governance for Listed Companies*, the *Environmental Information Disclosure Guidelines for Listed Companies* by Shanghai Stock Exchange, and the *Environmental, Social, and Governance Reporting Guide* of the HKEX. In 2024, the Company formulated and issued the *Environmental, Social, and Governance (ESG) Management System* to establish a standardized and effective ESG management and information disclosure system and ensure the orderly flow of ESG work.

ESG Governance: As the highest decision-making body of the Group responsible for ESG management, the Board is responsible for overseeing and approving ESG strategies, work plans, and other key matters. The Board regularly reviews the progress of ESG goals and ensures the effective operation of the risk management system. As the supervisory and advisory body for ESG matters, the Audit Committee reviews the Company's ESG strategy and reports while reporting progress to the Board. To strengthen ESG management, the Company has established a dedicated working group that collaborates with various departments and subsidiaries to ensure the enforcement of various policies. In 2024, the Board reviewed the environmental targets from the previous year to ensure their steady progress.

ESG Risk Management: Each year, the Board conducts a comprehensive assessment of ESG materiality based on the Company's development to determine key directions for ESG risk management. CanSinoBIO regularly reviews and updates the ESG risk management plans to meet the demands of the Company's strategic operation. Under the guidance of the Audit Committee, CanSinoBio continuously enhances its ESG risk management system, ensuring the efficient operation of its risk management mechanism.

The Report truthfully discloses the ESG development and achievements of CanSinoBIO in 2024, which will be issued after approval from the Board on March 25, 2025.

ESG Philosophy and Strategy

CanSinoBIO integrates ESG philosophy into its core strategy, striving for sustainable development. We aim to promote ESG practices across our daily operation through four strategic pillars: Green Development, Product Responsibility, Value Creation, and Governance Enhancement.

In terms of green development, we follow a green and low-carbon development path by optimizing production management and minimizing emissions and energy consumption. Besides, we take efforts to implement efficient waste management strategies, realize strategic management of water and energy resources, and proactively address climate change, striving to achieve harmonious coexistence with the environment.

In terms of product responsibility, we strictly enforce product quality control and monitoring, continuously promote innovation and R&D, and enhance healthcare accessibility. We are committed to protecting customer rights and collaborating with international organizations, governments, and enterprises to advance the pharmaceutical industry, contributing to global health cause.

In terms of value creation, we attach great importance to employee rights and benefits, striving to foster a diverse, equitable, and inclusive work environment. We provide competitive salaries and diversified growth opportunities to support the shared development of both employees and the Company. Meanwhile, we actively engage in community development and charity, responding to the health needs of various sectors and contributing to the advancement of public health.

In terms of governance enhancement, we continuously optimize our governance system, deeply integrating ESG governance with corporate governance to ensure compliant and transparent operations. We emphasize ESG management for our supply chain, collaborating with suppliers to build a transparent, honest, and mutually beneficial business environment. Committed to business ethics, we firmly oppose corruption to lay a solid foundation for sustainable development.

ESG Governance System

CanSinoBIO persists in practicing the philosophy of sustainable development, attaches great importance to ESG governance, and promotes the in-depth integration of ESG governance and corporate governance system to improve our governance structure. CanSinoBIO has built an ESG governance structure consisting of consisting of the Board, the Audit Committee, and the ESG Working Group. The Board and the Audit Committee constitute the governance body responsible for strategy formulation and monitoring, while the ESG Working Group leads and coordinates all departments to strengthen overall ESG management. Along with that, the Company incorporates each department and business unit into the ESG governance system to leverage the capabilities of each tier and implement the philosophy of sustainable development in a comprehensive, systematic, and effective manner.

CanSinoBIO has formulated the *ESG Management System*, which clearly defines key ESG management tasks. It covers ESG responsibilities, principles, and philosophy, division of management responsibilities, ESG management framework, ESG management content, as well as ESG data collection and assessment. By assigning critical tasks to responsible departments, the Company has laid a solid foundation for the effective implementation of ESG matters.

We attach great importance to the ESG risks that may impact our operations, and have promoted the ESG risk recognition and management system to improve our anti-risk capability. After the Audit Committee identifies ESG risks, the Board conducts a risk assessment and develops corresponding plans. The ESG Working Group coordinates all departments to implement risk management measures. We conduct regular internal audits and on-site inspections, and organize risk management training for our employees to ensure effective prevention and control of ESG risks.

CanSinoBIO 2024 ESG Governance Structure

CanSinoBIO 2024 Duties at Different Levels of ESG Structure

The Board

- Comprehensively supervise and approve the Company's ESG strategy, work plan, and other important affairs
- Review the Company's major ESG issues and ESG goal achievement progress
- Approve and determine the ESG risks and opportunities related to the Company's development, ensure ESG-related risk management and internal control are carried out appropriately and effectively
- Approve the Company's annual ESG report, including but not limited to the ESG Report and/or Corporate Social Responsibility Report/Sustainability Report

Audit Committee

- Review the Company's ESG strategy and work plan
- Review the Company's major ESG risks and opportunities
- Review ESG-related policies
- Review the Company's annual ESG report, including but not limited to the ESG Report and/or Corporate Social Responsibility Report/Sustainability Report

ESG Working Group

- Carry out management and practice under the direct leadership of the Audit Committee, and regularly report to the Audit Committee/Executive Committee
- Develop ESG strategies, work plans, and specific targets for ESG management and goal achievement
- Take the lead in identifying and assessing ESG-related risks and opportunities, collecting assessment results and corresponding countermeasures
- Sort out the existing ESG policies, improve ESG policies on various issues, and coordinate duties among various departments

Functional Department and subsidiary

- Ensure the completion of internal ESG matters and the achievement of goals based on ESG goals and work plans
- Complete information disclosure, project implementation, etc.
- Enhance communication with the stakeholders, understand the stakeholders' ESG requirements, and communicate the Company's ESG work and effectiveness

SDG's Performance and Response

CanSinoBIO actively contributes to charity by collaborating with various industry associations to carry out diverse public welfare activities, including medical and educational support programs. In 2024, the Company's total charitable donations amounted to approximately RMB 447,700.

Corresponding Chapters: Community Development and Public Welfare

CanSinoBIO has always upheld the concept of building a shared community of health for humanity, pledged to provide the public with access to safe vaccines, supported the *Doha Declaration on the TRIPS Agreement and Public Health*, and continuously improved the accessibility and affordability of medicine across the globe.

Corresponding Chapters: Medical Health Accessibility

CanSinoBIO attaches great importance to gender equality to ensure that women employees are provided with fair promotion opportunities and career development. In 2024, 51.40% of the employees were women.

Corresponding Chapters: Employee Employment and Rights and Interests

CanSinoBIO continues to improve its employee compensation and welfare system and incentive mechanism to ensure a fair, transparent, and competitive workplace environment. In 2024, the employee incentive coverage reached 14.57%.

Corresponding Chapters: Employee Remuneration and Benefits

CanSinoBIO upholds the vision of "Innovation for a Safer World", and has carried out sustainable vaccine R&D and innovation in more than ten disease areas. We also actively promote the localization of products in developing countries for research and production, with the aim of building immunity barriers across the globe.

Corresponding Chapters: Relentless Innovation and Joint Efforts for An Epidemic-Free World Product R&D, Production Innovation and Development, Medical Health Accessibility

CanSinoBIO respects equality and human rights and is committed to improving global health inequalities. We are concerned about the disease prevention needs in underdeveloped countries or regions, and by technology transfer and localized cooperation, we aim to improve the accessibility of vaccines in these regions, contributing to the equality of the global health environment.

Corresponding Chapters: Relentless Innovation and Joint Efforts for An Epidemic-Free World Product R&D, Medical Health Accessibility

CanSinoBIO has established a full-process quality system and strengthened pharmacovigilance and product recall mechanisms, to ensure the safe supply of vaccines to the public.

Corresponding Chapters: Product Safety and Quality

CanSinoBIO is committed to green development, taking proactive measures to address climate challenges. The Company aligns its practice with the national "carbon peaking and carbon neutrality" policy by reducing its carbon footprint in daily operations and contributes to national carbon goals and global climate governance.

Corresponding Chapters: Green Development: Upholding Environmental Protection Concept for a Low-carbon Future

CanSinoBIO adheres to the philosophy of compliant and responsible operations, establishes an effective governance system, develops and implements diversification of board members, and adheres to the highest standards of business ethics and integrity.

Corresponding Chapters: Governance Optimization: Improving Governance System, Empowering Robust Development

CanSinoBIO integrates advantageous resources to strengthen cooperation with research institutions, government authorities, international organizations, and other entities, building a shared community of health for humanity and contributing to an epidemic-free world.

Corresponding Chapters: Relentless Innovation and Joint Efforts for An Epidemic-Free World Product R&D, Medical Health Accessibility, Responsible Supply Chain

Stakeholder Communication

Stakeholder	Demands	Response from the Company
Government and regulators	• Comply with laws and regulations • Ensure product quality and safety • Accept supervision from the government and promote the healthy development of the industry • Pay taxes according to law and drive the regional economy development	• Fulfill all obligations in accordance with laws and regulations • Report operational performance as scheduled • Continue to increase access to healthcare • Promote the synergy of upstream and downstream companies in the industry • Establish internal control mechanisms for compliant operation • Pay taxes according to law
Shareholders and investors	• Know the Company's business performance and governance norms; ensure strict risk controls • Conduct business steadily to bring returns on investment • Guarantee fair, impartial, and open information disclosure	• Disclose compliance information • Conduct investor communication through telephone, email, and online conversations Shareholders` meetings • Annual General Meeting of Shareholders • Investor communication meetings and on-site visits
Employees	• Protect employees' basic rights and interests • Care about employees' physical and mental health and safety • Provide training and career advancement for employees • Offer generous benefit packages	• Employee communication meeting • Employee satisfaction survey • Solicit opinions and feedback from employees • Employee training • Employee benefits
Customers and users	• Protect consumers' basic rights and interests • Comply with business ethics • Ensure product safety and timely recall of faulty products	• Strictly and fully follow the quality control of vaccines • Protect customer information and optimize the compliant mechanism • Handle consumer complaints and opinions
Suppliers and partners	• Maintain good and stable partnerships • Operate in good faith and ensure product compliance • Promote sustainable supply chain	• Regular communication • Standardized management and enforcement of contracts and agreements • Jointly fulfill social responsibilities
Media and NGOs	• Understand environmental pollution and emission reduction measures • Timely and effective reply to complaints • Undertake social welfare responsibilities	• Disclose data on environmental performance and set targets for environmental conservation • Establish complaint channels on the official website and social media accounts • Organize charitable activities
Communities	• Emphasize the impact of manufacturing and operation on the local communities • Drive local economy and help vulnerable groups • Recycle product packaging and waste to reduce environmental pollution	• Engage in charity • Regularly provide assistance in certain areas • Participate in volunteer services

Double Materiality Assessment

For the purpose of enhancing its ESG information disclosure system, and with the consideration of the new expectations from stakeholders toward the Company's management and development and compliance requirements, CanSinoBIO has conducted comprehensive identification and assessment for ESG double materiality. By integrating industry and business characteristics, CanSinoBIO has assessed the materiality of ESG issues to the Company's operation and financial performance in 2024. As a result, the Company identified 18 material issues for 2024 and developed a corresponding materiality matrix.

Double Material Issue Identification Process

Establish List of Issues

In accordance with regulatory compliance requirements, CanSinoBIO systematically identifies issues that influence its operations and financial performance. This process draws on key issues outlined by international rating agencies for the pharmaceutical industry, information disclosure practices from industry leaders, and the Company's own operational and business characteristics.

Stakeholder Engagement

CanSinoBIO defines assessment factors and rating ranges for assessing the importance of ESG issues to the Company's operation and financial performance. The Company communicates with various stakeholders to collect their feedback for the materiality assessment of the issues.

Issue Ranking

CanSinoBIO analyzes assessment results and integrates management insights, combining both external and internal information sources to finalize stakeholder assessments of the importance of ESG issues to the Company's operation and financial performance, ultimately formulating a material issue matrix.

CanSinoBIO 2024 materiality to economic social and environmental impacts



ESG Highlights in 2024

Green Development

Invested in environmental protection RMB **2.96** million

Organized environmental training sessions **2** times

Completed an environmental risk assessment for the Rongsheng Building; assessments for the industrialization plant and COVID-19 vaccine plant remained valid, with **no** significant environmental risks identified

Comprehensive energy consumption decreased compared with 2023, by **8.15%**

Greenhouse gas emissions decreased compared with 2023, by **2.05%**

Waste gas emissions decreased compared with 2023, by **4.94%**

Waste water pollutants decreased compared with 2023, by **22.47%**

Water consumption decreased compared with 2023, by **38.51%**

Hazardous waste reduction decreased compared with 2023, by **62.26%**

Non-hazardous waste decreased compared with 2023, by **52.90%**

Value Creation

The Company won **"2024 China Best ESG Employer"**

51.4% of female employees

45.22% of female managers

100% of employees received training

37.8 hours of training per employee

The total amount of charitable donations reached RMB **447,700**

Product Responsibility

Conducted quality supervisions and audits, with **no** major deficiencies identified

Report **no** actual product recall

100% employee coverage of quality training

Garnered RMB **82.26** million of external research funding

Invested a total of RMB **511** million in R&D, including expensed R&D cost and capitalized R&D cost

Obtained a accumulative of **70** authorized patents

Supported the ***Doha Declaration on the TRIPS Agreement and Public Health***

Enhanced Governance

Reported **no** lawsuits or cases related to corruption, violation of business ethics, or unfair competition

Certified to **Dual Compliance System Certification** to ISO 37301 compliance management system and ISO 37001 anti-bribery management system

The compliance training hours for employees reached **24.5** hours/person

The anti-corruption training hours for employees reached **4.5** hours/person

The signing rate of the *Anti-Corruption and Business Ethics Commitment Letter* reached **100%**

Completion rate of business partner compliance questionnaires reached **100%**

The signing rate of the *Confidentiality Agreement* and the *Integrity Agreement* by the supplier reached **100%**

Obtained the **three-level information system security certification** of the People's Republic of China

Feature

Continuous Innovation and Joint Efforts for An Epidemic-Free World

On the journey towards global health undertaking, CanSinoBIO has always shouldered the mission and upheld the concept of building a community of health for humanity, striving to become a “global vaccine supplier based in China”. We are keenly aware that vaccines safeguard human health, thus we see it as our mission to provide high-quality, innovative, and affordable vaccines, aiming to secure a strong health defense line across the globe. With this goal in mind, we are deeply engaged in R&D to ensure the excellent quality of vaccines; we keep innovating and expanding our global presence. Moreover, we join hands with all parties to enhance the accessibility of medicines, and contribute to the global public health cause as a benefactor from China by virtue of innovative vaccines, helping to build a shared community of health for humans.

Deeply Engaging in R&D to Assure Quality and Quantity

At CanSinoBIO, we have always been committed to the R&D of innovative vaccines, ensuring the innovation and reliability of vaccines through a sound R&D system and strict quality control. The Company has successfully developed multiple innovative vaccines based on the five core technology platforms. CanSinoBIO always adheres to high standards of quality management in R&D and manufacturing and strictly controls every link from raw material procurement, and production process optimization, to rigorous conducting of clinical trials, thus ensuring the safety and efficacy of vaccines. As of the end of the Reporting Period, numerous vaccines are at the R&D and clinical stages, with the aim of constantly providing high-quality solutions for the global health industry and contributing to the development of global public health.

R&D Innovation

Since its establishment, CanSinoBIO has been concentrating on technological innovation, and energizing the development of China’s innovative vaccines with long-term determination. The Company has secured multiple achievements through independent R&D, including Menhycia® - Asia’s first tetravalent meningococcal conjugate vaccine, Menphecia® - a bivalent meningococcal conjugate vaccine, Convidecia® - a novel coronavirus (COVID-19) vaccine certified by the WHO, Convidecia® Air® - the world’s first COVID-19 vaccine for inhalation, and Ad5-EBOV - Asia’s first Ebola vaccine.

CanSinoBIO is committed to building a top-notch management and innovation team, to provide a strong impetus for innovative technologies and vaccine development by virtue of a talent pool with global perspectives. The Company’s core technical team members boast extensive experience in the biopharmaceutical industry, providing professional support in R&D and operations. Our R&D team comprises senior experts and scientists engaged in the research and application of cutting-edge technologies.

Underpinned by the five major technology platforms: adenovirus-based viral vector technology, synthetic biotechnology, protein structure design and VLP assembly, mRNA and LNP technology, formulation and drug delivery technology, CanSinoBIO has established a comprehensive technological R&D system, laying a solid foundation for the development of existing vaccines, and offering great potential for the R&D of innovative vaccines in the future.

CanSinoBIO Accelerated the Marketing of DTcP Infant

CanSinoBIO continues to promote the development process of DTcP Infant. This vaccine adopts advanced DPT components combined with vaccine technology, where each pertussis antigen can be purified separately and formulated in precise proportions, significantly improving the quality consistency and stability between batches of vaccine. In addition, the Company has developed proprietary strains of pertussis and increased antigen output through core patented processes, thereby further consolidating its manufacturing advantages.

The development of DTcP Infant fills the gap in the domestic market for DPT components combined vaccine; besides, it lays a foundation for further R&D of Tdcp Adolescent and Adult as well as related combined vaccines. As of the end of the Reporting Period, the Phase III clinical trial for the vaccine has been launched, and fundamental immunization and data collection have been completed. This vaccine has been officially granted the priority review status of NMPA in February 2025.

CanSinoBIO's Protein Structure Design and VLP Assembly Technology Platform Achieved Positive Progress in the R&D of Recombinant Poliomyelitis Vaccine

CanSinoBIO has always paid close attention to the needs of disease prevention across the globe, and actively responds to the WHO's Global Polio Eradication Initiative (GPEI). We are committed to developing a Recombinant Poliomyelitis Vaccine based on our advanced protein structure design and VLP assembly technology, contributing to the control and eradication of polio across the globe. The GPEI believes that the VLP poliomyelitis vaccine is a potential ideal poliomyelitis vaccine product for eradicating polio. The non-infectious VLP poliomyelitis vaccine is also recommended by the WHO as one of the preferred vaccines for the future eradication of polio.

In October 2024, the Company and the Bill & Melinda Gates Foundation re-signed a project funding agreement on the Recombinant Poliomyelitis Vaccine. According to the agreement, the Foundation will grant a project funding of over USD 17 million to CanSinoBIO to support the clinical research, process development, and scale up for this vaccine.

In December 2024, CanSinoBIO launched Phase I/II clinical trials of Recombinant Poliomyelitis Vaccine for age-specific infants in Indonesia and the first trial patient case has been formally enrolled.

Product Assurance

CanSinoBIO has built a product portfolio covering a wide range of vaccines and vaccine candidates for such diseases as meningitis, pneumonia, DPT, COVID-19, Ebola, herpes zoster, and tuberculosis. This aligns with the mission of developing, manufacturing, and commercializing high-quality, innovative, and affordable vaccines.

CanSinoBIO's product strategy focuses on the global market, with innovative vaccines for unmet medical needs across the globe, as well as first-in-class vaccines in China to replace existing mainstream vaccines with higher-quality products. In 2024, the Company accelerated the commercialization of MCV4 and actively promoted the marketing of PCV13*i*. Meanwhile, the Company steadily advanced the clinical trials and research for such vaccine candidates as DTcP Infant, Tdcp Adolescent and Adult, DTcP components combined vaccine, Tetanus Vaccine, PBPV, Recombinant Poliomyelitis Vaccine, Recombinant Zoster Vaccine, and Hib vaccine.

Always observing the core principle of "quality and quantity assured", CanSinoBIO ensures the safety, efficacy, and consistency of every vaccine through a strict quality management system and advanced production technology. In the future, the Company will continue to advance vaccine R&D, promote the progress of all ongoing projects, and establish new technology platforms in line with industry trends to expand the R&D field.

Progress of CanSinoBIO Vaccine Candidates



MCV4

Menhycia®, a MCV4 developed by CanSinoBIO, has filled the gap in the protection of YW135 for infants and young children under 2 in China and opened up a new pattern of prevention of infantile meningitis in China. As of December 2024, Menhycia® was available in approximately 30 provinces, autonomous regions, and municipalities across China, providing vaccine protection at the globally advanced technology level. In 2024, the supplementary application of Menhycia® has been accepted by NMPA, further expanding the age group from children aged 3 months - 3 years (47 months) to 3 months - 6 years (83 months). With the innovative vaccine Menhycia®, CanSinoBIO has been awarded the title of "The Fifth Batch of Manufacturing Single Champion in Tianjin Municipality", which signifies that the vaccine is endowed with leading manufacturing technology and processes in its specific segmented market. In December 2024, the Badan Pengawas Obat dan Makanan (BPOM) in Indonesia granted a registration certificate for this vaccine. In February 2025, Menhycia® was granted a Halal Decree by the Assessment Institute for Foods, Drugs, and Cosmetics of Majelis Ulama Indonesia (LPPOM MUI), marking its launch in the globally recognized Muslim market, and accelerating the Company's internationalization.

MCV2

Menphecia®, a MCV2, is used to prevent Neisseria meningococcal serum group A and C infections. Using CRM197 as a carrier protein, it improves the quality and safety of vaccines. Relying on the polysaccharide-protein conjugate technology platform of CanSinoBIO, this conjugate vaccine effectively overcomes the deficiencies of polysaccharide vaccines, further enhancing immune response and bringing stronger immune protection.

PCV13*i*

PCV13*i* adopts the covalent binding method of polysaccharide antigen and protein carrier to convert the polysaccharide into a T-dependent antigen, which can not only induce a high level of specific antibody in infants under 2 years old but also produce memory B cells and generate immunological memory. In addition, the Company adopts a dual-carrier technology, which can reduce the immunosuppression caused by co-injection with other vaccines. In terms of production technology, the Company adopts an animal-free fermentation medium to reduce the risk of animal-derived biological factors and avoid the toxic residue caused by the phenol purification method in the traditional purification process. In February 2024, the application for domestic drug registration and marketing license of PCV13*i* was accepted by NMPA. The Company expects to obtain new drug approval for PCV13*i* in 2025.

PBPV

As a globally innovative pneumococcal vaccine, PBPV is designed based on pneumococcal surface protein (PspA, a highly conserved protein expressed by almost all pneumococcal bacteria). Unlike the existing PPV23 and the PCV13, PBPV is not a serotype-specific vaccine; therefore, it has higher serum coverage (at least 98% of pneumococcal strain coverage). This characteristic enables it to effectively prevent "serotype replacement". Beyond that, PBPV has a simpler production process, facilitating large-scale production and quality control. PBPV has demonstrated excellent safety in the Phase I clinical trial, with no level 3 adverse reactions or special safety risks observed. Based on the preliminary results of Phase I clinical trials, the Company is evaluating and planning for the subsequent R&D of PBPV.

DTcP Infant

As an innovative DPT components combined vaccine, the DTcP Infant developed by CanSinoBIO utilizes the technology where antigens are purified separately and formulated at a determined ratio to ensure product quality consistency between batches and more stable product quality. As of the reporting date, there are no DPT components combined vaccine developed by domestic vaccine manufacturers approved for marketing, and the DTcP Infant developed by the Company will substitute imported products. What's more, the development of this vaccine also lays a foundation for further R&D of Tdcp Adolescent and Adult vaccines and DPT components combined vaccines. In December 2024, the application for domestic drug registration and marketing license of DTcP Infant was accepted by NMPA. This vaccine has been officially granted the priority review status of NMPA in February 2025.

Tdcp Adolescent and Adult

The Tdcp Adolescent and Adult developed by CanSinoBIO is suitable for people aged 6 and above and is used as a DPT booster vaccine for adolescents and adults. This vaccine has been widely incorporated into routine vaccination plans in major developed countries; however, there are currently no approved similar products domestically. Upon successful launch, Tdcp Adolescent and Adult are expected to fill the gap in the domestic market. In December 2024, Phase II/III clinical trials have been officially launched and the Phase II first subject enrollment has been completed for the vaccine. As of March 2025, Phase III subject enrollment has been completed.

Hib vaccine

CanSinoBIO is developing a DPT components combined vaccine, in which Hib vaccine acts as an important component. This vaccine adopts purified Hib capsule polysaccharides covalently bound to tetanus toxoid protein, with a freeze-dried design, which is expected to effectively induce immune protection. In November 2024, a Phase I clinical trial was launched for this vaccine and the first subject enrollment has been completed successfully.

Recombinant Zoster Vaccine

The Recombinant Zoster Vaccine developed by CanSinoBIO adopts the chimp adenovirus vector technology route to stimulate both cellular immunity and humoral immunity. The clinical trial product of this vaccine is manufactured using internationally advanced technology as well as quality control systems conforming to international standards. The whole vaccine manufacturing process uses no animal-derived ingredients, significantly improving the safety of the final product. Pre-clinical research data show that this vaccine is on par with the zoster vaccine Shingrix (a recombinant subunit adjuvant vaccine developed by a multinational pharmaceutical company) in terms of stimulating humoral immunity, while the level of systemic cellular immunity is significantly higher than that of Shingrix. It is expected that this product will reveal outstanding protective efficacy. As of the end of the Reporting Period, a Phase I clinical trial is being conducted in Canada, to evaluate the safety and preliminary immunogenicity of the two delivery methods of intramuscular injection and inhalation.

Recombinant Poliomyelitis Vaccine

The Recombinant Poliomyelitis Vaccine developed by CanSinoBIO is based on protein structure design and VLP assembly technology. It is expected to contribute to the control and eradication of poliomyelitis across the globe. This vaccine does not rely on live viruses during production, thus significantly reducing biological safety risks. It is anticipated to have good safety and immunogenicity. Unlike the currently available attenuated and inactivated poliomyelitis vaccines, the VLP poliomyelitis vaccine is recommended by the WHO as one of the preferred vaccines for the future eradication of poliomyelitis due to its unique technological advantages. In October 2024, the Company secured further grant funding from the Bill & Melinda Gates Foundation for the development of Recombinant Poliomyelitis Vaccine. The latest round of support also extended to possible related combined vaccine candidates. In December 2024, Phase I/II clinical trial among age-specific infants has been launched in Indonesia and first subject enrollment has been completed.

Tetanus Vaccine

Tetanus Vaccine is mainly used to prevent non-neonatal tetanus. The vaccine is fermented using animal-free culture media, which enhances its safety profile. We have successfully identified stable industrial-scale processes for its production. The Phase III clinical trial has been successfully completed in 2024. In February 2025, NMPA granted a *Notice of Acceptance* to our new drug application for the Tetanus Vaccine.

Unremitting Innovation for Global Presence

Leveraging its professional capabilities and taking market opportunities, CanSinoBIO deeply engages in technological R&D and international exchanges, joins hands with local enterprises in various countries, promotes the global presence for vaccine products and technologies, creates a robust and sustainable business model and achieves collaborative development across the globe. We are willing to work together with global innovators as well as upstream and downstream enterprises to promote international cooperation in vaccines, fulfill social and international responsibilities, and contribute to the vision of "Innovation for a Safer World". In 2024, CanSinoBIO made an appearance at CPHI Worldwide 2024 with its innovative vaccine products, including the world's first Ad5-nCoV for inhalation and Recombinant Poliomyelitis Vaccine. This event not only showcased CanSinoBIO's leading position in vaccine R&D and production but also attracted the attention of over a hundred potential customers and industry experts across the globe, further consolidating its influence in the global vaccine field.

CanSinoBIO Concluded a Cooperation Agreement with the NIBM

In July 2024, CanSinoBIO signed a Memorandum of Agreement (MoA) with the NIBM to engage in intensive cooperation on the R&D, production, technology transfer, and talent exchange of mRNA multivalent influenza vaccines, to help Malaysia achieve its localized vaccine production goals by 2030. In October, both parties officially signed a cooperation agreement for mRNA vaccine R&D projects, clarifying the joint efforts in mRNA multivalent influenza vaccine R&D, and assisting in influenza prevention across the globe. According to the Agreement, CanSinoBIO will receive funding of over RMB 10 million from the Ministry of Science, Technology and Innovation (MOSTI), providing a financial guarantee for the project.

CanSinoBIO at the Signing Ceremony

CanSinoBIO Entered into Biopharmaceutical Cooperation Agreement with PT Etana Biotechnologies Indonesia

During the China - Indonesia Business Forum held in November 2024, CanSinoBIO and its Indonesian partner Etana concluded a biopharmaceutical cooperation agreement. According to the agreement, both parties will focus on cutting-edge technology R&D for inhaled tuberculosis vaccine and further strengthen cooperation. CanSinoBIO, with its professional experience in technology transfer and localized manufacturing, will work closely with Indonesian partners to jointly promote innovative projects such as the tuberculosis vaccine and meningitis vaccine. In addition, CanSinoBIO will fully support Indonesia in building a regional vaccine production center, assist in the construction of a community with a shared future between China and Indonesia, and contribute to global disease control.

CanSinoBIO at China - Indonesia Cooperation Agreement Signing Ceremony

CanSinoBIO Signed a Memorandum of Understanding (MOU) on Strategic Cooperation with the Butantan Institute in Brazil

In November 2024, CanSinoBIO and the Butantan Institute in Brazil officially signed a memorandum of understanding (MOU) on strategic cooperation. Both parties will promote the development of innovative vaccines and mRNA technology, engage in further cooperation between China and Brazil in the field of public health, and strive to build a global partnership. The conclusion of this agreement marks a comprehensive and intensive cooperation between both parties in key areas such as vaccine R&D, mRNA technology, and supply chain, laying a solid foundation for close cooperation between China and Brazil in the field of public health.

CanSinoBIO at the Signing Ceremony

In 2024, CanSinoBIO continued to expand its global presence and remained committed to improving the global accessibility of vaccines. The Company has been engaged in a wide range of cooperations in Africa, South America, North America, Europe, Asia, and Oceania.

North America

Canada: Phase I clinical trial for Recombinant Zoster Vaccine was conducted to evaluate the safety and preliminary immunogenicity of the two delivery methods of intramuscular injection and inhalation

Mexico: We established a vaccine manufacturing base to realize localized manufacturing

Europe

Hungary: We obtained the EU GMP certificate for Ad5-nCoV and obtained the local emergency use authorization

Sweden: We signed product supply cooperation framework agreement with AstraZeneca AB

Asia

Indonesia: Menhycia® was granted a registration certificate by BPOM. The clinical trials on the safety and immunogenicity of Menhycia® upon vaccination among people aged 18-55 were under evaluation; Convidecia® and Convidecia® Air® were officially approved in Indonesia; Convidecia® passed the Halal Decree. Convidecia® Air® obtained an emergency use permit issued by BPOM; CanSinoBIO and the Indonesian Biopharmaceutical Company - Etana signed a tripartite cooperation agreement on inhaled tuberculosis vaccine and China-Indonesia cooperation agreement in the biomedical field

Malaysia: The Vaccine manufacturing base was built to realize localized manufacturing; Convidecia® was used locally as a general-purpose booster, Convidecia® Air® obtained a clinical trial permit in Malaysia; CanSinoBIO carried out more in-depth vaccine cooperation with Malaysia on behalf of China, signing a share subscription agreement with Solution Group Berhad; CanSinoBio signed a cooperation agreement with the National Institute of Biotechnology Malaysia (NIBM) for an mRNA vaccine research and development project

Pakistan: Convidecia® obtained emergency use authorization, and a vaccine manufacturing base was built to realize localized manufacturing

Kyrgyzstan: Convidecia® obtained emergency use authorization

United Arab Emirates: Convidecia® obtained emergency use authorization

Saudi Arabia: We signed cooperation framework agreement on innovative vaccine with Saudi Arabia's pharmaceutical manufacturing company SPIMACO

South America

Argentina: Convidecia® obtained emergency use authorization and was officially registered in Argentina and recommended as a heterologous booster

Chile: Convidecia® obtained emergency use authorization

Ecuador: Convidecia® obtained emergency use authorization

Brazil: CanSinoBIO and the Butantan Institute in Brazil officially signed a memorandum of understanding (MOU) on strategic cooperation

Africa

Morocco: Convidecia® Air® obtained an emergency use permit from the Ministry of Health and Social Protection in Morocco

Oceania

Australia: We launched the Phase I clinical trial of Recombinant Poliomyelitis Vaccine in Australia and the first trial patient case was formally enrolled; The Group re-signed a project funding agreement with the Bill & Melinda Gates Foundation on the Recombinant Poliomyelitis Vaccine, and the Foundation will grant a total of over USD 17 million to support the development of the Recombinant Poliomyelitis Vaccine

Together for Accessible Health Care

At CanSinoBIO, we uphold the strategic concept of “Together for Accessible Health Care”, adopt a multi-level and differentiated strategy, and remain committed to improving vaccine accessibility across the globe. We actively respond to the initiatives of international organizations such as the WHO and the Bill & Melinda Gates Foundation and are dedicated to serving the global public health market through innovative R&D and safeguarding vaccine accessibility. Moreover, we adjust our cooperation mode in a flexible manner according to the specific situation in each country: we directly supply vaccines to meet urgent needs for countries short of local production capacity; we assist in establishing research capabilities for countries with clinical research resources; we transfer production and technology in stages for countries with high technological demand and help them establish local production capacity. In 2024, we continued to engage in further cooperation with developing countries. We jointly promoted the R&D of mRNA multivalent influenza vaccine with the NIBM; we cooperated with Etana in Indonesia to develop an inhaled tuberculosis vaccine and obtained funding of USD 17 million from the Bill & Melinda Gates Foundation to advance the Recombinant Poliomyelitis Vaccine project.

CanSinoBIO Invited to Attend WHO Meeting

On World Polio Day (October 24, 2024), CanSinoBIO was invited to participate in the 23rd Annual Consultation of WHO’s GPEI held in Geneva. Dr. Yu Xuefeng, Chairman and CEO of the Company, shared the latest development progress of CanSinoBIO’s Recombinant Poliomyelitis Vaccine in the meeting.

The 23rd Annual Consultation of WHO’s GPEI

At CanSinoBIO, we have established a Scientific Advisory Board (SAB) to gather global expertise and obtain strategic guidance for improving pharmaceutical accessibility. In 2024, the CanSinoBIO SAB Academic Conference 2024 was held in Tianjin, bringing together several top-notch international experts to discuss cutting-edge technologies, research achievements, and CanSinoBIO’s innovation strategies. During the conference, the experts conducted in-depth analyses of the R&D data and potential public health value of innovative products such as CanSinoBIO’s Recombinant Poliomyelitis Vaccine and PBPV and discussed new trends in inhalation administration technology and mRNA field.

CanSinoBIO Attended the 25th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN)

The 25th Annual Conference of the Developing Countries Manufacturers Alliance (DCVMN) was held in São Paulo, Brazil in October 2024, CanSinoBIO was invited to attend as a member. Dr. Yu Xuefeng, Chairman and CEO of the Company, delivered a speech at the CEO Forum and discussed with the participants the development trends and R&D ideas of cutting-edge vaccine technology platforms.

Dr. Yu Xuefeng at the CEO Forum during the 25th Annual Conference of the DCVMN

CanSinoBIO Invited to Boao Forum for Asia Annual Conference 2024

In March 2024, Dr. Yu Xuefeng, Chairman and CEO of CanSinoBIO, was invited to attend the Boao Forum for Asia Annual Conference 2024 and discussed global medical cooperation and health equity with several international experts at the “Health Without Borders - International Medical and Health Cooperation” Forum. Dr. Yu Xuefeng emphasized that CanSinoBIO is committed to providing innovative, high-quality, and affordable vaccines by virtue of its five major technology platforms and multiple innovative vaccine products, with the aim of promoting the sustainable development of global healthcare.

At the Boao Forum for Asia’s “Health Without Borders - International Medical and Health Cooperation Roundtable”

01 Green Development

Upholding Environmental Protection Concept for a Low-carbon Future

At CanSinoBIO, we uphold the green development concept, actively respond to the national strategy of carbon peaking and carbon neutrality, and incorporate environmental protection into all of our activities. We take concrete actions to fulfill our commitments towards sustainable development by establishing a sound environmental management system, promoting efficient resource utilization, constantly optimizing energy structure, reducing carbon emission intensity, and cutting pollutants discharge in a proactive manner, with the aim of contributing efforts to environmental protection.

Relevant Public Policies in this Chapter

Environmental Management System

Response to Climate Change

At CanSinoBIO, we are keenly aware of the profound impacts of climate change, thus we adopt a variety of measures to address such challenges and proactively respond to China's carbon peaking and carbon neutrality strategy. The Company has comprehensively evaluated and managed climate change risks associated with governance, strategy, risk management, indicators, and targets, with reference to the framework and recommendations of the International Sustainability Standards Board (ISSB). We have been strengthening our capabilities to respond to climate change and striving for carbon footprint reduction in operations by constantly optimizing the climate governance system, intensifying green technology innovation, improving resource utilization rate, and helping achieve the national "carbon peaking and carbon neutrality" goals and global climate governance.

Governance

At CanSinoBIO, we strengthen top-tier design in the climate change management system, and define clear-cut responsibilities and work divisions, to comprehensively manage and advance the Company's energy conservation and carbon reduction activities. As the highest responsible and decision-making body for ESG and addressing climate change, the Board of Directors oversees and reviews climate risks and opportunities. The Audit Committee is responsible for promoting the Company's environmental management and following up on the achievement of environmental targets, while the ESG Working Group under the Audit Committee implements specific tasks and sets relevant environmental targets. In addition, the Company has established an Energy Efficiency Leading Group where the Chief Executive Office (CEO) acts as the group leader, the Chief Operations Officer (COO) acts as the deputy group leader, the Vice President, and department heads act as group members, safeguarding the comprehensive implementation of climate change response efforts.

Organization Chart of CanSinoBIO's Energy Efficiency Leading Group



Climate Strategy

The Company attaches great importance to the risks and opportunities presented by climate change, conducts climate risk evaluation and opportunity identification in a systematic way, and has developed response measures from two perspectives: physical risk and transition risk.

Major Physical Climate Risk

Risk Type		Risk Description	Risk Response
Acute physical risks	Typhoon/ Tropical cyclone	• Typhoon-related strong wind and rainstorms damage buildings, production equipment, vehicles as well as other assets, resulting in an increase in additional maintenance expenses and a reduction of asset operation capacity; • They affect and threaten staff health and safety, resulting in operation interruptions; • They affect transportation, leading to a shortage of production materials and operation interruptions.	Strengthen typhoon protection measures, improve emergency response plans for extreme weather and staff safety management systems, optimize supply chain resilience, and establish an emergency material reserve system.
	Extreme rainfall	• Extreme rainfall damages machinery or parts, requiring additional maintenance costs and increasing the Company's cost investment; • Water pollution causes a shortage of freshwater resources, which will increase the cost of wastewater treatment and reduce the Company's productivity, resulting in a decrease in revenue.	Systematically reduce production interruptions and cost risks by reinforcing key facilities, optimizing equipment maintenance and emergency reserves, strengthening the water resource assurance system, and introducing intelligent monitoring technology.
	Extreme cold	• Low-temperature periods in winter in northern regions may result in temperature control system deviations in precision equipment such as bioreactors, affecting the stability of core processes and leading to a decrease in the qualification rate of production batches; • The icy road may obstruct the transportation of raw materials in and out of the factory, causing production interruptions; • Potential freezing hazards in the water treatment system will directly affect the continuity of vaccine solution production, causing production interruptions; • Continuous low temperatures may pose a risk of frost cracking on the factory's fire pipelines, which may cause water system shutdown, and a potential fire hazard would affect factory safety.	Strengthen freeze protection and insulation measures for key production equipment, establish emergency response plans for logistics supply chains in extreme weather, carry out climate adaptation renovation of core production systems such as water treatment, implement all-weather risk monitoring and emergency response mechanisms in parallel, and ensure the stability of vaccine production and supply chain continuity in low-temperature environments.

Risk Type		Risk Description	Risk Response
Acute physical risks	Extremely hot weather	• Ventilation, cooling, and other equipment will be running due to hot weather, leading to an increase in energy consumption and operating costs; • Dry weather may easily cause accidents such as fires, explosions, leaks, and poisoning. Since flammable and explosive reagents are used in the factory, prolonged operation of air conditioning systems poses risks of fires and explosions due to high temperatures; • The power system may experience consumption peaks, leading to transmission interruptions and affecting normal production; • Hot weather may cause vaccine transportation cold chain failure, resulting in product loss and customer rejection; • High-temperature operating environment reduces the work efficiency of production staff and increases health management costs.	Optimize the energy management system in the factory and improve equipment energy efficiency, complete power supply assurance, and off-peak scheduling mechanism, strengthen temperature control protection and emergency alternative solutions throughout the cold chain transportation, improve high-temperature working environment and employee health protection measures.
Chronic physical risks	Sea level rise	• Coastal factories are facing the threat of storm surges, which may cause flooding in production workshops and damage to equipment; • The seawater intrusion aggravates the salinization of groundwater, increasing the cost and quality risks of water purification for vaccine production; • The upgrading of flood control standards or relocation of coastal factories leads to an increase in costs and production shutdowns.	Fully assess local climate risks and geographical conditions to avoid potential risks that may be caused by natural disasters in selecting operating sites; resort to such measures as a dike to strengthen the disaster protection capabilities of coastal factories.
	Draught and water shortage	• Water shortage directly threatens key links in vaccine production, leading to shutdown of cell culture and other processes, causing a decrease in revenue; • High-priced procurement of medical-grade pure water or investment in seawater desalination systems increases operating costs; • The lack of water in the factory cooling system will aggravate the risk of hazardous chemical storage or trigger work safety accidents.	Improve the strategic reserve and recycling system for water resources, optimize production water-saving processes and cooling system safety protection, establish a graded response mechanism for water shortage risk, and comprehensively assure the stability and cost controllability of vaccine production.

Major Transition Risks

Risk Type	Risk Factor	Risk Description	Risk Response
Policy and regulatory risks	Energy conservation and emission reduction-related policies becoming increasingly strict	More stringent policies push the Company to increase investments in energy conservation and emission reduction to meet higher environmental standards, leading to an increase in compliance costs for enterprises.	Closely follow energy conservation and emission reduction policies, accelerate the upgrading of green production processes and application of low-carbon technologies, and enhance environmental compliance capabilities.
	More stringent emission reporting obligations and compliance requirements	Due to more stringent emission reporting obligations and compliance requirements, the Company has to invest more manpower and funds in environmental monitoring and data reporting, thus increasing operating costs.	Optimize compliance monitoring processes and strengthen the application of digital management tools to achieve collaborative management of environmental compliance and production operations.
	Carbon pricing	The Company needs to pay higher carbon taxes or purchase carbon emission allowances, which would directly lead to an increase in production costs.	Accelerate the application of low-carbon technologies and optimize production processes to reduce actual emissions, balance carbon pricing compliance costs and green transformation competitiveness enhancement, promote pricing mechanisms in line with international standards, conform to ESG trends, and consolidate recognition from upstream and downstream partners.
	Litigation risk	The Company subject to legal actions for violating climate change laws and regulations may face financial losses such as penalties, as well as a business shutdown.	Strengthen the climate change compliance management system and dynamic monitoring of legal risks, improve litigation response plans and environmental liability insurance coverage, and take the initiative on disclosing emission reduction progress to boost stakeholder trust.

Risk Type	Risk Factor	Risk Description	Risk Response
 Technological risks	Technological innovation R&D failure	Large-scale investment in clean energy technology, efficient production equipment, and low-carbon process upgrades may increase financial stress in the short term. Moreover, insufficient technology maturity or low market adaptability will lead to transformation failure.	Take low-carbon and energy-saving measures in daily operations and manufacturing processes to reduce carbon emissions in R&D, manufacturing, equipment maintenance, warehousing, transportation and supply, etc.
 Market risks	Market share decline	As customers increasingly tend to use low-carbon products and services, the Company's failure to improve the green and low-carbon properties of its products and services may lead to a reduction in the Company's market share.	Accelerate the green and low-carbon upgrading of products and optimize supply chain carbon footprint, strengthen the brand green value and the mechanism for meeting customers' sustainable needs.
 Reputation risks	Stakeholder feedback	As the regulatory agencies, investors, customers, and consumers put forward increasingly stringent climate performance requirements, the Company's inappropriate climate management performance may result in increased negative feedback from stakeholders.	Continuously strengthen information disclosure, enhance communication with stakeholders, and meet stakeholders' concerns and demands through comprehensive and accurate information disclosure. Regularly disclose the achievement status of environmental goals, and adjust/update targets in a timely manner based on actual performance, thereby proactively shaping a corporate image of low-carbon sustainability and social responsibility fulfillment.

Driven by the national strategy of carbon peaking and carbon neutrality as well as related policies, the pharmaceutical industry is facing new opportunities for green transition and sustainable development. At CanSinoBIO, we identify and evaluate potential climate opportunities in business development as a vital opportunity for industry innovation and upgrading. We have identified major climate change-related opportunities in resource efficiency, energy sources, products and services, as well as market development.

Opportunities

Opportunity Type		Opportunity Description
Resource efficiency	• Resource utilization improvement	• We lower the cost of energy resource procurement by improving production processes and enhancing energy efficiency (such as optimizing steam, water, and power systems).
Energy sources	• Renewable energy sources	• We reduce the impact of energy price fluctuations on production costs by increasing the proportion of renewable energy in the energy structure; in addition, we fully utilize government incentives for renewable energy projects, such as installing renewable energy equipment (e.g. photovoltaics in factories) at a lower cost.
Products/ Services	• Low-carbon products R&D and innovation	• By adopting green production processes, the Company's product recognition will be enhanced, gaining the trust of public health institutions and product users, and leading to revenue growth.
Market	• Emerging markets	• We grab incremental market share in emerging markets and increase revenue by complying with the access restrictions on product carbon footprint in other countries and regions. We participate in sustainable healthcare initiatives of international organizations, enter the global public health procurement system, and expand brand influence by virtue of certified low-carbon products.
Resilience	• Resources substitution/Diversification	• We aim to reduce the impact of extreme weather and energy shortages on production through climate risk assessments and collaboration with suppliers, thereby enhancing supply chain continuity and delivery stability. We carry out climate adaptive transformation on production plants, warehouses, etc. to reduce the risk of production shutdown due to floods and high temperatures while enhancing asset resilience and long-term market valuation.

Risk Management

At CanSinoBIO, we keep upgrading the climate risk management system and integrate climate change risks into our ESG risk management system, thus enhancing capabilities against climate change risks through identification, assessment, response, and management activities, and ensuring sustainable and stable operations.

Risk identification and assessment	• Conduct risk identification regularly and determine the risk impact.
Risk warning	• Keep a check on dynamic information of natural disasters such as extreme weather, promptly issue warnings, and report to the superior while taking effective precautions.
Emergency Management	• Develop the *Emergency Management Procedures on Water Cut-offs, Water Leaks, and Industrial Steam Shutdown*, and strengthen emergency response capabilities against energy and resource shortages due to environmental incidents; • Inspect the emergency equipment and facilities and carry out drills regularly to ensure they are running efficiently at all times.

Indicators and Targets

At CanSinoBIO, we set climate change targets such as carbon emission as a vital reference and guidance for energy conservation and emission reduction. We encourage employees, suppliers, and partners to pursue the low-carbon concept with joint efforts to achieve carbon emission targets.

CanSinoBIO's GHG Emission Reduction Target[1]

With 2023 as the benchmark year, the total GHG emissions per unit floor area of production and auxiliary facilities will be reduced by

10% in 2030

[1] In 2024, the Company adjusted its GHG emission targets based on comprehensive factors such as project construction, future production capacity planning, and technological iteration to ensure a dynamic balance between environmental targets and business development.

CanSinoBIO's GHG Emissions in 2024

Total GHG emissions (Scopes 1 and 2)[2]

31,075.31 tCO_2e

Total GHG emissions per unit floor area of production and auxiliary facilities[3]

0.46 tCO_2e per square meter

Direct GHG emissions (Scope 1)

Natural gas

1,176.73 tCO_2e

Diesel fuel

5.30 tCO_2e

Gasoline

13.46 tCO_2e

Refrigerant

668.61 tCO_2e

Indirect GHG emissions (Scope 2)

Purchased power

17,485.91 tCO_2e

Purchased steam

11,725.30 tCO_2e

[2] GHG inventories include carbon dioxide, methane, nitrous oxide and hydrofluorocarbons, mainly produced from the purchased electricity, purchased steam, fuel, and refrigerant use. GHG emissions are presented in carbon dioxide equivalents and are calculated based on the *Guidelines for Accounting and Reporting of Greenhouse Gas Emissions by Enterprises - Power Generation Facilities (Revised Version in 2022)* issued by the Ministry of Ecology and Environment and the 2006 IPCC Guidelines for National Greenhouse Gas Inventories issued by the Intergovernmental Panel on Climate Change (IPCC). The emission factors of purchased electricity are calculated with reference to the *2023 National Electricity Carbon Footprint Factors* issued by the Ministry of Ecology and Environment.

[3] Floor areas of the Company's projects under construction and R&D projects not included.

Environmental Management

At CanSinoBIO, we have established a sound environmental management system to meticulously implement environmental management measures and pursue the green development concept, striking a balance between economic benefits and environmental benefits.

Environmental Management System

CanSinoBIO carries out environment management in strict compliance with environmental laws and regulations including the *Environmental Protection Law of the People's Republic of China*, the *Law of the People's Republic of China on Prevention and Control of Water Pollution*, the *Law of the People's Republic of China on the Prevention and Control of Noise Pollution*, and the *Law of the People's Republic of China on the Prevention and Control of Air Pollution,* and in compliance with requirements such as ISO 14001 Environmental Management System and ISO 50001 Energy Management System, with the aim of continuously improving environmental management system. We have developed internal management systems, such as the *Environmental Management System* and *Management System for Environmental Protection Equipment and Facilities,* to refine environmental management requirements for all business and operational locations, ensure effective implementation of a variety of environmental protection measures, and achieve continuous improvement of environmental performance.

CanSinoBIO's Commitment to Environmental Protection

- To strictly comply with national and governmental laws and regulations, and establish scientifically reliable and systematic environmental management systems.
- To realize the target of energy conservation and emission reduction by using green energy, introducing projects of energy conservation, and recycling resources.
- To put risk prevention first and identify environmental factors in products, processes, equipment, and facilities; effectively control environmental factors and prevent pollution through inspection, maintenance, and monitoring.
- To promote the awareness of environmental conservation to our employees and encourage them to participate in relevant activities.
- To provide our clients, contractors, and suppliers with assistance, guidance, and audit regarding environmental protection.

The Company has formulated the *EHS Targets and Responsibility Management System* and the *EHS Reward and Punishment Management System*, integrated the EHS performance (including environmental performance) into the staff performance appraisal, and viewed it as a critical veto item. Where an employee fails to meet the Company's requirements in terms of EHS, his/her overall performance will be appraised as non-compliance, this safeguards the overall achievement of EHS targets.

At CanSinoBIO, we conduct external and internal audits of the environmental management system for all business and operational locations regularly, with a focus on advancing the environmental management system. As for internal audit, we ensure the overall environmental compliance of project construction and production operations through the process of "Auditing by Health and Safety Committee - Reporting and Decision-Making by the Management - Implementation by Engineering Service Center". As for external audits, we actively cooperate with and accept various environmental inspections conducted by regulatory authorities, meticulously implement rectifications, and issue rectification reports.

During project execution and renovation, the Company strictly abides by the “Three Simultaneities” system of environmental protection facilities being designed, constructed, and commissioned at the same time together with the principal part of the construction, and establishes an environmental management mechanism for contractors. During tendering, we put forward energy consumption requirements for the equipment selected by the contractors; when we enter into construction contracts with the contractors, we also enter into the *Civilized Construction Management Agreement*, outlining construction environmental protection management requirements; during construction, we request all contractors to enter into construction waste removal agreement with qualified waste disposal companies and ensure that all construction wastes are transported to government approved disposal sites for recycling. As for construction dust, we request the contractors to implement dust suppression measures such as foggers to reduce environmental impact.

In 2024, CanSinoBIO

Did not have any environmental violations or emergencies, and was **not** subject to any environmental administrative penalties.

Invested about RMB

2.96 million in total on environmental protection and management.

Completed

6 environmental compliance renovations.

As an important step in sustainable development, CanSinoBIO enhances environmental protection awareness among all employees through diverse training programs and communication campaigns.. In 2024, the Company organized two environmental protection training sessions to help employees master environmental protection knowledge and skills. We maintain regular environmental publicity through WeChat groups, official accounts, and other channels. We carry out themed publicity activities during World Water Day and World Environment Day to encourage employees for green behaviors in work and daily life. In addition, the Company takes an active part in public welfare activities organized by environmental protection associations, such as tree planting, garbage collection, and environmental protection knowledge contests to further enhance the sense of environmental responsibility among employees.

Environmental Protection Training

Employees Participated in Green Hiking on the World Environment Day

Environmental Risk Management

At CanSinoBIO, we conduct a comprehensive environmental risk assessment once every three years to identify, analyze, and control potential risks having an impact on the environment. The Company promptly identifies potential risks and develops targeted prevention and emergency response plans through scientific risk assessment, standardizing environmental risk management and response procedures. In 2024, the Company completed an environmental risk assessment of the Rongsheng Building. The environmental risk assessments for industrialized plants and COVID-19 vaccine production plants remain valid, with no major environmental risks identified.

The key environmental risk currently impacting the Company arises from government-enforced production shutdowns during severe air pollution episodes, as mandated by regulatory authorities. CanSinoBIO, as a company in the biopharmaceutical industry, generates low pollutant emissions in our daily production and operation activities, with less impact on the weather and air. Nevertheless, the Company will strictly comply with relevant production reduction requirements, ensure compliant operations, and actively fulfill environmental responsibilities. We have established an emergency office and a heavy pollution weather response leadership group led by the COO to be responsible for unified scheduling and command of emergency measures. The Company has developed an *Emergency Response Plan for Heavy Pollution Weather* to strengthen such basic activities as emergency resource investment and material guarantee and carry out emergency drills regularly, achieving the synchronous implementation of routine management and emergency management measures.

At CanSinoBIO, we regularly organize environmental risk emergency drills or training to ensure quick response in the event of environmental incidents and minimize negative environmental impacts.

CanSinoBIO Organizes Emergency Drill for Environmental Incident

In 2024, the Company organized an emergency drill for temporary hazardous waste storage units by simulating the scenario of pollution due to organic waste liquid overflow, and the staff strictly followed the emergency response plan for rapid handling. This drill achieved the expected purpose, and tested the operability of the Company's emergency response plan and the employees' emergency response capabilities.

Organized Emergency Drills for Environmental Incident

Use of Resources

At CanSinoBIO, we stick to the resources management policy of "Continuously Scientific Consumption Reduction at the Source by All Employees", implement energy conservation and emission reduction measures in daily operations, and optimize resource utilization rate, with the aim of minimizing environmental impact.

CanSinoBIO strictly abides by laws and regulations such as the *Law of the People's Republic of China on Energy Conservation* and the requirements of governmental departments. With reference to standards such as the *Energy Management System - Requirements and Guidelines for Use (GB/T 23331-2020)*, the Company has developed energy management systems such as the *Regulations of Energy Management*, the *Energy Management Guidelines*, and the *Regulations of Gas Fired Boiler Production and Operation* to ensure standardized, systematic and efficient energy use, safeguarding the target of energy conservation and emission reduction. To implement energy conservation work in an all-around way, the Company has established an Energy Saving Working Group to arrange energy-saving management wrap-up meetings regularly, analyze the difficulties and pain points in current implementation, and discuss solutions. Beyond that, we have incorporated energy conservation targets into the performance appraisal system of departments and employees to encourage their active involvement in energy conservation and emission reduction work.

At CanSinoBIO, we conduct energy system audits, evaluate energy efficiency, and accept external audits or inspections. The Company enhances energy management and promotes green and low-carbon transition by identifying optimization opportunities and developing improvement measures. In 2024, the Company passed the energy consumption dual control self-assessment organized by the governmental departments.

In 2024, the resources used by CanSinoBIO in R&D, manufacturing, and daily office operations mainly include electricity, natural gas, steam, gasoline, diesel, water, and packaging materials.

CanSinoBIO's Energy Consumption Target[4]

With 2023 as the benchmark year, the energy consumption per floor area of production and auxiliary facilities will decrease by

10% by 2030

CanSinoBIO's Water Consumption Target[5]

With 2023 as the benchmark year, the water consumption per floor area of production and auxiliary facilities will decrease by

10% by 2030

CanSinoBIO takes multiple measures to reduce resource consumption. The Company integrates energy-saving concepts into the design and construction of factories and projects, thus effectively avoiding high energy consumption and high renovation investment at a later stage through forward-looking energy-saving plans. We prefer low-energy products in purchasing new equipment. In 2024, our new sewage treatment plant fully considered energy conservation, saving about 20% of electricity compared with the existing treatment plant. Moreover, we used information technology to refine energy management by monitoring, comparing, and analyzing the Company's energy consumption data. In 2024, we achieved centralized management and real-time display of all energy data, tracked and adjusted energy consumption in a dynamic and timely manner, thereby providing data reference for energy-saving measures and achievement of energy consumption targets.

[4] In 2024, the Company adjusted its energy targets based on comprehensive factors such as project construction, future production capacity planning, and technological iteration to ensure a dynamic balance between environmental targets and business development.

[5] In 2024, the Company adjusted its water consumption targets based on comprehensive factors such as project construction, future production capacity planning, and technological iteration to ensure a dynamic balance between environmental targets and business development.

CanSinoBIO's Major Energy Management Measures

Power

- We advanced energy-saving renovation of lighting systems, use high-efficiency energy-saving lamps, and promote solar streetlights, to reduce lighting energy consumption;
- We implemented refined control of clean systems, optimized season-based operating parameters, and adjusted equipment operating modes, to save power resources;
- All departments worked together for energy conservation and consumption reduction in offices, optimized the management of electrical equipment, strengthened the management of office lighting, air conditioners, computers, and other electrical equipment, defined the responsibilities for energy-saving work areas, reduced lighting and air conditioner operation in staff canteen outside normal mealtime. In 2024, we saved 3,700 kWh of office lighting electricity.

Steam

- We bought municipal steam to replace gas-fired boilers in several factories and executed projects such as condensate waste heat recovery and recycling of concentrated water from manufacturing in cooling towers, with the aim of tapping into energy potential and promoting efficient cascade utilization.

Gasoline

- We reduced vehicle fuel consumption by optimizing driving routes and enforcing strict approval procedures for official vehicles.

Diesel fuel

- We optimized the routes of diesel vehicles to reduce diesel consumption.

Water resources

- The Company's water resources mainly come from municipal water, and there have been no problems in obtaining suitable water resources.
- We optimized water equipment parameters, maintained and upgraded plant water supply networks, eliminated leaks and spills, and effectively reduced water resource waste.

Resource and Energy Use of CanSinoBIO in 2024

Indicators	Unit	Statistics in 2024
Direct energy consumption		
Natural gas	cubic meter	537,603.00
Gasoline	liter	6,191.61
Diesel fuel	liter	2,000.00
Indirect energy consumption		
Purchased power	kWh	28,180,350.00
Purchased steam	tons	40,224.00
Comprehensive energy consumption	MWh	76,161.28
Municipal water supply	tons	210,136.00
Water consumption per floor area of production and auxiliary facilities	tons per square meter	3.12
Energy consumption per floor area of production and auxiliary facilities	MWh per square meter	1.13
Consumption of packaging materials	tons	296.77
Consumption of refrigerant	kilos	437.00

Management of Waste Gas, Wastewater, and Solid Waste

CanSinoBIO has always adhered to the clean production concept and strictly controls all wastes generated during R&D, manufacturing, and operations, such as waste gas, wastewater, solid waste, and noise, to strive for harmonious coexistence with the environment. In 2024, we updated *Regulations on Waste Gas Management* and *Regulations on Wastewater Management*, and further refined discharge and control measures, thereby ensuring compliance of all discharge indicators with national and local environmental protection regulations.

CanSinoBIO is open to governmental supervision and review and invites third-party institutions for emission audits. In 2024, the Company accepted 3 audits on waste gas and solid waste and completed all rectifications, including 6 environmental compliance renovations covering sewage treatment plant renovation and hazardous waste storage marking updating. In 2024, multiple pollutants of the Company passed the detection of China Metrology Accreditation for Environmental Emissions (CMA).

Information Form of CanSinoBIO Pollution Discharge in 2024

Name of main pollutants	Chemical oxygen demand(COD),ammonia nitrogen
Discharge method	Discharged into the municipal sewage system
Number of discharge outlet	1
Discharge concentration	45.32mg/L of chemical oxygen demand (COD), 4.91mg/L of ammonia nitrogen
Exceeding standards emission	None
Pollutant discharge standard	500mg/L of chemical oxygen demand (COD), 45mg/L of ammonia nitrogen
Discharge amount examined	42.59 tons of chemical oxygen demand (COD) and 1.48 tons of ammonia nitrogen

CanSinoBIO's Waste Gas Emission Target[6]

Waste gas **100%** compliant emission

CanSinoBIO's Waste Target

With 2023 as the benchmark year, the hazardous waste generation during product production of a single batch will be reduced by **10%** by 2030[7]

CanSinoBIO's Wastewater Target[8]

With 2023 as the benchmark year, the discharge of wastewater pollutants per unit building area at drainage sites will be reduced by **10%** by 2030

[6] In 2024, the Company adjusted its waste gas targets based on comprehensive factors such as project construction, future production capacity planning, and technological iteration to ensure a dynamic balance between environmental targets and business development.

[7] The hazardous waste generation during product production of a single batch = The total hazardous waste generation / The number of all product batches.

[8] In 2024, the Company adjusted its wastewater targets based on comprehensive factors such as project construction, future production capacity planning, and technological iteration to ensure a dynamic balance between environmental targets and business development.

The gas emissions of the Company mainly include GHG, particulate matter, and nitrogen oxides from the use of purchased electricity, purchased steam, and the burning of natural gases. To effectively control exhaust emissions, the Company has conducted low nitrogen renovation on boilers and standardized the waste gas discharge outlets in the factories. Furthermore, we have installed an online monitoring system for volatile organic compounds (VOC) to ensure transparent and traceable discharge data. In 2024, we replaced activated carbon adsorption units and repaired pipeline damage to ensure the efficient operation of waste gas treatment facilities and reduce fugitive emissions.

The wastewater discharged by the Company mainly includes industrial wastewater and domestic wastewater. The major pollutants include chemical oxygen demand (COD), ammonia nitrogen (NH_3), and suspended solids (SS). We strictly comply with the relevant requirements of the *Integrated Wastewater Discharge Standard* (*DB12356- 2018)* to ensure that the wastewater is discharged after standard treatment. In 2024, we completed renovations on the sewage discharge facilities in multiple operational locations and installed a reclaimed water recycling system in a new sewage treatment plant, with 100 tons of reclaimed water recycled daily, thereby effectively reducing sewage discharge.

The hazardous wastes generated by the Company mainly include contaminants, organic and inorganic waste liquids, animal padding, animal corpses, expired chemical reagents, abandoned vaccines, and solid hazardous waste. The non-hazardous wastes mainly include kitchen waste and domestic waste. In terms of waste generation, the Company conducts various training sessions to enhance employees' environmental awareness and operational skills, reducing waste generated at the source. In terms of waste disposal, the Company has focused on promoting the intelligent upgrade of hazardous waste management this year and installed all-in-one hazardous waste management equipment to achieve real-time synchronization of hazardous waste weighing data with the national hazardous waste platform, ensuring accurate and reliable data. As for hazardous waste, the Company entrusts qualified third-party institutions for specialized disposal to ensure safe and compliant transportation and treatment.

CanSinoBIO's Waste Disposal Measures

Waste Type		Disposal Measure
Hazardous Wastes	Waste liquid and empty reagent bottles from the laboratory	Keep a record and store them in the designated temporary hazardous waste storage unit.
	Biological waste	The containers for biological waste are labeled as biological waste. After being sterilized in autoclaving, biological waste is collected for subsequent treatment with other hazardous wastes.
	Contaminated substances	Contaminated substances are collected in designated hazardous waste garbage bags.
Non-hazardous Wastes	Domestic waste, kitchen waste	To be collected and processed by a third-party organization with professional qualifications.

CanSinoBIO's Key Performance Indicators for Emissions

Wastewater

Total wastewater emissions	221,776.80 tons
Chemical oxygen demand	10.05 tons
Suspended solids	3.60 tons
Ammonia nitrogen	1.09 tons
Discharge of wastewater pollutants per unit building area at drainage sites[9]	0.00017 tons per square meter

Waste gases

Total waste gas emissions	462,312,072.00 cubic meter
Non-methane hydrocarbon	2.66 tons
Oxynitride	1.48 tons
PM (particulate matter)	0.13 tons
Waste gas pollutants emission during product production of a single batch	0.0118 tons/batch

Non-hazardous waste

Total non-hazardous waste	84.89 tons
Non-hazardous waste emissions per unit area of production and auxiliary facilities	0.0013 tons per square meter

Hazardous waste

Total hazardous waste	216.42 tons
Hazardous waste generation during product production of a single batch	0.60 tons/batch

[9] All wastewater from the Company's various plant sites is centrally collected and treated at a single sewage treatment station, with discharge density calculated based on the drainage plant area.

02 Product Responsibility

Tightening Quality Control, Pioneering Vaccine Innovation

CanSinoBIO always prioritizes product safety and quality, ensuring that every vaccine meets the highest safety standards through a comprehensive medical affairs system and pharmacovigilance mechanism. We continue to increase our investment in R&D, constantly enhancing the innovation and market competitiveness of our products. Meanwhile, we have established a comprehensive customer service system to effectively protect customer rights and contribute to building a safer and more accessible healthcare environment.

Relevant Public Policies in this Chapter

Responsible Marketing Statement

Product Safety and Quality

CanSinoBIO has established a quality management system covering the entire lifecycle of R&D, production, and distribution, improved the product recall mechanism, and integrated quality awareness into the corporate culture. Through continuous quality improvement and full participation, we are constantly enhancing our quality management level to provide the public with safe and reliable vaccine products.

Quality Management System

CanSinoBIO strictly follows international standards such as the *Good Manufacture Practice (GMP), the WHO Good Manufacture Practices for Pharmaceutical Products,* and *the EU GMP,* while also benchmarking against regulatory requirements such as those of the FDA[10]. In accordance with the guidelines of the *International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)*, and technical specifications such as the *2020 Edition of the Pharmacopoeia of the People's Republic of China*, and the *European Pharmacopoeia (10.0 Edition)*, we have formulated internal systems such as the *Quality Manual* and the *Management Procedures for Acquisition and Implementation of Domestic and Foreign New Regulations* to build a complete quality management system. In 2024, the Company revised the *Management Procedures for Acquisition and Implementation of Domestic and Foreign New Regulations*, further optimizing the quality governance structure. Relying on the new regulations gap analysis process, the Company completed 63 gap analysis tasks for five new guidelines, including the *Technical Guidance Principles for Pharmaceutical Research and Changes of Biological Products During Clinical Trials (Trial)* and 58 draft opinions such as the *Draft Quality Control Standards for Experimental Animals Used in the Production and Testing of Biological Products*, and submitted suggestions for 12 of the draft opinions, providing strong support for the continuous optimization of the quality management system.

Clinical quality is a core element in ensuring the scientific validity and reliability of clinical trials. The Company strictly adheres to the requirements of the *Good Clinical Practice for Drug Trials (GCP)*, and the *Guidelines for Quality Control of Vaccine Clinical Trials (Tentative),* implementing strict quality control throughout the entire clinical operation process and continuously optimizing the standard operating procedures (SOP) for clinical trials. As of the end of the Reporting Period, the Company's current SOP for clinical operation has reached 108 documents, including 20 management procedures and 88 operational procedures. In 2024, the Company added 3 new SOPs and upgraded 16 SOPs, standardizing key processes such as the full document management system for clinical trials, unblinding procedures, and safety assessments, optimizing core aspects such as drug management for clinical trials, clinical pharmacovigilance and safety management, data management, maintenance of blinding, and protocol deviations, thereby enhancing the standardization and operability of various stages of clinical trials.

[10] The Food and Drug Administration.

Full Process Management of Product Quality

The Company has established a quality management system that spans the entire product lifecycle, implementing strict controls from research and design, and raw material procurement, to production and product release. We have developed clear management standards and operating procedures for management objects such as suppliers, laboratories, facilities, and manufacturing workshops, effectively reducing product quality risks through source control and process supervision.

Full Process Management of Product Quality in CanSinoBIO

Material Quality Management

- System building: We follow national sampling and inspection standards, standardize the sampling process of raw materials, excipients, and packaging materials, and ensure the standardization of sampling quantity. In 2024, we expanded the scope of re-inspection materials, strengthened quality control of materials during storage, and ensured the safety and effectiveness of materials during use.
- Audit management: We create profiles of material suppliers, and conduct regular audits of key materials suppliers, involving written audits, on-site audits, remote audits, and third-party audits. In 2024, based on production needs, we selected and audited backup suppliers for those with compliance risks, supply risks, and frequent complaints. In addition to commercial product suppliers, we increased audits for R&D product material suppliers and certain high-risk sterile consumable suppliers. To meet the needs of the Muslim market, we also introduced audits for suppliers' halal content.
- Risk control: We conduct risk assessments on production consumables, implement release management for high-risk consumables, and reduce quality risks during use. In 2024, the release strategy for disinfectants and cleaners was optimized and adjusted, with item-by-item identification of excipients based on actual use to enhance quality management accuracy.
- Information-based management: We introduce the SAP system to realize the digital management of material release labels, reduce manual operations, reduce error rates, and improve material management efficiency.

Production Process Control

- System building: We establish a complete production process management system, covering key links such as personnel management, equipment and facility management, process control, and environmental monitoring, to ensure the standardization and standardization of production process quality management. We also develop detailed SOP guidance documents and conduct daily monitoring of the production environment to ensure stability and controllability of production.
- Responsibility implementation: We prepare instructions to departments and positions, implement work safety and quality responsibility into annual performance targets, ensure that responsibilities are implemented through a performance appraisal mechanism, and strengthen the quality awareness and safety production awareness of all employees.
- Environment control: We strictly follow the requirements of laws and regulations on sterility assurance and implement sterility control measures in the production process; Utilize an Environmental Monitoring System (EMS) with alarm functions to monitor, record, and archive on-site environmental parameters in real-time, ensuring timely response and handling of abnormal situations to maintain the stability and compliance of the production environment.
- Commercial production site management: Detailed monitoring points are established for the production areas of all marketed products, and the corresponding monitoring frequency and inspection strategy are determined according to the risk level. Our management focuses on document consistency, thoroughness of deviation investigations, effectiveness of CAPA, and comprehensiveness of change assessments.
- Clinical research site management: Based on the characteristics of the clinical research site, new on-site monitoring points and inspection strategies are added.
- Information-based management: We introduce online control systems for the production process to realize intelligent workshop manufacturing control, transparent production process, CNC manufacturing equipment, and integrated production information, improve the stability of the production process, and ensure data integrity and traceability.
- Technology optimization: We continuously optimize the production process, and scientifically adjust the product culture medium formula and stock solution preparation scale, while increasing production capacity, reducing quality risks caused by operational errors, and ensuring the efficiency and reliability of the production process.

Laboratory Management

- Responsibility implementation: We establish a safety responsibility system for all laboratory personnel, clarify the specific responsibilities of each laboratory personnel, and ensure that the laboratory fully meets management requirements in terms of chemical and biological safety protection levels;
- Process control: We implement full-process management of samples from sampling, reception, inspection, retention, to destruction, standardize the use of instruments and equipment, establish a standardized management system covering instruments and equipment, reference materials, sample management, and testing processes, and ensure the accuracy and reliability of test results;
- Information-based management: We deploy information platforms such as Laboratory Information Management System (LIMS) and Chromatography Data System (CDS) to realize digital management of laboratory testing processes. In 2024, enhance water system monitoring in the LIMS system to comprehensively improve the compliance and traceability of inspection work.

Distribution, Storage and Transportation Management

- System building: We continuously optimize the circulation quality management system covering initial orders from the customers, vaccine entry and exit, warehouse management, cold chain transportation and verification, complaint handling, and other links. In 2024, we revised management and operating procedure documents 17 times.
- Logistics network construction: We continue to optimize the international and domestic logistics distribution systems, set up entrusted storage warehouses covering multiple regions in China, and work with trunk transport operators to optimize the layout of the transportation network to improve distribution efficiency and timeliness. As of the end of the Reporting Period, the Company had a total of seven domestic and international logistics service providers and has established 10 vaccine regional warehouses in Guangdong, Zhejiang, Chongqing, Jiangxi, Guangxi, and Shaanxi. Logistics service providers are managed through annual quality audits, monthly business reviews, and quarterly quality communications to ensure compliance with the quality of product storage and transportation. All logistics providers have completed quality audits and filing, with a 100% qualification audit pass rate.
- Transportation validation: Based on the annual verification plan and business development, in 2024, domestic and international transportation verification of finished products and raw liquids was carried out to ensure product transportation quality.

Quality Audit

- Company self-inspection: In 2024, the Company carried out a total of 7 self-inspections, covering the entire life cycle of the product, including the R&D site and the production site. Self-inspection content covers quality management, production management, quality control, product release, material management, facility and equipment management, validation management, product shipment and recall, and pharmacovigilance.
- Audits by domestic drug regulation authorities: In 2024, the Company underwent a total of 6 inspections by official drug regulation authorities, including 2 registration site inspections, 3 GMP compliance inspections, and 1 annual vaccine inspection.
- Audits by overseas drug regulation authorities: In 2024, the Company underwent one GMP compliance inspection and one halal certification by overseas drug regulation agencies, and there were no serious defects.

Release Management

- Daily management: This covers three stages including the release of intermediate product/stock solution, the release of finished products after self-inspection, and the commercial release of finished products after passing the inspection of the national statutory drug inspection authority, with a focus on production process control and release status of materials to ensure that each link meets quality standards.
- Procedures for the release of raw, excipients, and packaging materials: We strictly inspect raw materials, excipients, and packaging materials that directly contact drugs and production consumables, and issue an inspection report; Materials must pass inspection before release to ensure the quality and compliance of the production process.

Technical Feasibility Assessment

- Daily monitoring: We continuously carry out daily monitoring of the workshop environment to ensure that the production environment always meets relevant standards and requirements during operation, and to ensure the stability of the production process and product quality.
- Information-based management: Through information technology, we collect and analyze the production condition data of clinical trial supplies, provide a scientific basis for technology transfer and market registration, and issue technical feasibility reports to help efficiently connect R&D and production.

Lot Release Management

- Insititutional building: In 2024, the approval and issuance process was reorganized, each link was analyzed item by item, and corresponding measures were formulated for links that may shorten the approval and issuance cycle.
- Release application: We submit the lot release application to the China National Institute for Food and Drug Control after the first stage of release of each batch of products. In 2024, the lot release work was completed on time, with a lot release qualification rate of 100%.
- Product inspection: We send samples and product information sampled by the Provincial Drug Administration to the designated testing agency for acceptance and testing, the products may only be marketed upon the second stage of release after being confirmed to be qualified.
- Capacity building: We continuously summarize questions from official drug testing agencies during the lot release process, analyze high-frequency issues, conduct abnormal trend analysis promptly, improve response efficiency, and organize relevant training. In 2024, the median duration of lot release decreased by 8% compared to 2023.

Document and Training Management

- Document management: The document management system (DMS) system was launched in 2024 to achieve full-process management of GMP system documents, strictly control various approval processes, and perform version control and management of documents. The system also featured hierarchical management of record distribution and retrieval, and enabled full tracking through barcode technology, ensuring the accuracy and traceability of document management.
- Training management: The training management system (TMS) system was launched in 2024 to achieve full progress tracking and management of various types of training and ensure that the document training coverage rate reaches 100%. The system conducted version control and approval management for training elements such as courseware and exam papers, ensuring the integrity, reliability, and traceability of data, and making the training management process fully compliant with regulatory requirements.

To ensure vaccine quality and safety during production and distribution, CanSinoBIO has formulated internal systems such as the *Deviation Management Regulations* and the *Change Management Regulations* to conduct deviation investigation and identification, assessment and classification, correction and prevention, and deviation closure. The Company also regularly reviews the implementation of deviation, strictly controls deviation events such as process equipment abnormality and operation errors, and terminates the production or release of the batches that may affect product quality, with the aim to prevent the risk of reduced vaccine efficacy or adverse reactions due to errors. In 2024, we refined the deviation and change management processes, strengthened the responsibilities of on-site quality assurance personnel, and improved the evaluation and tracking mechanisms after changes were implemented, comprehensively enhancing our management level.

Quality Inspection and Authentication

CanSinoBIO strictly adheres to national standards and implements quality testing throughout the entire lifecycle of all product batches. The testing scope comprehensively covers all aspects, including process water, raw materials and excipients, packaging materials, intermediate products, bulk solutions, semi-finished products, and finished products, ensuring comprehensive control of product quality from source to end.

CanSinoBIO's Full Lifecycle Quality Testing on Products

- **Early Stage**
  - Inspection of raw materials and excipients
- **Intermediate stage**
  - Inspection of intermediate products
- **Later stage**
  - Inspection of packaging materials
  - Inspection of product release

We monitor product testing data in real time and conduct trend analysis to ensure strict control over product quality. For out-of-specification (OOS) and out-of-trend (OOT) events that occur during the testing process, the Company has established a clear handling procedure for abnormal events, conducting in-depth investigations into abnormal trends that meet quality standards, and accurately recording the occurrence and handling process of unexpected events. Meanwhile, the Company strictly adheres to regulatory requirements, retaining samples and conducting regular stability assessments for each batch of marketed products to ensure that the quality of products within their shelf life meets registration standards. In 2024, CanSinoBIO revised the *Management Procedures for OOS/OOT/AD*, to further improve the scope of application, investigation processes, and job responsibilities based on relevant regulations, ensuring that product quality complies with regulatory requirements throughout its entire lifecycle.

Processing Flow of AD or OOS and OOT Events of CanSinoBIO

Discovery and Reporting	In the event of atypical data (AD) in the laboratory, the experimenter shall report it to the department head and Out of Specification (OOS) administrator within 24 hours and leave the site as it is and related records.
Preliminary Assessment	The head of departments should conduct a preliminary assessment of the abnormal situation, determine its category, and establish a preliminary handling process. It is necessary to determine whether the anomaly is caused by laboratory operations through basic investigations and hypothetical experiments.
Laboratory Investigation	If the initial assessment indicates a laboratory operation issue, an internal laboratory investigation shall be initiated to conduct an in-depth analysis of the cause and implement appropriate corrective measures.
Product Quality Investigation	If the initial assessment suggests that the abnormality is related to product quality, the incident must be transferred to the Production and Warehousing Department for further investigation to identify the root cause and develop corrective actions.
Annual Quality Review	An annual comprehensive review of all abnormal incidents shall be conducted to assess investigation progress, classify and summarize the causes, analyze trends, and provide a basis for the continuous improvement of the quality management system.

CanSinoBIO actively conducts internal and external quality supervision and auditing work, proactively identifying and preventing potential risks. The Company closely monitors high-frequency defects identified in domestic and international official inspections, accurately identifying high-risk areas based on its product characteristics, and conducting targeted internal audits. Meanwhile, based on issues identified in previous external audits, we have developed a detailed self-inspection checklist to effectively improve self-inspection efficiency. In addition, the Company actively introduces external experts and third-party organizations for audits to obtain objective and impartial evaluation opinions. In 2024, CanSinoBIO orderly advanced quality supervision and audit work, with no serious defects found.

CanSinoBIO's Quality Supervision and Audit Activities in 2024

Internal

- We conducted seven internal quality audits covering the entire product lifecycle, including development and production sites. The audits encompassed key areas such as quality management, production management, quality control, product release, material management, facility and equipment management, validation management, product shipment and recall, and pharmacovigilance. As of the end of the Reporting Period, 72% of the corrective actions had been completed.
- We carried out ten clinical trial inspections involving five products across nine domestic and international clinical trial projects. These inspections were conducted in accordance with the *Vaccine Administration Law of the People's Republic of China*, the *Declaration of Helsinki*, the *Good Clinical Practice (GCP)* guidelines, and other relevant regulations, guidance documents, clinical trial protocols, and on-site SOPs. The inspections covered critical areas such as site qualifications, investigator qualifications and training, drug management, sample management, and clinical trial implementation. As of the end of the Reporting Period, all on-site corrective actions had been completed.
- We conducted two audits of clinical monitoring service providers and clinical trial data statistics providers.

External

- The National Center for Vaccine Inspection conducted one vaccine inspection.
- The Center for Food and Drug Inspection of NMPA carried out two on-site registration inspections.
- The Tianjin Drug and Cosmetics Evaluation and Inspection Center conducted three GMP compliance inspections.
- BPOM performed one GMP compliance inspection.
- The Indonesian halal certification body, LPPOM, conducted one halal certification inspection.
- A total of five on-site clinical trial inspections were conducted, including one by NMPA and four by BPOM.

CanSinoBIO Conducted the First On-site Audit of Overseas Clinical Trial Projects

In April 2024, to ensure the smooth completion of overseas clinical trials, CanSinoBIO conducted its first on-site audit of overseas projects. This audit was based on the exploration of online audits in 2023 and further improved the quality management of overseas clinical trials. The inspected projects involved 2 sites, where the audit team conducted detailed checks on the qualifications of clinical trial sites, personnel qualifications, equipment implementation, informed consent, screening and enrollment, vaccination visits, blood collection visits, sample management, and drug management through on-site audits, document reviews, and interviews. As of the end of the Reporting Period, the issues identified during the audit have been rectified on site.

On-site Audit of Overseas Clinical Trial Projects

In 2024, the main progress of the quality inspection and authentication collaboration with CanSinoBIO includes:

We coordinated with the First Regulatory Office of the Tianjin Municipal Medical Products Administration to carry out the disposal of non-compliant vaccines, establishing an effective supervision mechanism to ensure closed-loop management across all vaccine processes.

We engaged in multiple discussions with regulatory authorities and the on-site regulatory office regarding the method transfer for the newly established laboratory in the Quality Control Department. Through these discussions, we identified risks, formulated transfer strategies and plans, and carried out the transfer process in an orderly manner under regulatory guidance.

We commissioned the Tianjin Institute for Drug Control to conduct third-party testing of packaging materials, strengthening technical exchanges and communication with the institute. Additionally, we held technical discussions regarding changes in the requirements for excipients and packaging materials in the 2025 edition of the *Pharmacopoeia of the People's Republic of China*.

Product Recall

CanSinoBIO has established internal systems such as the *Management Procedures for Non-conforming Products*, the *Procedures for the Management of the Vaccine Traceability System,* and the *Recall Management Procedures for Marketed Products*, always prioritizing public safety. By tracing the source and destination of products, the Company ensures timely implementation of necessary recall and destruction actions, strictly controlling potential risks.

In 2024,

CanSinoBIO reported **no** actual product recall.

CanSinoBIO's Product Recall Process

Issue Identification and Assessment

When the product is found to cause potential safety concerns or quality problems, the Quality Assurance Department is responsible for analyzing and assessing the necessity of recall.

Establishment of an Investigation Team

If the assessment result indicates that the product might be recalled, the Company convenes relevant departments to set up an investigation team and assess the potential safety risks of the product comprehensively.

Recall Plan Development and Approval

After the recall decisions are made, the Distribution Quality Department drafts the recall plan, and the Distribution Quality Department submits the recall plan and relevant report to the Drug Administration upon approval by the Quality Evaluation Committee.

Recall Implementation

After being approved by the Drug Administration, the products will be recalled at different levels. The business departments are responsible for informing customers of product recalls, the Commercial Supply & Distribution Division is responsible for product transportation and storage after the returns, and the Quality Assurance Department shall regularly submit periodic recall progress reports to the Drug Administration.

Recall Summary and Analysis

After the recall is completed, the recall team shall write a finished recall report, summarizing and analyzing the completion of the recall during the Company's annual management review.

Destruction and Disposal

All recalled products are destroyed strictly according to the process to ensure the complete elimination of potential risks.

The Company regularly conducts product recall simulation drills, simulating real scenarios to strengthen the team's ability to respond to emergencies, ensuring that all operations can be executed quickly and efficiently during actual recalls. In 2024, we integrated product recall simulation drills with major safety incident simulation drills, conducting exercises based on hypothetical major safety incidents. With close coordination among departments, the drills were completed, enhancing the Company's ability to handle major safety incidents and other emergencies. This initiative also optimized interdepartmental collaboration mechanisms and effectively mitigated safety risks, ultimately ensuring the highest level of public health and safety.

Cultivating Quality Culture

CanSinoBIO is committed to building an excellent quality culture, establishing management systems such as the *Responsibilities of Quality Management Person* and the *Responsibilities of Quality Authorized Person* to clarify quality responsibilities. Meanwhile, the Company incorporates quality responsibilities into the performance evaluation system to encourage employees to enhance their quality awareness.

In terms of quality training, we have improved the *Regulations on the Management of Employee GMP Training,* the *Regulations on the Management of Sampling Personnel Training,* and other key position training regulations to ensure that training is conducted in an orderly manner. The Company has established a comprehensive quality training system that covers induction, pre-employment training, expansion, annual GMP, and external training, enabling precise training for different levels and positions. In 2024, we conducted annual quality training for all employees and third-party employees[11]. We organized systematic training to enhance employees' understanding of the latest quality standards and processes and conducted regular operational assessments for relevant employees to ensure that they meet job skills and requirements, providing solid guarantees for product quality.

[11] It involves over 20 departments with full-time employees and third-party staff related to vaccine production and quality.

Quality Training System of CanSinoBIO

Orientation Training

Basic training on the Company's quality safety and data reliability regulations (including GMP knowledge, safety knowledge, vaccine management laws, etc.). New employees must complete induction training within three months of joining to ensure a comprehensive understanding of the Company's product quality management policies and basic measures.

Pre-employment Training

New employees and those who have changed positions must complete the training and assessment of the corresponding position training matrix and can only take up their posts after passing the position qualification confirmation. The job training matrix is divided into four stages:

- General training: Aimed at all employees, including basic legal regulations training and general GMP document training.
- Department-specific training: Targeted at the center or department to which the position belongs, covering GMP management document training related to departmental responsibilities.
- Essential training for the position: Includes training on management procedures and standard operating procedures.
- Operational skills training: Specialized training courses designed for positions that require practical operational skills.

Extended Training

It includes continuing education training, document revision training, online video courses, and external training by foreign experts, aimed at enhancing employees' professional skills and overall quality.

Annual GMP Training

It refers to quality training for all employees involved in drug production and quality management (including contractor employees). The annual company-level and department-level training plans cover all content related to legal regulations, professional capabilities, and essential knowledge for the position.

In 2024, the annual GMP training was successfully conducted, with a total of **6** company-level training sessions held, achieving a **100%** coverage rate for personnel involved in GMP production and quality management, totaling **2,783** training participants. Department-level training was conducted **475** times, with a total of **7,399** training participants.

The Company Conducted Quality Communication with the On-site Inspection Team

In 2024, CanSinoBIO invited the Tianjin Municipal Medical Products Administration's on-site inspection team to conduct specialized training on quality-related regulations for company employees and provided analysis and guidance on typical cases from the national vaccine inspection in the previous year. Meanwhile, the Company invited experts from the on-site inspection team to join the internal audit team for a comprehensive evaluation of production management and the quality system. The on-site inspection team conducted field inspections in the manufacturing workshop, storage areas, and quality control laboratories, offering optimization suggestions from a professional regulatory perspective, and providing expert guidance for the continuous improvement of quality management.

On-site Inspection by the Inspection Team

The Company Invited External Experts for Specialized Training

In October 2024, CanSinoBIO invited external experts to conduct specialized training for personnel in the technical operations and product supply sectors, as well as the R&D sector, with the theme "How to Successfully Prepare for and Host an FDA Supervision Inspection". The training content mainly focused on the process of FDA inspections and precautions to take when preparing for inspections, organized in a combination of on-site and online training, with over 270 participants in total.

"How to Successfully Prepare for and Host an FDA Supervision Inspection" Training Course



Product Innovation and R&D

CanSinoBIO is committed to building a globally competitive R&D system by creating a high-quality research team, continuously optimizing the R&D pipeline layout, and achieving breakthrough progress in multiple cutting-edge fields, providing innovative solutions to enhance disease prevention and safeguard public health.

R&D Management

CanSinoBIO has established a collaborative quality control mechanism to provide solid support for R&D innovation. The Company strictly adheres to the *Law of the People's Republic of China on Pharmaceutical Administration*, the *Law of the People's Republic of China on Vaccine Administration,* the *Good Manufacturing Practice - Appendix of Drugs for Clinical Experiments (Trial),* the *Guidelines for Quality Risk Management of Drugs Produced in Common Pipelines* and the *ICH Q10: Pharmaceutical Quality System* as well as other domestic and international drug regulation laws and standards, establishing a comprehensive quality management system. In 2024, the Company revised the *Naming System for R&D Products* to further enhance the standardization and scientific nature of R&D management. The Company continuously optimizes the R&D quality management process to ensure that R&D activities always operate within compliance.

CanSinoBIO lays a solid foundation for innovative R&D through a comprehensive project management process and a strong reserve of technical talent. The Company has established a project management system to enhance the efficiency of R&D project management through visualization, standardization, and process-oriented methods, ensuring the smooth progress of projects. The system establishes an experience database to enhance the transparency of R&D experiences and achieves full-process project management through management modules such as project initiation, planning, knowledge base, and risk management. The Company evaluates task urgency based on project priority and arranges work reasonably to ensure that key projects progress steadily as planned. In addition, each project team regularly organizes project meetings to conduct technical presentations and problem discussions, promptly resolving R&D challenges to ensure smooth R&D operations.

The Company focuses on attracting innovative R&D talents, leveraging a team of experienced master's and doctoral graduates in the biopharmaceutical field to inject key technological strength into the expansion of the R&D pipeline. As of December 31, 2024, the R&D personnel of the Group accounted for nearly 22.35% of total employees, and approximately 55.87% of R&D personnel had master's degrees or above.

As of December 31, 2024, the R&D personnel of the Group accounted for nearly

22.35% of total employees

approximately

55.87% of R&D personnel had master's degrees or above

R&D Progress

CanSinoBIO, guided by market demand, focuses on the prevention of human diseases and has built an innovative vaccine R&D system covering major infectious disease prevention and control. The Company's R&D pipeline has comprehensively covered over ten disease areas, including meningitis, pneumonia, diphtheria, tetanus, pertussis, COVID-19, and Ebola virus disease. In 2024, the Company continued to increase its R&D investment, with annual R&D investment reaching RMB 511 million, and obtained external scientific research support funds of RMB 82.26 million, making breakthrough progress in core research projects such as PCV13*i*, DTcP, and Recombinant Poliomyelitis Vaccine. Meanwhile, the DTcP-Hib-MCV4 Combined Vaccine has received a clinical trial approval notice, and the global innovative Recombinant Poliomyelitis Vaccine using the VLP technology platform has commenced Phase I/II clinical trials in Indonesia, marking an important step for the Company in the construction of multivalent vaccines and new vaccine technology platforms, laying a solid foundation for subsequent product launches.

The Company attaches great importance to the transformation and sharing of scientific research achievements, actively promoting the dissemination and exchange of innovative results in the academic community. In 2024, we published a total of 5 high-quality academic papers in international authoritative journals, covering Ad5-nCoV, PCV13*i*, PBPV, etc.

In 2024, CanSinoBIO published several important research findings in the internationally renowned medical journal *Vaccines*

Vaccination with Adenovirus Type 5 Vector-Based COVID-19 Vaccine as the Primary Series in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Clinical Trial: This study evaluated the immunogenicity and safety of the Ad5 vector-based COVID-19 vaccine in adult subjects, showing that the vaccine could induce strong humoral and cellular immune responses.

Immunogenicity, Safety, and Immune Persistence of One Dose of SARS-CoV-2 Recombinant Adenovirus Type-5 Vectored Vaccine in Children and Adolescents Aged 6–17 Years: An Immunobridging Trial: This study confirmed that CanSinoBIO's recombinant Ad5 vector vaccine has good immunogenicity and safety in the adolescent population, providing scientific evidence for the vaccine's application in teenagers.

The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in Infants: A Double-Blind, Randomized, Phase III Trial: This study evaluated the safety and immunogenicity of PCV13*i* in infants. The results showed that the vaccine can effectively induce protective antibodies, providing strong support for the prevention of pneumococcal infection.

Academic Exchange and Cooperation

CanSinoBIO emphasizes research collaboration, actively integrating advantageous resources, and closely partnering with universities and research institutions to accelerate technological innovation and promote industrial development through cooperation and exchange. In 2024, the Company reached a strategic cooperation agreement with Shanghai Asymchem Biotechnology Co., Ltd., focusing on cutting-edge technological innovation and industry market demands. The two parties will carry out innovative cooperation in the fields of plasmids, mRNA, LNP, and other biopharmaceutical macromolecules, achieving complementary advantages and jointly promoting the research and industrialization process of mRNA technology.

2024 Academic exchange highlights of CanSinoBIO

We co-hosted the Second Tsinghua Forum on Infection and Immunization, focusing on cutting-edge research and immunization strategies with over a hundred experts and scholars to promote the development of the field of infection and immunology.

We were invited to attend the 4th China Biologics CMC Conference, engaging in academic exchanges with domestic and international drug regulation agencies, experts in biologics pharmacy, and scholars from academia and industry to share advancements in biologics technology.

We published the *Progress in the Development of Global Meningococcal Polysaccharide Conjugate Vaccines*, keeping up with current events and conducting public education on the dangers of meningitis in response to the meningitis outbreak in Xining, enhancing public awareness of the hazards of meningitis.

We proactively laid out the research on the combined vaccination of Menhycia®, presenting results at the National Vaccine Conference, with related data articles winning the second prize at the *8th Academic Exchange Conference on Vaccination Issues, Strategies, and Prospects*, providing data support for domestic vaccine use.

As a representative of the biopharmaceutical industry-education alliance in the Economic-Technological Development Area, we were invited to attend the Tianjin Economic-Technological Development Area Biopharmaceutical Industry-Education Consortium Exchange Promotion Conference and participated in the signing ceremony for the Tianjin Higher Education Undergraduate Teaching Quality and Teaching Reform Research Project.

Group Photo from the Second Tsinghua Forum on Infection and Immunization

The Company is committed to building an open and shared R&D innovation ecosystem by establishing a cross-departmental academic exchange platform to promote knowledge sharing and collaborative innovation. In 2024, we continued to deepen our internal academic exchange mechanisms, conducting six high-quality academic salon events focused on cutting-edge technology areas, including topics such as “AI-Driven Intelligent Vaccine Design” and “Efficacy Evaluation of Inhaled Vaccines”, with a total participation of over a hundred people.

“Academic Salon” Activity

Intellectual Property Management

The Company has established an organizational structure centered around the Intellectual Property Management Committee to comprehensively coordinate intellectual property management work. We strictly adhere to laws and regulations such as the *Patent Law of the People's Republic of China*, the *Copyright Law of the People's Republic of China*, the *Anti-Unfair Competition Law of the People's Republic of China,* and the *Corporate Intellectual Property Management Code*, and have formulated multiple internal regulations including the *Intellectual Property Management System*, the *Intellectual Property Contingency Plan*, the *Copyright Management Regulations*, the *Trademark Management Regulations*, the *Patent Management Regulations*, and the *Technical Secrets Management Regulations*. In 2024, the Company revised the *Technical Secrets Management Procedure* to refine the management process of technical secrets and comprehensively enhance management levels.

The Company continuously improves its knowledge management capabilities and has established the IDM (Invention and Creativity Collection Management System) and standardized processes for Intellectual Property Due Diligence (IP-DD). The IDM system integrates knowledge management into project management systems, categorizing and protecting inventions and ideas. Intellectual Property Due Diligence (IP-DD) clarifies the objectives and scope of due diligence at different stages through standardized management, enhancing the awareness of intellectual property risk prevention among project managers and participants.

Based on the protection of its intellectual property, the Company conducts intellectual property research and investment due diligence for product development projects to ensure that new product development is legal and compliant, while also improving the management mechanism for innovative achievements. The Company actively carries out "Patent Navigation" to clarify key areas of R&D, provide early warnings of infringement risks, proactively avoid potential infringement actions, and formulate corresponding response strategies. In addition, the Company promotes a global Freedom to Operate (FTO) analysis project, providing customized business strategy recommendations based on patent technology to help the Company effectively reduce patent infringement risks.

CanSinoBIO has established a globally oriented intellectual property strategy system, conducting systematic patent layouts in major pharmaceutical markets such as China, the United States, Europe, and Japan. In 2024, the Company obtained a total of 8 authorized patents. Meanwhile, the Company actively promotes the international patent layout of platform technologies such as adenovirus vector vaccines, mRNA vaccines, and polysaccharide-protein conjugate vaccines, covering major pharmaceutical markets worldwide and laying a solid foundation for product internationalization.

Application and Acquisition of Patents of CanSinoBIO in 2024

	The new increased number in 2024				Cumulative number as of December 31, 2024			
	Patents applied (number)		Patents granted (number)		Patents applied (number)		Patents granted (number)	
	Domestic	Overseas	Domestic	Overseas	Domestic	Overseas	Domestic	Overseas
Invention patents	39	13	2	1	72	46	36	12
Utility model patents	1	0	2	0	1	0	17	1
Design patents	0	0	3	0	0	0	4	0
Total	40	13	7	1	73	46	57	13

The Company actively fosters an innovative atmosphere, encouraging researchers to engage in invention and creation. We provide corresponding spiritual recognition or material incentives to inventors based on their contribution level, in accordance with relevant systems such as the *Patent and Invention Creation Reward Regulations*, including the issuance of patent bonuses and trade secret rewards.

The Company emphasizes enhancing employees' awareness of intellectual property rights by providing relevant training to all employees through both online and offline formats. Online courses such as "Necessary Conditions for Patent Application Authorization" focus on the basics of intellectual property, allowing employees to arrange their learning time independently, while also setting relevant test questions to ensure learning quality. Offline, we conduct customized training for personnel in the R&D and manufacturing sectors, covering topics such as patent mining, the use of patent search systems, and patent infringement determination, and organize training on patent and literature search, as well as practical applications of patent technology navigation for all employees. In 2024, the Company introduced new prizes for patent training, rewarding employees with excellent test scores after learning, to stimulate their motivation to learn.

In 2024, the Company organized a total of **5** intellectual property training sessions

with a total of **204** participants

The Company actively participates in government intellectual property projects, leveraging its professional advantages in the field of intellectual property to engage in industry co-construction and exchange cooperation in intellectual property protection. In 2024, we attended two intellectual property conferences in the pharmaceutical industry, engaging in in-depth discussions with industry experts and peers, and learning about the latest intellectual property laws, regulations, and industry trends.

2024 Highlights in Intellectual Property Cooperation of CanSinoBIO

- Successfully passed the 2024 National Intellectual Property Advantage Enterprise acceptance review.
- Completed customs registration of nine patents.
- Recognized as a Model Enterprise for Trade Secret Protection in the Tianjin Binhai New Area Economic-Technological Development Area.
- For the upcoming launch of the component DTP vaccine product, comprehensive patent analysis and high-value patent cultivation was carried out, successfully applying for the key funding project for intellectual property in Tianjin, which was ultimately approved and received special funding for high-quality intellectual property creation.
- Participated in the construction of the intellectual property exhibition hall of the Intellectual Property Bureau in the Tianjin Binhai New Area Economic-Technological Development Area, where the Company's core products and vaccine nebulization-related equipment are displayed.

Clinical Trial Ethics

CanSinoBIO fully considers ethics and moral factors in clinical trials and animal experiments, conscientiously protects the rights and safety of clinical trial subjects, is deeply concerned about the welfare of laboratory animals takes measures to reduce the discomfort of animals, and respects ethical well-being while promoting scientific research.

Clinical Trial Ethics

CanSinoBIO adheres to strict standards in clinical trials, following international ethical guidelines such as the *World Medical Association Declaration of Helsinki*, and regulatory requirements like *Good Clinical Practice (GCP)*, and advancing work under the guidance of ethics committees to ensure trial compliance.

CanSinoBIO always places the protection of participants' rights and safety at the core of clinical trials, fully respecting participants' rights to informed consent, autonomy, and privacy, while actively preventing and properly handling any serious adverse events (SAE) that may occur during the trials. By establishing a transparent and trust-based research relationship with participants, the Company integrates the protection of participants' rights throughout the entire process of clinical trial preparation, implementation, and conclusion, ensuring the ethicality and compliance of the trials.

Before Clinical Trial

Protection of Autonomy and Right to Know

During the clinical trial process, researchers are urged to conduct thorough informed consent procedures and engage in two-way communication with clinical trial participants to ensure their autonomy.

Organizing Informed Explanation

Researchers provide participants with a comprehensive introduction to the key information about the trial, including its purpose, process, potential benefits, and risks, ensuring that participants fully understand and have the right to ask questions. Based on this, participants can independently decide whether to join the study. Infants and other minors shall be subject to the informed consent of their guardians.

To help children better understand, researchers created promotional animations. For adult participants, especially the elderly, researchers use simple and easy-to-understand language and local dialects to explain, ensuring that the informed consent process is thorough and effective.

Signing the *Form of Informed Consent*

Researchers sign the Informed Consent Form, approved by the ethics committee, with participants on a one-on-one basis. This form details the overview of a clinical trial, the purpose of trial, the steps to be followed, the obligations of human subjects, the experimental items involved in clinical trial, the risks or inconveniences that may be caused to the human subjects due to the trial, the expected benefits of trial and the possibility of no benefit, salary and treatment available in case of any damage related to the trial, the salary for human subjects, the limited confidentiality of personal data, and the principle of voluntary participation.

In accordance with GCP and relevant regulatory requirements, an age-appropriate *Form of Informed Consent* has been specially designed for child participants aged 8 and above, to respect and collect the child's wishes. If a child is under 8 at the time of enrollment but reaches 8 during the trial, they must undergo the informed consent process again and sign the age-appropriate *Form of Informed Consent*.

Assurance of Free Participation and Withdrawal Rights

We ensure that participants do not suffer any form of discrimination or retaliation when they refuse to participate or withdraw from the trial at any stage, and fully protect their medical treatment and legal rights.

During and After Clinical Trial

Protection of Human Subjects' Privacy

CanSinoBIO attaches great importance to the protection of human subject privacy, strictly complies with privacy-related laws and regulations and ethics standards, and adopts strict protection measures in the collection, storage, and utilization of human subject personal information. The Company assigns research codes to participants in the trial, uses codes instead of human subject information in trial documents, and publishes clinical trial results while maintaining the confidentiality of human subject identity information, with the aim to minimize the risk of human subject privacy leakage.

The *Form of Informed Consent* clearly states that the collected biological samples cannot be used for purposes other than those required by the protocol. If samples need to be analyzed for other purposes, informed consent from participants must be obtained again.

Control of Adverse Event

Prevention of Adverse Event

The Company ensures that researchers conduct regular follow-ups on AEs according to the trial protocol and carry out case investigations and full follow-ups on SAEs through management methods such as monitoring and auditing, while strictly adhering to legal and regulatory requirements for case recording and reporting. The internal clinical PV team of the Company closely monitors and implements an early warning mechanism to timely identify safety signals in clinical trials, collaborating with the research team to address safety risks and protect the health rights of participants.

Handling of Adverse Event

Clinical trial researchers have formulated SAE management plans, signed green channel agreements for medical treatment with local medical institutions capable of providing care, and maintained open channels. During the clinical trial, professional medical staff from the medical institutions are stationed on-site to take rapid response measures based on the actual conditions of participants, ensuring their safety and health. In 2024, the Company purchased clinical trial liability insurance for human subjects/drugs for eight clinical projects in which enrollment has been launched, providing insurance coverage for expected and unexpected adverse events for all enrolled participants.

CanSinoBIO actively builds a culture of ethical compliance in research by deeply studying the latest industry guidelines and policy documents through seminars and employee training, integrating various requirements into the clinical trial process. Meanwhile, we actively participate in external trainings and exchanges to master cutting-edge clinical ethics knowledge in the industry. In 2024, the Company continues to pay attention to newly released ethical guidelines both domestically and internationally, organizing online training on the "2024 Revision Interpretation of the *World Medical Association Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Participants*", to timely learn from expert interpretations and ensure that trials comply with the latest ethical standards.

Animal Experiment Ethics

CanSinoBIO strictly complies with the *Laboratory Animal - Environment and Housing Facilities* (GB 14925-2023) and has formulated and refined regulations such as the *Regulations for the Administration of Affairs Concerning Laboratory Animals*, the *Feed and Padding Management Regulations*, the *Management Regulations for Employee Dress Changing in Animal Quarters*, the *Standard Operating Procedures for Environmental Management of Animal Quarters*, the *Standard Operating Procedures for Goods in and out of Animal Quarters,* and the *Standard Operating Procedures for Quarantine of Laboratory Animals*, to standardize the management in terms of the purchase, acceptance, reception, use, feeding and corpse disposal of laboratory animals. In 2024, the Company revised and supplemented relevant management regulations based on the upgraded *Laboratory Animal - Environment and Housing Facilities* (GB 14925-2023) and added the *Animal Quarters Management Regulations* to comprehensively manage animal quarters in terms of personnel requirements, hygiene and epidemic prevention systems, pest control, and management of instruments and experimental materials. A new *Disinfectant Preparation and Usage Operating Procedure* was introduced, clearly specifying the types of disinfectants, applicable scopes, disinfection methods, and steps to ensure that the animal facility environment complies with regulatory requirements and that laboratory animals always live in suitable conditions.

To meet the Company's future animal testing needs, a modern animal testing center has been established to provide strong support for the pre-clinical research of innovative vaccines. The newly established animal testing center has obtained the License for the Use of Laboratory Animals, ensuring that all animal experiments are conducted under strict ethical guidelines and animal welfare standards.


实验动物使用许可证

许可证号：SYXK（津）2024－0017

单位名称：康希诺生物股份公司

法定代表人：Yu xuefeng

设施地址：天津经济技术开发区西区新桂路16号动物实验中心二、三层

适用范围：普通环境：兔
屏障环境：大鼠、小鼠、豚鼠

有效期：2024年12月13日至2029年12月12日

天津市科学技术局
2024年12月13日

License for the Use of Laboratory Animals

To ensure the scientific and ethical integrity of experiments, the Company has established an Animal Experiment Ethics Committee responsible for reviewing the *Laboratory Animal Welfare and Ethics Review Application*, ensuring that experimenters adhere to welfare and ethical principles and that animal experiments can only commence after project approval. Meanwhile, the Company actively accepts external supervision, conducting annual inspections of animal quarters to ensure that the environment and equipment meet standards, thereby safeguarding animal welfare and ethical compliance.

We place great importance on promoting awareness of animal protection, enhancing employees' understanding and emphasis on animal welfare through various means. In 2024, the Company conducted animal ethics training through a combination of online and offline methods. The training content covers the "3R principles", the *Laboratory Animal - Environment and Housing Facilities* (GB 14925-2023), and the *Laboratory Animal - Guideline for Ethical Review of Animal Welfare* (GB/T 35892-2018). The training targets include contract employees, cleaning staff, and suppliers, achieving a training coverage rate of 100%. Meanwhile, we have built a "Laboratory Animal Memorial" next to the newly constructed animal research center, and we plan to hold a memorial service and offer flowers to laboratory animals every year on April 24th, World Day for Laboratory Animals, to enhance employees' awareness of animal welfare protection.

CanSinoBIO's Animal Welfare Measures in 2024

Animal welfare optimization

- We continuously improved experimental protocols, strictly implemented the "3R" principle (reduction, optimization, and substitution), and significantly reduced the use of experimental animals by increasing pre-experimental tests and developing alternative methods;

Improvement of the feeding environment

- A new modern animal experiment center was built, the feeding area was increased by 2,000 square meters, the feeding density per unit area was reduced, a new ventilation system and low-density feeding mode were adopted, and cage equipment was updated to comprehensively improve the quality of the animal living environment;

Environmental monitoring upgrade

- We appointed dedicated personnel for the management of the environmental monitoring system (EMS), optimized the alarm handling process, and ensured that experimental animals were always in the best living environment.

Customer Service and Pharmacovigilance

CanSinoBIO always puts customer needs first and establishes comprehensive systems for customer communication and services. The Company listens to customer feedback through diverse channels, such as a hotline, online service platform, regular customer follow-ups, and survey questionnaires, to ensure rapid response to problems like suspected abnormal reactions to vaccination.

Service Assurance

CanSinoBIO has established efficient and smooth communication channels to actively listen to feedback and inquiries from vaccine recipients, their families, and healthcare professionals. The Company has established a professional customer service team to efficiently respond to and quickly resolve customer issues, as part of the efforts to provide an exceptional service experience to clients. CanSinoBIO also constantly optimizes products based on customer feedback and market conditions to improve product quality and competitiveness. In 2024, to further enhance customer service quality, the Company set a goal to increase the Net Promoter Score (NPS) for phone customer service and WeChat official account customer service to 50% and 35%, respectively, to strengthen customer trust and loyalty.

CanSinoBIO's Customer Communication Channels

CanSinoBIO's hotline for vaccine products and services: 400-922-2099

- We analyzed caller identity and inquiry topics, revealing that 39% of calls came from family members of potential vaccine recipients and 38% were product-related inquiries. This reflects public concern about vaccination and product quality, guiding customer service optimization.
- During the Reporting Period, the hotline received 1,511 calls in total, with a 99.40% response rate and a 100% completion rate.

Email for reporting adverse reactions: cansinoPV@cansinotech.com

- CanSinoBIO comprehensively monitors information about adverse reactions from diverse channels and promptly issues warnings to ensure vaccine safety effectively. In 2024, the email received 64 adverse reaction reports submitted by vaccine recipients and other healthcare professionals.

WeChat Official Account

- In 2024, the account received a total of 1,225 interactions, with a 99.10% response rate within 15 minutes, and a 100% overall resolution rate. This ensures service integrity and continuous improvement in customer satisfaction.

To improve service quality, CanSinoBIO standardizes the handling process of complaints for all products according to the *Management Procedures for Complaints of Marketed Products* to ensure efficient solutions. Additionally, the Company strictly controls access to customer information to prevent information leakage.

CanSinoBIO's Customer Complaint Handling Process

1. Receive customer complaints
2. Provide feedback to the Distribution Quality Department within 24 hours, and the Distribution Quality Department will take urgent response measures within 24 hours upon any complaint.
   - The Quality Assurance Department organizes investigation teams to determine whether a complaint event is valid, and the type and level of substantiated complaints.
3. Organize relevant departments to conduct investigations and follow up with corrective actions based on the investigation results.
4. The Distribution Quality Department monitors the investigation progress and communicates the findings back to the customer.
5. Resolve complaints within 30 natural days.

In 2024, all complaints from the customers were effectively settled, with a complaint closing rate of **100%** for several consecutive years.

CanSinoBIO's AEFI Handling Process

Data collection

- Collect information on AEFI from different sources and preliminarily analyze and process them.

Incidents evaluation

- Type data in the safety database, and evaluate the anticipation, severity, and relevance of the incident

Follow-up investigation

- Further follow-up or investigation of incidents required by the Company

Incident reporting

- Send the reports of eligible suspected adverse events following immunization to the county-level center for disease control and prevention where the AEFI[12] takes place within the time limit as provided for by laws and rules.

Subsequent handling

- We review product safety information regularly, and conduct signal detection and validation. For validated signals, we carry out signal assessments, hold signal evaluation meetings, and make decisions based on these evaluations. This helps us identify potential safety risks promptly and implement risk minimization measures to ensure a balance between risks and benefits.
- We handle the cases demanding claims, such as obtaining investigation and diagnosis reports, organizing internal medical assessments, supporting medical appraisal and insurance compensation, and providing compensation according to laws and rules.

[12] Adverse Event Following Immunization.

CanSinoBIO consistently prioritizes the protection of vaccine recipients' rights and interests and has purchased compensation insurance for adverse events following immunization of all vaccines marketed as required in the *Vaccine Administration Law of the People's Republic of China*. In 2024, the Company has optimized *the Compensation Process for Abnormal Reactions to Vaccination* by collecting, handling, and reporting cases and providing insurance and humanitarian compensation according to the *Collecting Process for Suspected Abnormal Reactions to Vaccination,* the *Handling Process for Suspected Abnormal Reactions to Vaccination, the Measures for Compensation for Adverse Event Following Immunization* and relevant regulations from local compensation measures. For an emergency case, the Company promptly assists the government departments and units in properly treating the patients and their families.

CanSinoBIO's AEFI Compensation Procedure

Adverse reactions occur after the recipients are vaccinated

Report the reactions to the vaccination area or disease control center.

Investigation and diagnosis expert group of disease control organization conclude the evaluation.

The Company accepts the conclusion from the investigation and diagnosis and provides corresponding compensation to the recipients through the insurance company.

Pharmacovigilance

CanSinoBIO complies with national laws and regulations such as the *Law of the People's Republic of China on Pharmaceutical Administration,* the *Law of the People's Republic of China on Vaccine Administration,* the *Administrative Measures for the Reporting and Monitoring of Adverse Drug Reactions*, the *Pharmacovigilance Quality Management Regulation*, and local guidelines such as the *Pharmacovigilance Quality Management Guidelines for Pharmaceutical Marketing Authorization Holders in the Beijing-Tianjin-Hebei Region (Trial)*. The Company constantly optimizes the pharmacovigilance management system by developing and improving internal system documents such as the *Constitution of the Drug Safety Committee,* the *Safety Signal Management Process,* the *Pharmacovigilance Management System,* the *Regulation for Pharmacovigilance Management during Clinical Trials*, and the *Major Safety Incidents Handling Procedures*. Through these documents, we have established a full lifecycle pharmacovigilance management and quality management system covering the non-clinical stage, clinical stage, and post-marketing stage, ensuring standardized and systematic pharmacovigilance efforts and vaccine recipients' safety.

CanSinoBIO's Pharmacovigilance Management System

Organizational Structure

A Drug Safety Committee with clearly defined responsibilities has been established to handle major pharmacovigilance-related issues. The committee is composed of the legal representative, the head of pharmacovigilance, and heads of the pharmacovigilance department and other business departments. The committee operates under the *Constitution of the Drug Safety Committee* to ensure the scientific and timely handling of major incidents. A regular meeting is held every six months to conduct targeted discussions based on the nature of the incident to ensure the prevention and control of safety incidents. In 2024, CanSinoBIO's Drug Safety Committee held a total of three meetings, two of which were regular meetings regarding work summaries and action plans, and the other one was temporary meeting for handling emergencies.

Quality Objectives

We have established six quality objectives for pharmacovigilance to standardize the operational process of pharmacovigilance work, provide guidance for pharmacovigilance work, and help improve the efficiency of pharmacovigilance management.

Pharmacovigilance System

We have installed a global pharmacovigilance system - Deep-PV - covering all data sources, to conduct real-time monitoring of data, ensure efficient collection, evaluation, and reporting of drug safety information, integrate refined management into the whole process of pharmacovigilance work, help promptly understand the medication and control potential risks. Beyond that, we take advanced measures to protect the privacy and sensitive information in the pharmacovigilance system and apply such means as access control, permission assignment, audit trail, authorization changes, and e-signatures to ensure data security in a scientific and effective way.

Safety Signal Management

We have developed a signal management strategy based on product safety characteristics and in accordance with regulations to accurately guide the signal detection process. In 2024, we conducted 13 signal detections for products such as Convidecia®/Convidecia® Air®, Menphecia®, Menhycia®, and Ad5-EBOV, with no signals identified.

Data Exchange

The relevant internal departments and partners regularly share safety data with the pharmacovigilance department to ensure consistent management of the data and a unified understanding of the product's safety.

The Company conducts pharmacovigilance-related internal audits and external inspections to identify and rectify potential risks and vulnerabilities and ensure the compliance and efficient operation of the pharmacovigilance system. In 2024, CanSinoBIO conducted an internal audit of its pharmacovigilance system and accepted special inspections from the Tianjin Medical Products Administration. Both inspections met the required standards, and all identified issues have been rectified. Additionally, the Company conducted an audit of the pharmacovigilance data system suppliers, with the audit results confirming compliance. The suppliers have completed all rectification works, ensuring the safety and compliance of the Company's product safety data storage and usage.

CanSinoBIO actively conducts internal and external pharmacovigilance training sessions and exchanges throughout the product lifecycle to enhance its pharmacovigilance capabilities as well as those of partners.

Highlights of CanSinoBIO's Pharmacovigilance Training Sessions and Exchanges in 2024

- We utilized the E-Learning training system to launch courses, ensuring all employees complete online training on the fundamentals of pharmacovigilance.
- We delivered targeted pharmacovigilance training for new sales employees during onboarding, both online and offline, incorporating quizzes to assess training effectiveness.
- We organized specialized internal training on pharmacovigilance and participated in external pharmacovigilance training organized by NMPA, institutes for advanced study and industry organizations, industry organizations, and regulatory bodies. Topics covered included risk management, pharmacovigilance compliance and quality, and pharmacovigilance for international markets.
- The Company has partnered with PATH[13]. Through this collaboration, PATH has provided multiple overseas pharmacovigilance training sessions covering topics such as handling individual safety reports, signal detection, internal audits, external inspections, and pharmacovigilance agreements, thereby laying a solid foundation for establishing an internationally standardized pharmacovigilance system for the Company.
- We participated in NMPA's "Overseas Serious Suspected Adverse Events Following Immunization Management Research Project," offering professional insights on the project rationale and proposal development.
- As a corporate representative, the Company took part in the Annual Meeting on Medical Appraisal of the Tianjin Medical Association, where a dedicated session on "How to Assess Vaccine AEFI" was presented at the main venue.
- As a corporate representative, the Company attended the inauguration of the Tianjin Pharmacovigilance Center, actively contributing to the capacity building and enhancement of the industry's pharmacovigilance system.
- We signed multiple pharmacovigilance agreements with overseas partners in compliance with both Chinese and local laws and regulations. These agreements cover individual case reports, periodic safety update reports, risk management plans, and more. Through extensive communication on the agreement details, we have strengthened partners' pharmacovigilance capabilities and jointly ensured the safety and accessibility of products.

[13] PATH, an international nonprofit organization founded in 1979 dedicated to improving global health through innovation, especially in developing countries. Since the 1980s, PATH has operated projects in China to promote the international standardization of pharmaceutical technologies and products.

Responsible Marketing

CanSinoBIO practices responsible marketing by complying with all applicable laws, regulations, and industry standards in the areas where it operates, ensuring the compliance of all marketing activities and safeguarding the sustainability of the business ecosystem. The Company strictly complies with the *Drug Administration Law of the People's Republic of China*, the *Vaccine Administration Law of the People's Republic of China*, the *Advertising Law of the People's Republic of China*, and other laws and regulations, and improved the *Compliance Operation Standard Manual* and the *Responsible Commercial Statement* and other management systems to regulate and guide the Company's marketing and communication activities. In 2024, CanSinoBIO had no lawsuits related to claims of false marketing.

We have established a comprehensive marketing compliance management framework that fully covers marketing management for both domestic and overseas operations. The Company has set up a Commercial Operations Center Management Committee (the "COC Management Committee"), led by the Chief Commercial Officer as the highest responsible person. The COC Management Committee is responsible for formulating and supervising the implementation of responsible marketing strategies, reviewing marketing audit reports, and regularly reporting on marketing activities to the Board of Directors. In addition, we have established a marketing compliance control system that spans the entire process of "pre-control - in-process monitoring - post-event supervision and inspection" to effectively avoid potential marketing risk events.

Marketing Compliance Control System

Pre-control

- Establish comprehensive marketing compliance standards and compliance systems.
- Regularly conduct marketing compliance risk assessments.
- Provide systematic marketing compliance training.

In-process monitoring

- Carry out marketing compliance performance management.
- Promote close cooperation among all departments and form a joint marketing management mechanism.

Post-event supervision and inspection

- Conduct an internal audit of commercial marketing covering the whole Company every year, including content output audit and audit of daily sales code of conduct.
- Supervise and check the compliance of marketing activities and the effectiveness of risk control.

We actively promote responsible marketing through e-learning platforms, providing training on responsible marketing policies to employees. Meanwhile, we complete product knowledge and sales skills training for marketing team employees and external partners through the "Kangmiaoyou+" UMU online learning platform. In 2024, we conducted one compliance marketing training session. There were 282 participants, with a total of 1 training hour and a 99% employee coverage rate.

In 2024, we conducted **1** compliance marketing training session

There were **282** participants

with a total of **1** training hour

a **99%** employee coverage rate

Medical Health Accessibility

As an innovative vaccine company based in China and serving the global market, CanSinoBIO is committed to building a community of shared health for humanity. We have established a global collaboration network covering R&D, production, and supply by deepening strategic cooperation with international organizations, governments, and industry partners, enhancing vaccine accessibility, and promoting the global sharing of the Company's innovative achievements.

Strategy and Commitment

CanSinoBIO is dedicated to promoting global health equity by enhancing vaccine accessibility through innovative cooperation models. In response to the product and technology needs of developing countries and low-income regions, we have established differentiated market strategies and collaborated with local companies in emerging markets such as Southeast Asia, the Middle East, and Latin America to promote localized R&D and production through training, exchanges, and capacity building, thereby enhancing local vaccine supply capabilities.

CanSinoBIO is committed to:

- Supporting the *Doha Declaration on the TRIPS Agreement and Public Health*.
- Adhering to international and domestic fair pricing strategies, and pricing our products reasonably based on pharmaco-economics and the actual purchasing power of customers, referring to the pricing mechanisms of similar products at home and abroad, and setting reasonable prices for products to ensure that product prices in countries with different income levels align with local realities.

CanSinoBIO has established a Scientific Advisory Board composed of authoritative experts from various fields such as public health and infectious diseases, which regularly conducts in-depth discussions on topics such as product R&D, pharmaceutical accessibility, industrialization, and industry trends, providing professional advice.

Accessible Product and Technology

CanSinoBIO actively engages in communication and cooperation with governments and local enterprises in developing countries, accelerating the output of its knowledge and experience through efficient technology transfer methods, and contributing to the widespread promotion and application of advanced and reliable R&D and production technologies in developing countries, thereby contributing Chinese strength to global public health.

In 2024, CanSinoBIO

- Jointly advanced the R&D of a multivalent mRNA influenza vaccine with the NIBM, contributing to global influenza prevention and control;
- Signed a cooperation agreement in the field of biomedicine with the Etana, focusing on the cutting-edge R&D of inhalable tuberculosis vaccines to further strengthen collaborative efforts;
- Received over USD 17 million in funding from the Bill and Melinda Gates Foundation for the recombinant poliomyelitis vaccine project.

Capacity Building in Developing Countries

The Company assists developing countries in establishing efficient and transparent pharmaceutical supply systems. In recent years, the Company has actively expanded in Southeast Asia, the Middle East, and Latin America, establishing an efficient and stable pharmaceutical distribution network to ensure a stable supply of raw materials and products in resource-scarce and underserved areas. In 2024, the Company further optimized risk control in the transportation process and completed the verification of international transportation routes to Morocco and Mexico based on business needs. Meanwhile, the Company has established a GS1 traceability system that meets international standards and achieved full-process traceability of product information through advanced packaging coding technology.

To enhance the healthcare level in developing countries, the Company conducted systematic professional training for partners in several developing countries, including Malaysia, covering various fields such as laws and regulations, clinical trials, drug safety monitoring, and product knowledge, effectively improving local public health service capabilities.

03 Value Creation

Putting People First and Fulfilling Social Responsibility

CanSinoBIO values talent development and consistently provides employees with competitive salaries and benefits, creating an inclusive and safe work environment to help employees achieve personal value and career growth. In addition, the Company actively engages in community building, focusing on social and livelihood issues, and contributes to the construction of a harmonious society through practical actions.

Relevant Public Policies in this Chapter

Employee Rights and Interests Protection Statement

Employee Employment and Rights and Interests

CanSinoBIO ensures compliant employment and provides employees with an equal, inclusive, and diverse workplace environment, guaranteeing that every employee has the opportunity for development under fair and just conditions.

Employee Rights and Rights Protection

CanSinoBIO adheres to the *Labor Law of the People's Republic of China*, the *Labor Contract Law of the People's Republic of China*, the *Provisions on Prohibition of Child Labor*, and other laws and regulations, as well as the *Ten Principles of the United Nations Global Compact* and relevant international human rights conventions and labor standards. The Company has established regulations such as the *Employee Handbook,* the *Statement of Employee Rights and Interests*, and the *Attendance, Overtime, and Leave Management System*, which stipulate against forced labor and child labor, discrimination, and harassment, thereby protecting the legal rights of applicants and employees.

Our Commitments

- Respect and uphold all employee rights
- Never participate in any acts that disregard or violate human rights
- Eliminate any discrimination in employment and occupation, and uphold equal pay for equal work
- Avoid all forms of forced labor and child labor
- Prohibit workplace harassment
- Defend employees' freedom of association and ensure the right to collective bargaining
- Ensure employees' occupational health and safety

Encourage suppliers and all business partners to jointly adhere to the above commitments.

The Company continuously strengthens the supervision of recruitment and employment processes, integrating the principles of equality and non-discrimination into hiring, promotion, and termination practices, opposing any form of forced labor and employment discrimination, and insisting on providing inclusive and fair employment opportunities for employees of different nationalities, races, places of birth, genders, sexual orientations, economic statuses, political beliefs, or religious beliefs. During the reporting period, there were no incidents of child labor, forced labor, employee discrimination, or harassment at CanSinoBIO.

Child Labor and Forced Labor Prohibition Measures

Before hiring

The Company requires candidates to meet the legal working age and corresponding educational and experience requirements in the recruitment information.

After hiring

With the candidate's consent, a third party is commissioned to conduct a background check to ensure the information is accurate.

After induction

Upon joining, new employees must submit accurate information and documents, and sign a declaration of authenticity, and the human resources department will re-verify key information.

CanSinoBIO has established a reporting process and channels for discrimination and harassment, requiring all employees to immediately report any illegal or irregular activities such as child labor, forced labor, discrimination, or harassment to the Human Resources Department or their direct supervisor upon discovery. We solemnly promise to take every employee's complaint seriously, promptly initiate a special investigation procedure, ensure that the investigation process is fair and transparent, and strictly keep the relevant complaint information confidential to protect the rights of the complainants.

In 2024, we were awarded the "Aon's 2024 China Best ESG Employer" by the Aon Group for three consecutive years, reflecting the high recognition of the Company's human resource management from the outside world. In addition, CanSinoBIO's HR team has also won the "Best Practices in Human Resource Management" awarded by HRA for their outstanding performance.

Aon's 2024 China Best ESG Employer

As of the end of the reporting period, CanSinoBIO had a total of **1,105** employees, with **91** new hires within the year. The number of female managers reached **90**, accounting for **45.23%**, showing a gender-balanced workforce within the Company. Nearly **77.83%** of employees hold a bachelor's degree or above, while more than **23.71%** of employees hold a master's degree or above. In 2024, our Company's overall employee turnover rate was **10.45%**, with a voluntary turnover rate of **7.53%**.

CanSinoBIO's Employment in 2024

Number of Employees
1,105 persons

Number of new salaried employee(s) this year (including those who joined and left)
91 persons

Labor Contract Signing Rate
100%

By gender

By age

By employment type

Female management

By job type



- Senior management - female employees
- Middle management - female employees
- Production personnel
- Sales personnel
- Management personnel
- R&D personnel
- Quality personnel
- Financial personnel

By education background

Doctoral students and above	21 persons	1.90%
Master's Degree	241 persons	21.81%
Bachelor's Degree	598 persons	54.12%
Associate Degree and Below	245 persons	22.17%

By ethnic group

Han	1,049 persons	94.93%
Chinese minority	46 persons	4.16%
Foreign employees	10 persons	0.90%

By nationality

Chinese (including Hong Kong, Macao, and Taiwan)	1,095 persons	99.10%
Overseas	10 persons	0.90%

Turnover[14] 90 persons

Turnover rate[14] 7.53%

By gender

Male 49 persons 8.36%

Female 41 persons 6.73%

By age

Below 30
29 persons 11.84%

30 (inclusive) - 50 (exclusive)
60 persons 6.44%

50 and above
1 persons 5.26%

By employment type

Junior employees
77 persons 7.83%

Middle managers
11 persons 5.70%

Senior managers
2 persons 10.53%

[14] The statistical calibre of employee turnover and turnover rate only includes employees that left the Company voluntarily.

Diversity and Inclusion

CanSinoBIO firmly believes that diversity is the cornerstone of sustainable employee development. We are committed to creating a diverse and harmonious workplace environment for our employees while providing ample humanistic care to support each employee's self-growth and development in an inclusive atmosphere.

We uphold the concept of gender equality, creating equal career development opportunities for male and female employees, and fully support female employees in realizing their potential and enhancing their value on the Company platform. On International Women's Day, we provide welfare packages for female employees and offer comprehensive maternity protection and benefits, including maternity leave, parental leave, and maternity insurance. Additionally, we have set up three nursing rooms to provide convenience for female employees during pregnancy and breastfeeding. In 2024, CanSinoBIO had a total of 568 female employees, accounting for 51.40% of the workforce.

Nursing Room Provided for Female Employees

Supporting the Employment and Development of Local People with Disabilities

CanSinoBIO actively responds to the *Three-Year Action Plan for Supporting Employment of People with Disabilities (2022-2024)* and consistently provides job opportunities for people with disabilities. In 2024, the Company provided employment opportunities in public service positions for a total of 14 people with disabilities, helping them achieve successful employment and realize their self-worth.

Democratic Management

CanSinoBIO actively promotes the construction of trade unions to effectively implement democratic management. The Company holds employee representative meetings on time to communicate various systems and policies related to the Company, listen to the opinions and suggestions of employee representatives, and fully respect employees' rights to know and vote. In 2024, the Company held a total of 10 employee representative meetings and completed the election process, adding 2 vice presidents and 7 union committee members. Among the new trade union members, the trade union committee consists of 15 people, including 8 female members.

CanSinoBIO Held Employee Representative Meeting

In November 2024, the Company held an employee representative meeting. At the meeting, the union committee discussed and voted on matters related to the "Human Resources Department System Update". After the meeting, the union engaged in efficient communication and negotiation with the Company's management to ensure that employees' opinions and demands were fully valued and considered.

Employee Remuneration and Benefits

CanSinoBIO values the contributions of every employee and strives to enhance their sense of happiness and belonging. We build a comprehensive remuneration incentive system, offer a variety of remuneration and benefits programs, establish multi-channel communication mechanisms, and conduct diverse union activities to create a harmonious and caring work environment.

Remuneration Incentives and Performance Management

CanSinoBIO continuously improves its remuneration incentive system and performance evaluation mechanisms, adopting a combination of short-term and long-term incentive models to fully stimulate employees' work enthusiasm and support the joint development of the Company and its employees. In 2024, CanSinoBIO officially implemented a performance-oriented comprehensive remuneration model system. We provide employees with more competitive salaries, a rich variety of benefits, challenging career development paths, and personalized learning and development opportunities to motivate employees to improve their performance and promote the Company's sustainable development.

In addition, the Company sorted out and standardized all allowances and benefits to enhance the competitiveness and fairness of remuneration and benefits. As of the end of 2024, the coverage rate of employee incentives was 14.57%.

As of the end of 2024, the coverage rate of employee incentives was

14.57%

Key Work of CanSinoBIO's Subsidies

Management Regulations for Domestic Remote Work Dispatch

- Refine division of responsibilities
- Update welfare programs
- Optimize approval processes

Management Regulations for Overseas Hardship Subsidies

- Establish subsidy standards for overseas hardship projects

Other Subsidies

- Sort out and standardize applicable groups for communication subsidies, transportation subsidies, position subsidies, etc.
- Adjust historical discrepancies with standards

In 2024, the Company comprehensively upgraded its employee performance evaluation methods, closely linking them with corporate culture, values, and compliance safety. The Company established an independent scoring and evaluation mechanism, separating the assessment of work goal achievement from behavioral performance. The evaluation scoring system has also been optimized, and a three-point scale, a nine-grid method, and five levels of evaluation were adopted.

Employee Care

CanSinoBIO has built a comprehensive benefits system, providing various welfare programs for all employees. The Company complies with the legal requirements of China or region where it operates, ensuring full payment of pension, medical, unemployment, work injury, maternity insurance, and housing provident fund for all employees, fully protecting their legal rights. In 2024, the total amount allocated for employee benefits and supplementary bonuses was RMB 74.32 million.

In terms of employee physical and mental health, the Company offers customizable health check-up packages for employees and their families. Employees can customize personalized health check-up packages based on their annual points. During the reporting period, the coverage rate for employee health check-ups was 100%. In addition, the commercial insurance provided by the Company has a coverage level higher than the market average, encompassing comprehensive protection projects such as medical, personal, critical illness, and accident insurance. Meanwhile, the Company also provides medical insurance for employees' children, allocates high-end medical insurance for executives, offers overseas travel insurance for employees on business trips, and provides optional million-dollar medical insurance services for employees and their families.

The Company has established a flexible benefits platform themed "Health Care", allowing employees to choose benefits that suit their personal needs and preferences flexibly. In 2024, the flexible benefits platform was upgraded again. The selected products include optional insurance coverage for employees and more healthcare products, which continuously improved employee satisfaction with benefits.

We organize various employee activities, including family day events, trade union Dragon Boat Festival activities, and the first "Who Will Be the Best" badminton match, allowing every employee to feel the Company's cultural care. During the reporting period, we held a total of 12 employee activities.

During the reporting period, the coverage rate for employee health check-ups was

100%

During the reporting period, we held a total of

12 employee activities

The First Employee Badminton Match

In 2024, to strengthen communication and interaction among employees, the Company held the first badminton match, with nearly a hundred employees participating. During the match, employees formed multiple strong teams to compete. The competition featured various formats to ensure that every participant could enjoy the fun of the game. After intense competition, this competition has successfully concluded, injecting new vitality into the Company's corporate culture building.

CanSinoBIO's First Badminton Match

Employee Communication

CanSinoBIO values communication and interaction with employees. We actively establish efficient and diverse communication mechanisms, listen to employees' voices, and understand their demands. By responding to their concerns and conducting regular internal evaluations, we implement targeted improvement measures to enhance employee engagement and satisfaction.

CanSinoBIO's Employee Communication Initiatives

Values Workshop

- Over 100 opinions from employees at all levels were collected through the values workshop. The main areas covered include team integration and collaboration, efficiency improvement, leadership, and employee development needs.
- In response to the collected feedback regarding leadership in management, the Company management (representatives) provided answers or announced relevant action plans during the workshop.
- For efficiency improvement, team integration and collaboration, and employee development needs, the Human Resources Department collected and organized the information uniformly and arranged subsequent action plans, such as initiating relevant team workshops and training.

HR Assistant

- We provide employees with efficient and convenient comprehensive answers to human resources inquiries, breaking through the time limitations of traditional manual services, and allowing employees to access the information they need at any time.
- In 2024, 3,195 questions were answered on average per month, ensuring timely responses to employee inquiries and needs.

HR Business Partner (HRBP)

- Each business unit within the Company is equipped with a corresponding HRBP, allowing employees to communicate directly with the HRBP of their segment whenever they encounter workplace issues.

According to the *Employee Handbook*, CanSinoBIO has established an employee complaint mechanism. When employees face infringement of rights or unfair treatment, they have the right to file a complaint. During this process, relevant management personnel will intervene promptly to verify employee rights and provide necessary support and assistance. Employees can submit written materials through the Company's designated complaint channels, detailing the events and their expected resolution, along with relevant evidence. Upon receiving the complaint, the Company will organize a dedicated management team to investigate and handle the matter, ensuring that the results are promptly communicated to the employee while properly preserving relevant documentation. Throughout the complaint process, the Company strictly maintains confidentiality of all information to effectively protect the legal rights of employees.

The Company encourages employees to properly file complaints by submitting a written complaint via voice@cansinotech.com, describing the unfair treatment and the expected resolutions with relevant supporting materials and witness information (including names and contact details). The HR Department promptly handles complaints together with the supervisor of the informant, feeds back the results, and keeps them filed.

Employee Training and Development

Talent cultivation and development are the foundation of the Company's steady growth. We carefully formulate diverse talent acquisition strategies, establish clear promotion paths, and create a comprehensive training system to fully support employee growth.

Talent Attraction and Retention

The Company places great importance on the construction of a talent pipeline and has carefully developed a talent development strategy internally. In 2024, the Company continued to organize the "Leadership Program" to seek and match suitable talent development solutions, collaborating with business departments to tailor training plans based on the actual situation of employees. During the implementation process, we will regularly track relevant data and reimburse corresponding training expenses based on evaluation results, thereby supervising and motivating employees to actively engage in learning and ensuring effective learning outcomes. In 2024, we provided funding and other support for employees participating in English courses, pursuing an MBA, and enrolling in on-the-job doctoral programs.

Meanwhile, the Company actively supports employees in applying for professional titles and honors. In 2024, we helped 23 employees in applying for professional titles, including 9 for associate senior titles, 6 for intermediate titles, and 8 for assistant titles. Currently, 11 individuals have obtained certificates, including 5 for associate senior titles, 5 for intermediate titles, and 1 for an assistant title.

Promotion Channels

To promote talent mobility, the Company has established a comprehensive promotion system that matches suitable career development paths for different types of employees. Based on fair competition, we provide promotion and development opportunities for outstanding talents at all levels. The Company builds two career development paths: the "Professional Channel" and the "Management Channel", providing employees with equal and suitable growth opportunities based on their strengths. The "Professional Channel" focuses on cultivating expert talents with excellent professional skills, while the "Management Channel" is dedicated to nurturing management talents with leadership qualities.

Professional Development Channel at CanSinoBIO



To optimize talent development and position management, the Company has implemented multiple measures. In terms of management levels, the organizational structure has been streamlined to no more than four levels, clarifying the requirements for management positions and functions, and optimizing the organizational structure and processes for promotion assessments. In terms of position management, a clear job level system has been established through the Job Description (JD) project, redefining job concepts to ensure consistency across various departmental job level systems, and facilitating personnel mobility and allocation. Currently, the JD project has been fully completed, covering communication between all employees and the signing of optimized job descriptions, providing strong support for the Company's future talent development and management.

Talent Cultivation

CanSinoBIO values the training and career development of its employees, relying on the *Training Management System* to standardize employee training planning, implementation processes, and evaluation of training effectiveness. In 2024, the Company updated 20 online general skills training courses, aligning the curriculum with its values and gradually opening them to all employees. For different employee groups, the Company carefully sets up mandatory and elective courses, enhancing employees' general skills while stimulating their enthusiasm for self-directed learning through flexible and diverse course operation methods, thereby accurately identifying high-potential employees and uncovering new employee needs.

To build a learning-oriented organizational culture, the Company utilizes internal communication channels to compile the essence of training content into graphic materials, sharing them periodically with all employees to stimulate interest in learning and increase course participation. In addition, the Company holds an annual "Top Learner" selection and reward event aimed at identifying proactive learners within the organization, establishing benchmarks, and expanding influence. During the reporting period, CanSinoBIO invested RMB 4.1 million in employee training, with an average training duration of 37.8 hours per employee and a training coverage rate of 100%.

During the reporting period, an average training duration of

37.8 hours per employee

a training coverage rate of

100%

CanSinoBIO's Employee Training System

General Skills Training

- In 2024, the general skills training program covered 1,087 people, with 874 participants, resulting in a participation rate of 80.4%.
- By organizing and selecting quality notes from the course discussion area, 37 "Top Learners" were recognized and awarded for the year.

First-Line Manager Growth Bootcamp

- To enhance the basic leadership skills of first-line managers and improve the management awareness of primary managers. Starting in 2023, the Company launched the first-line Manager Growth Camp talent development project. In 2024, a total of four courses were offered, covering topics such as "Performance Management and Employee Motivation", "Problem Solving", and "Mindfulness Effectiveness". The number of training sessions reached 115, with a total learning duration of 588 hours.

Leadership Program Phase I

- In 2024, the Company provided strong support for the talent development plan for participants in Leadership Program Phase I, launching an executive coaching program to provide one-on-one coaching for 4 senior managers, comprehensively enhancing their leadership and personal management skills.

Customized Training for Business Departments

- To meet the training needs of the business, the Human Resources Department has tailored courses for the business units. In 2024, the Human Resources Department collaborated with the Engineering Service Center to successfully design and implement the "Efficient Meetings" workshop. During the workshop, team members actively participated and jointly developed the department's "Meeting Charter". This process not only enhanced the team's learning effectiveness but also promoted mutual understanding and team integration among members.

"First-Line Manager Growth Bootcamp" Training

In 2024, the Company continued to carry out the "First-Line Manager Growth Bootcamp" training program, helping all first-line managers achieve comprehensive improvement in self-management, work promotion, and team collaboration. The training utilized diverse methods such as theoretical learning, case discussions, and role-playing, allowing participants to systematically learn core content such as scientific management of time and tasks, effective communication and team motivation, and the correct establishment of work decisions. This training not only promotes the leadership development of each manager but also becomes the core driving force for facilitating efficient team operations and healthy growth.

"First-Line Manager Growth Bootcamp" Training Program

General Skills Training and Top Learner Selection Activity

In 2024, the Company launched an online general skills training program for all employees. The content of this training course was updated based on the results of employee needs surveys to better meet their learning requirements. To stimulate employees' interest in learning and increase course participation, we compiled the highlights of the training content into graphic materials and shared them with all employees periodically. In addition, the Company held an annual "Top Learner" selection and reward event, aimed at recognizing proactive learners within the organization, setting learning benchmarks, and further expanding the influence of training and learning.

General Skills Training Site

Customized Training Course - "Effective Meetings" Workshop

To meet the actual needs of the business departments, we collaboratively designed and developed the "Effective Meetings" workshop based on the pain points of each department. This course is specifically tailored for the business departments to ensure that the training content is more targeted and effectively helps employees solve real business problems. Meanwhile, this training opportunity has enhanced mutual understanding among team members and promoted team integration.

The "Effective Meetings" Workshop

Average training hours per employee **37.8** hours

Average training hours by employment type

Middle and senior managers

33.92 hours

Junior employees

38.65 hours

Percentage of employees trained by employment type

Senior managers **1.54%**

Middle managers **16.47%**

Junior managers **81.99%**

Average training hours by gender

Male employees

39.19 hours

Female employees

36.48 hours

Percentage of employees trained by gender

Male employees **48.60%**

Female employees **51.40%**

Occupational Health and Safety

CanSinoBIO places great importance on the health and safety of its employees. We establish a comprehensive safety management system, strictly control the safety behavior of contractors, and regularly conduct safety culture activities to create a safe and healthy working environment.

Occupational Health and Safety Management

CanSinoBIO strictly adheres to laws and regulations such as the *Law of the People's Republic of China on Work Safety* and the *Law of the People's Republic of China on the Prevention and Control of Occupational Diseases*, continuously revising and implementing internal management systems including the *CanSinoBIO Occupational Health Management System*, *Worker Protection Materials Management System*, *Targets and Responsibility Management System*, *EHS Rewards and Punishment System*, *Safety Management System of Special Equipment*, and *Hazardous Chemical Safety Management System*. Meanwhile, the Company has established a comprehensive occupational health and safety management system based on the *Guidelines on Occupational Safety and Health Management Systems* proposed by the International Labour Organization and the ISO 45001 Occupational Health and Safety Management System standard. During the reporting period, CanSinoBIO did not receive any administrative punishment related to occupational health and safety.

To ensure the efficient operation of the EHS system, the Company has set clear safety goals and assessment mechanisms and has fully achieved the established goals. In 2024, we completed the preparation and organization of safety responsibility agreements for all positions, achieving a signing rate of 100%. The annual departmental safety responsibility assessment was completed, successfully, and all total scores met the standards.

We regard safety risk identification and hazard investigation as the two core pillars of enterprise safety production management. The Company conducts risk assessment work on an annual basis. We completed a comprehensive annual risk assessment review in 2024 and identified a total of 746 risks, including 28 major risks, 316 general risks, and 403 low risks. Corresponding measures were taken to address these risks. Meanwhile, we conduct a graded approach to hazard identification, including external inspections, BP inspections, departmental self-inspections, and special inspections, encouraging full participation. In 2024, a total of 1,475 safety hazards were identified, with 1,462 addressed, resulting in a hazard rectification rate of 99.12%.

To further strengthen safety management, in 2024, we underwent 22 external audits and inspections related to occupational health and safety, identifying 30 defects (with no severe non-conformities). All identified defects have been rectified.

CanSinoBIO conducts safety management for laboratories, hazardous chemicals, and occupational diseases to comprehensively reinforce the safety barrier.

During the reporting period, CanSinoBIO did **not** receive any administrative punishment related to occupational health and safety

we completed the preparation and organization of safety responsibility agreements for all positions, achieving a signing rate of **100%**

a total of 1,475 safety hazards were identified, with 1,462 addressed, resulting in a hazard rectification rate of **99.12%**

we underwent 22 external audits and inspections related to occupational health and safety, identifying 30 defects (with no severe non-conformities). All identified defects **have been rectified**

Occupational Health and Safety Measures of CanSinoBIO

Occupational Health and Safety Measures	Content of Occupational Health and Safety Measures
Laboratory Safety Management	• Risk identification and hazard rectification: A comprehensive risk identification and hazard inspection of the Company's laboratory areas was conducted, with 28 moderate risks and 316 general risks identified, and a rectification completion rate of 99.9%. • Specialized training and assessment for laboratory personnel: Approximately 12 specialized training sessions were conducted for laboratory personnel on "Chemical Safety"," Basic Knowledge of Biosafety", and "Laboratory Safety", with a passing rate of 100%. • Laboratory emergency drills: 19 emergency drills were conducted for laboratory personnel on laboratory fire emergency response, fire evacuation, biosafety, cardiopulmonary resuscitation, and Heimlich maneuver, with 508 participants.
Hazardous Chemicals Full Lifecycle Management	• Procurement Introduction: We upgraded the *SOP-SFY-032 Hazardous Chemicals Management System* to include the introduction process for hazardous chemicals. • Transportation and Receipt: We reviewed the qualifications of hazardous chemical suppliers to establish a list of controlled chemical suppliers, and supervised the compliant transportation of all hazardous chemicals on the list. • Temporary Storage for Use: We focused on dedicated storage and management by designated personnel in laboratory areas for use and temporary storage, assisted departments with ledger and usage management, and clarified temporary storage requirements.
Occupational Hazard Factor Detection	• We monitored occupational hazard factors in all areas, with no occupational hazards detected. All monitoring results were qualified.
On-the-job Health Checkups	• We organized a total of 175 on-the-job health checkups, 29 off-the-job checkups, and 3 pre-employment checkups. No target diseases or contraindicated personnel were found.

Contractor Safety Management

To ensure the safety production of contractors, CanSinoBIO has established the *Contractor Safety Management System* and actively carries out safety management work for contractors. The Company has connected to the government information management platform, established contractor account files, and achieved information management of contractors. Meanwhile, the "Three Simultaneities in Safety" for new projects (i.e., the simultaneous design, construction, and production use of safety facilities and main projects) has been fully implemented.

Handling and Rectification of Safety Incidents

In June 2024, a safety incident occurred involving the Company's contractor. The Company responded quickly, penalizing the involved unit according to the contract and ordering rectification based on the investigation report. The Company redefined the safety management responsibilities of the project, clarified inspection frequency and scope, and strengthened supervision of duties. Key supervision was implemented for high-risk projects such as foundation pits and formwork, and on-site monitoring was conducted for dangerous operations like tower crane installation and dismantling, material hoist installation, scaffolding installation and dismantling, and steel structure hoisting. Daily on-site safety inspections and weekly joint inspections were conducted to promptly eliminate hazards.

Safety Culture Building

CanSinoBIO has developed a series of training courses and assessments on occupational health themes for professionals at all levels, tailored to the characteristics and needs of its business, ensuring that employees have a solid grasp of basic safety and occupational safety knowledge.

Annual EHS Training

The Company conducted annual EHS training. We held a total of 12 sessions covering topics such as safety awareness enhancement, EHS regulations and systems, safety in special operations and construction work, occupational health and safety, and environmental protection knowledge, with a total of 7,023 participants and a passing rate of 100%.

Training and Assessment for Those Transferring Positions, Returning to Positions, Third-party Personnel, and New Hires

A total of 94 employees, including those transferring positions, returning to positions, third-party personnel, and new hires, completed department-level and position-level training assessments.

EHS Knowledge Sharing

The EHS department shared a total of 906 EHS-related videos and knowledge materials through the Company's corporate WeChat groups and safety work groups.

The Company places great importance on the safety training and education of contractors. We conduct safety training for contractors and assess their performance, issuing certificates upon passing, clearly defining the standards and requirements for CanSinoBIO's construction operations. All construction personnel entering the site must undergo safety training and pass the assessment before they can enter the construction area. In addition, we have incorporated contractor emergency evacuation drills into the Company's overall drill plan, collaborating with local departments to conduct emergency drills. During the reporting period, the Company organized a total of 166 contractor training sessions, with a cumulative participation of 807 persons.

During the reporting period, the Company organized a total of

166 contractor training sessions

with a cumulative participation of

807 persons

Training Data on Occupational Health and Safety

Percentage of employees trained **100%**

Average training hours of total employees **14** hours

Total training sessions **312** sessions

Number of total employees trained **15,454** persons

Number of male employees trained **8,028** persons

Number of female employees trained **7,426** persons

Number of senior managers trained **13** persons

Number of middle managers trained **1,113** persons

Number of junior employees trained **14,341** persons

Community Development and Public Welfare

CanSinoBIO considers giving back to society as its responsibility, actively engaging in public health initiatives, supporting charitable causes, and contributing to social harmony and sustainable development.

Health Science Education

Upholding the concept of “Innovation for a Safer World”, CanSinoBIO is committed to the popularization of health knowledge. We actively participate in industry exchanges to provide the public with rich and scientific health information, enhancing overall health literacy.

Joining the Tianjin Nucleic Acid Vaccine and Drug Innovation Consortium

In 2024, the Tianjin Municipal Science and Technology Bureau announced the proposed list for the establishment of the Tianjin Innovation Consortium, with CanSinoBIO leading the formation of the Tianjin Nucleic Acid Vaccine and Drug Innovation Consortium. The consortium focuses on the nucleic acid industry in Tianjin, aiming to build a first-class domestic innovation technology platform for nucleic acid vaccines and drugs, addressing critical technological challenges and creating a positive regional demonstration effect.

CanSinoBIO Joined the Tianjin Nucleic Acid Vaccine and Drug Innovation Consortium

Attending the Year-end Chair Meeting of the Tianjin (Economic-Technological Development Area) Nucleic Acid Industry Alliance

In December 2024, we attended the Year-End Chair Meeting of the Tianjin (Economic-Technological Development Area) Nucleic Acid Industry Alliance. As an important member of the Alliance, CanSinoBIO, in line with current development, engaged in in-depth discussions with other organizations at the meeting on further innovative development in the nucleic acid industry, providing strong momentum for the growth of the biopharmaceutical sector.

CanSinoBIO Supported the Year-end Chair Meeting of the Tianjin (Economic-Technological Development Area) Nucleic Acid Industry Alliance

Joining the Tianjin (Economic-Technological Development Area) Biopharmaceutical Industry-Education Consortium

As a key participant in the Tianjin (Economic-Technological Development Area) Biopharmaceutical Industry-Education Consortium, CanSinoBIO actively promotes the integration of industry and education. In March 2024, CanSinoBIO attended the Exchange Promotion Meeting of Tianjin (Economic-Technological Development Area) Biopharmaceutical Industry-Education Consortium. At the meeting, ten enterprises and institutions, including CanSinoBIO, jointly participated in the signing and implementation of projects such as the Tianjin Higher Education Undergraduate Teaching Quality and Teaching Reform Research Program and the integration of vocational education and industry projects. We will work together with all parties to address the “gaps” and “bottlenecks” between talent cultivation and industry demand, to train various talents for the development of Tianjin’s biopharmaceutical industry.

CanSinoBIO Joined the Tianjin (Economic-Technological Development Area) Biopharmaceutical Industry-Education Consortium

Public Welfare and Charity

CanSinoBIO complies with the *Charity Law of the People's Republic of China*, the *Law of the People's Republic of China on Donation to Public Welfare*, and other relevant laws and regulations, continuously revising and implementing internal systems such as the *Donation Management System* to standardize the management of the Company's donation activities. In 2024, CanSinoBIO invested a total of 311 hours in public welfare and charity, with total donations amounting to approximately RMB 447,700.

In 2024, CanSinoBIO invested a total of **311** hours in public welfare and charity with total donations amounting to approximately RMB **447,700**

CanSinoBIO Donation Activity for Tsinghua University Education Foundation

In 2024, to support the development of domestic medical undertakings, we donated RMB 300,000 to Tsinghua Medicine to support its construction and development. This donation activity provides strong material support for the construction and development of the medical school, contributing to the cultivation of more outstanding medical talents.

Donation Activity

Syringe Donation

In 2024, CanSinoBIO continued to deepen its corporate social responsibility practices by optimizing the efficiency of medical resource utilization through charitable donations. Throughout the year, the Company established connections with the Red Cross Society in 32 provincial-level administrative regions across China, focusing on promoting targeted donation agreements with 11 Red Cross Societies in Hainan, Shaanxi, Sichuan, and the Chongqing municipality, donating a total of approximately RMB 2.5 million worth of single-use sterile syringes. This initiative supports primary vaccination efforts and emergency responses to public health incidents, helping to enhance the local primary medical equipment standards.

04 Governance Optimization

Improving Governance System, Empowering Robust Development

CanSinoBIO has always regarded compliance as the cornerstone of corporate development. The Company adheres to business ethics and integrity standards, establishes a comprehensive risk management and auditing system, continuously optimizes supply chain management, and ensures that all operational activities strictly comply with regulatory requirements. Meanwhile, we place a high priority on information security management, effectively protecting core data and business secrets to safeguard the long-term stable development of the Company.

Relevant Public Policies in this Chapter

Anti-Corruption and Fraud Management System

CanSinoBIO Compliance Manual

Supplier Code of Conduct



Corporate Governance

CanSinoBIO continuously optimizes its corporate governance structure, comprehensively strengthens the construction of the governance system, and is committed to improving decision-making processes to enhance the overall operational efficiency and effectiveness of the Company.

Governance Structure

CanSinoBIO strictly complies with laws, regulations, and regulatory requirements such as the *Company Law of the People's Republic of China*, the *Securities Law of the People's Republic of China*, the *Listing Rules of HKEX*, and the *Stock Listing Rules of the Science and Technology Innovation Board of the Shanghai Stock Exchange*. CanSinoBIO has established the Board and the Board of Supervisors based on the actual development needs of the Company, elects Directors and Supervisors in strict accordance with the recruitment procedures specified, and has formed a corporate governance structure and operating mechanism with shareholders' meetings, the Board, and the Board of Supervisors as the core. The Company has established a scientific, efficient, stable, and long-term decision-making and sustainable decision-making and supervision system to ensure the standardization of company operations and effectively safeguard shareholders' rights.

The Board of Directors is responsible for overall strategic development and has established the Audit Committee, the Remuneration and Assessment Committee, and the Nomination Committee. The Board of Directors and its specialized committees guide the Company's business plans, supervise the implementation of plans, monitor the Company's operational and financial performance, enhance the Company's operational efficiency, and continuously promote the Company's long-term and stable development. As of the end of the reporting period, the third session of the Board of Directors of CanSinoBIO consisted of three executive directors, one non-executive director, and three independent non-executive directors. In 2024, the Board held seven Board meetings and all members were present.

Governance Structure and Responsibilities of CanSinoBIO in 2024

Controlling shareholders and listed companies

- The controlling shareholder of the Company has always adhered to regulations, exercised shareholder rights in accordance with the law, and actively supported the Company's operations and development.
- In terms of business, personnel, assets, institutions, and finance, the controlling shareholder maintains independence from the Company, strictly complies with corporate governance rules, and has not intervened in the Company's decision-making or operational activities through means other than the shareholders' meeting.

Shareholders and general meeting

- As the highest authority of the Company, the shareholders' meeting is composed of all shareholders and has the power to elect and remove directors, determine the Company's operational strategies and investment plans, and make decisions on important company matters.
- We ensure that the convening, holding, and voting processes of the shareholders' meeting are standardized and rigorous, and we encourage active participation from shareholders, especially ensuring equal rights and status for minority shareholders.

Directors and the Board

- The Company continuously enhances the role of external directors in supervision and decision-making consultation, carefully considering their valuable opinions on industry trends and risk management, thereby improving the scientific and rational nature of Board decisions.
- The Board of Directors holds at least four regular meetings each year to ensure the continuity of the Company's operations and the timeliness of decision-making.

Supervisors and the Supervisory Board

- The Supervisory Board diligently performs its supervisory functions, conducting compliance oversight of the Company's business activities, related party transactions, and fundraising to ensure the Company's healthy development, stability, and long-term growth.

In 2024, CanSinoBIO held **2** shareholder meetings, **7** Board meetings, and **6** supervisory Board meetings. The committees under the Board held **4** Audit Committee meetings, **2** Remuneration and Assessment Committee meetings, and **2** Nomination Committee meetings.

Board Diversity

CanSinoBIO has always regarded the diversity of Board members as a key factor supporting the Company's sustainable development. To enhance the diversity of Board members, the Company has formulated and implemented the *Board Member Diversity Policy*, which comprehensively considers multiple factors such as gender, age, cultural background, educational experience, ethnicity, professional skills, industry experience, tenure, professional ethics, and the willingness to dedicate sufficient time to fulfill the responsibilities of Board members when selecting new members. Board members possess rich knowledge and practical experience in the fields of healthcare, finance and accounting, business management, and risk control, forming a complementary capability structure. Meanwhile, Board members continuously improve their professional capabilities to provide strong support for the Company's strategic decision-making. As of the end of the reporting period, the 3rd Board of CanSinoBIO consisted of seven directors, including one women director, accounting for 14.29%[15].

	Director type	Gender	Cultural and educational background	Age
The 3rd Board	3 executive directors	1 woman	2 hold a doctoral degree	1 aged 40 to 49
	1 non-executive director	6 men	5 hold a master's degree	6 aged 60 to 69
	3 independent non-executive directors			

[15] Information regarding the Board of Directors members can be found in the 2024 Annual Report as well as in announcements and communications.

Investor Relations

CanSinoBIO is committed to disclosing information truthfully, accurately, completely, timely, and effectively, and has established an open and equal communication mechanism. We actively and proactively convey the Company's business philosophy, operational results, and future strategic direction to investors through various channels such as the Company's investor communication platform, general meetings, and performance briefings, creating a sincere and trustworthy investor communication ecosystem and enhancing investors' recognition of the Company's value.

In 2024, the Company communicated with investors **hundreds of** times, published **13** copies of the *Investor Relations Activity Record Form*, responded to nearly **140** inquiries on the SSE E-interactive (online platform), and answered over **200** investor hotline calls.

CanSinoBIO Held the 2024 Investor Open Day Event

On November 27, 2024, CanSinoBIO successfully held its 2024 Investor Open Day event in Tianjin. The event, themed "Pioneering the Journey and Nurturing the Hope at CanSinoBIO", attracted approximately 80 investors, analysts, and other guests. The Company's management engaged in in-depth face-to-face discussions with investors on topics such as the Group's five-year journey since going public, strategic overview, R&D, commercialization processes, and strategies.

Dr. Yu Xuefeng, Chairman and CEO of CanSinoBIO, Delivered the Opening Speech

Compliance Construction

CanSinoBIO continues to deepen its compliance management, comprehensively enhancing its compliance operational capabilities, and firmly upholding the Company's compliance value baseline, laying a solid foundation for stable development.

CanSinoBIO strictly adheres to the *Company Law of the People's Republic of China* and other relevant laws and regulations, formulates the *CanSinoBIO Compliance Manual*, and has introduced a series of related systems such as the *Compliance Obligations and Risk Assessment Procedures, Project Compliance Management System, and Procurement Compliance Management System*, clarifying the Company's compliance commitments and responsibilities, the full-process compliance management system, compliance management measures, and accountability mechanisms to ensure the improvement and effective implementation of the compliance management system. In 2024, the Company established a new *Compliance Performance Management System*, which clearly defines the individual and management responsibilities for violations of compliance management regulations, and incorporates compliance behavior as one of the assessment indicators in the annual compliance performance evaluation.

CanSinoBIO continues to optimize its compliance control system. In 2024, the Risk and Internal Control Management Committee, as the highest decision-making body for compliance management, comprehensively coordinated the Group's compliance and risk control work, leading and supervising the effective implementation of internal governance. In 2024, the Company organized comprehensive compliance and special compliance management based on the organizational structure of the Legal and Compliance Department. We focus on improving the compliance BP management mechanism, dynamically identifying compliance obligations and risk changes in areas such as engineering, procurement, and marketing. Meanwhile, we establish and update lists of compliance obligations and compliance risks in key areas, and track the implementation of supervision measures to ensure effective control of compliance risks. During the reporting period, CanSinoBIO did not have any violations.

CanSinoBIO's Compliance Management Structure and Duties in 2024

Governance Level

Risk and Internal Control Management Committee

- As the highest decision-making body for compliance management in the Company, organize, lead, and coordinate comprehensive compliance management.
- Promote the improvement of compliance management systems and culture building and approve compliance performance evaluation results and annual compliance work reports.
- Approve the Company's compliance management plans, systems, and procedures, provide decision-making on major compliance risks, and prepare solutions.

Management Level

Legal and Compliance Department

- As the leading department for compliance management, organize and promote the operation and supervision of the compliance management system.
- Identify compliance obligations and translate them into executable policies, conduct compliance risk identification, analysis, and evaluation, and regularly review compliance performance.
- Set compliance objectives, supervise the consistency of compliance obligations and policies, organize compliance training, and issue annual compliance reports.

Internal Audit Department

- Supervise and evaluate the performance of compliance management work within Departments/Centers.
- Conduct regular specialized audits, propose internal control suggestions.

Executive Level

Heads of Departments/Centers

- As the first person responsible for the management within Departments/Centers, ensure the execution of the compliance work plan.
- Organize compliance risk identification, early warning, and response, and assist the Legal and Compliance Department in formulating compliance standards.
- Promote the implementation of compliance management requirements within this department/center to ensure effective control of compliance risks.

All employees

- Proactively identify and report compliance risks, and comply with the Company's compliance policies and requirements.

Suppliers and Business Partners

- Comply with the Company's compliance policies, standards, and prohibitive matters to ensure compliance in business cooperation.

In 2024, the Company established a compliance risk identification and early warning mechanism in accordance with the *Compliance Obligations and Compliance Risk Assessment Procedures*, dynamically sorting compliance risks in business management, and systematically assessing the likelihood, impact, and potential consequences of risks. In the fields of engineering, procurement, marketing, and information security, a dedicated compliance risk assessment checklist has been developed, and relevant departments regularly communicate changes in risks and track the effectiveness of response measures. By embedding compliance requirements into business processes, we ensure that business operations comply with laws and regulations, internal policies, and ethical standards, effectively reducing potential compliance risks.

In 2024, the Company successfully passed the external supervision audit of the ISO 37301 compliance management system, continuously applying scientific methods such as risk thinking, process control, and the Plan-Do-Check-Act (PDCA) cycle to operate the compliance system.

CanSinoBIO Launched the Third Compliance Promotion Month

In September 2024, CanSinoBIO successfully held the third Compliance Promotion Month with the theme “A Tiny Shot, A Foundation for Health; Compliance Assured, Vaccines Delivered”. Through compliance training and exchange workshops, company employees actively participated in compliance management, achieving a shift from awareness to joint governance. The activities covered various fields including corporate communication, trade secrets, internal audits, internal controls, human resources, legal affairs, and intellectual property, receiving positive responses from various sectors and departments of the Company.

Highlights of Compliance Risk Control Training at CanSinoBIO in 2024

The participation rate of Board members and management reached

100%

Average training hours for Board members reached

2 hours

Employee participation rate reached

99%

Average training hours for employees[16] reached

24.5 hours

[16] The scope of the data includes senior, mid-level management, and junior employees.

Risk Management

To ensure the effectiveness of compliance governance, CanSinoBIO has established a three-in-one risk control and audit supervision system of “beforehand prevention, in-process control, and afterwards supervision”. The Company continuously follows relevant systems such as the *Internal Control Manual* and *Internal Audit Management System*, clarifying the principles, processes, requirements, and key risk control points for internal control and audit management, covering key areas such as sales, procurement, production, fixed asset management, R&D project management, external investment, fund management, and engineering project management.

In 2024, the Company introduced a new *Audit Rectification Implementation Supervision System* to ensure the standardization and normalization of audit work, optimize the audit rectification supervision process, and improve the overall management efficiency of departments to some extent, further enhancing the internal control and audit system. In addition, the Company’s audit department conducts a comprehensive summary of the previous year’s audit project execution at the beginning of each year and reports the progress of audit projects to the audit committee quarterly, ensuring the transparency and timeliness of audit work.

The Company continuously optimizes its internal control and authorization management system, fully upgrading the Group’s GMS document management system. By introducing advanced process concepts and refining the hierarchical and graded management of documents, we achieve precise identification and improvement of key business areas. Throughout the year, we reviewed and established approximately 120 internal control management documents. In terms of internal control consulting management, leveraging past consulting experience, we have built a Q&A checklist to standardize responses, significantly saving communication time while ensuring the accuracy and consistency of the replies. In 2024, the internal control and audit teams collaborated to analyze audit rectification issues. Meanwhile, the audit team conducted in-depth internal control and special audits across multiple business sectors, including import and export management, asset management, CRO management, compliance and anti-bribery management, marketing expense management, and insider information management. Through comprehensive process management involving pre-risk assessments, strict in-process inspections, and post-rectification recommendations, we effectively identify business risks and timely issue the *Internal Audit Report*, providing solid support for the Company’s stable operations.

The leadership of Party Building

2024 was an important year for fully implementing the Party's policies and guidelines, and it was also a key year for CanSinoBIO to promote high-quality development. We adhere to high-quality party building to lead the innovative development of the enterprise, effectively implementing Xi Jinping's Thoughts on Socialism with Chinese Characteristics for a New Era into the Company's strategic goals. By identifying the points of intersection and focus for party building work, we leverage the exemplary role of party members to promote the widespread dissemination and practice of the Party's theories within primary party organizations. We continue to innovate training formats, combining online and offline approaches to strengthen the construction of primary party organizations, ensuring that party building plays a core role in the Company's development.

Deepening the Study of Reform Spirit to Promote the Company's High-quality Development

From September to December 2024, CanSinoBIO organized activities to promote and train in the spirit of the Third Plenary Session of the 20th Central Committee of the Communist Party of China. Each party branch organized 1 to 2 special study sessions, with a total of 106 active party members participating. Through the study, party members gained a deeper understanding of General Secretary Xi Jinping's new thoughts and new assertions on comprehensively deepening reform, enhancing their political awareness and theoretical level.

Training on the Spirit of the 20th National Congress of the Communist Party of China

Party Building Guided Collaborative Development and Promoted Business Innovation

In 2024, CanSinoBIO launched the "Party Building Guides Strong Marketing, Joint Efforts Empower New Development" initiative to promote communication and co-construction among party branches. The Fourth Party Branch and the Northwest Region conducted two co-construction sessions to gain insights into sales needs and provide guidance for product improvement. The Second Party Branch engaged in member exchanges with the Shanghai Center for Disease Control and Prevention and the Youth Branch to deepen the mechanisms of party building and business cooperation. In December, the First Party Branch held co-construction activities with party organizations such as the Guangzhou Preventive Medicine Association and the Center for Disease Control and Prevention, enhancing cooperation and development among party organizations.

Joint Party Building Activity of the Second Party Branch

Party Members' Pioneer Positions Supported the Company's Innovative Development

In 2024, CanSinoBIO launched the "New Achievements in Positions, Party Members as Pioneers" selection activity for Party Members' Pioneer Positions, further stimulating the exemplary role of Party members. Each Party branch established 2-3 Party Members' Pioneer Positions, focusing on corporate development and innovation strategies to promote the Company's transformation and breakthroughs under new circumstances. The activity aimed to create "Four New Talents" (new positions, new atmosphere, new journey, new contributions), encouraging Party members to take the lead in solving challenges in project advancement, playing a guiding role in Party building, and facilitating the achievement of the Company's strategic goals.

Award Ceremony for Party Members' Pioneer Positions

Business Ethics

CanSinoBIO strictly adheres to the *Anti-Monopoly Law of the People's Republic of China*, *Anti-Unfair Competition Law of the People's Republic of China*, and *Anti-Money Laundering Law of the People's Republic of China*, among other laws and regulations, upholding high standards of business ethics and resolutely resisting any form of corruption and unfair competition. To strengthen the norms of business conduct, the Company has developed and improved systems such as the *Anti-corruption and Anti-fraud Management System*, the *System of Conflicts of Interest,* and the *Employee Receiving Gift Management Process*, comprehensively regulating employee behavior during business operations and performance of duties. In 2024, the Company successfully passed the external supervision audit of the ISO 37001 Anti-Bribery Management System.

To ensure the effective implementation of anti-corruption and business ethics policies, the Company regularly conducts reviews and assessments of core policies and their execution. In 2024, the Company audited compliance systems such as the *CanSinoBIO Compliance Manual*, *Compliance Management System*, *Anti-corruption and Anti-fraud Management System*, *Punishment Regulations for Dereliction of Duty in Anti-Bribery and Anti-Fraud Management*, and *Compliance Management System for Business Partners*, as well as related policies on compliance reporting and investigation, compliance training, compliance performance, and compliance behavior. During the reporting period, the Company did not find any serious non-compliance issues.

In 2024, the Company continued to strengthen the management of a clean supply chain, achieving 100% of suppliers signing the *Supplier Code of Conduct*, *Integrity Agreement*, and *Confidentiality Agreement*. Meanwhile, the Company conducts special compliance training for channel partners, promoting requirements on anti-corruption, anti-bribery, conflict of interest, and intellectual property protection, clarifying the principle of zero tolerance for improper business conduct, and informing them of compliance reporting channels to encourage partners to jointly fulfill compliance commitments with the Company.

CanSinoBIO encourages reporting and complaints regarding corruption and violations of business ethics and has established various public complaint channels including phone, email, and mail. The Company continuously monitors and pays attention to reporting information 24/7 to ensure that every issue is properly addressed. The Company places great importance on whistleblower protection and has established systems such as the *Procedures for Compliance Whistleblowing, Reporting and Internal Compliance Investigation* to strictly ensure the information security of whistleblowers who report anonymously and prevent information leakage. Meanwhile, to encourage employees, suppliers, and business partners to actively participate in supervision, the Company has formulated the *Reward Process for Non-Compliance Reporting*, which stipulates that whistleblowers who provide valuable information that is verified to be true will receive corresponding rewards.

Main reporting channels of CanSinoBIO

- **Reporting hotline:** 022-58213600-6218
- **Reporting email:** compliance@cansinotech.com
- **Mailing address:** Rongsheng Building, 185 South Street, West District, Tianjin Economic and Technological Development Zone

The Company places great importance on anti-corruption training, incorporating it into the core aspects of employee career development. New employees are required to complete training covering anti-corruption, anti-fraud, conflict of interest, and business compliance upon joining, ensuring compliance awareness is established from the outset. Each year, the Company provides regular anti-corruption, anti-bribery, and anti-fraud specialized training for directors, supervisors, management, and all employees, and incorporates compliance training into performance evaluations. In addition, all employees (including interns and contract workers) must sign the *Anti-Corruption and Business Ethics Commitment Letter* to strengthen the awareness of compliance responsibilities among all staff. In 2024, the anti-corruption training hours for board members of the Company averaged one hour/person, about two hours/person for management, and about 4.5 hours/person for employees.

Highlights in Business Ethics of CanSinoBIO in 2024

Signing rate of employee commitment letters on anti-corruption and business ethics codes of conduct reached

100%

Completion rate of business partner compliance questionnaires reached

100%

The signing rate of the *Confidentiality Agreement* and the *Integrity Agreement* by suppliers reached

100%

Lawsuits or cases related to corruption, violation of business ethics, or unfair competition

0

In 2024, CanSinoBIO participated in multiple industry compliance and business ethics exchange and cooperation activities:

On January 11, 2024, we attended a pre-meeting organized by the ACCP monthly seminar on how companies can effectively implement preventive compliance under normal anti-corruption conditions.

On April 20, 2024, we attended the Pharmaceutical Compliance Promotion Conference organized by Hainan Yuanchuang Active Health Industry Development Research Institute.

On July 12, 2024, we attended a closed-door meeting on risk prevention of pharmaceutical commercial bribery and tax-related risks in the pharmaceutical industry.

On July 28, 2024, we participated in the training meeting on the synchronization and linkage of ethos policies.

On October 21, 2024, we participated in the RDPAC pharmaceutical compliance seminar.

On October 24, 2024, participate in the Medical and Pharmaceutical Industry Legal Compliance Summit organized by LCOUNCIL.

On December 3, 2024, we participated in a closed-door meeting discussing the new legal compliance cooperation model after the anti-corruption guidelines organized by EverPro.

On December 20-21, 2024, we participated in the first conference on conduct building in medical institutions and compliance management for pharmaceutical companies organized by the National Institute of Hospital Administration under the National Health Commission and the Shanghai Medical Ethos Association.

Responsible Supply Chain

CanSinoBIO is committed to deeply integrating sustainable development concepts into supply chain management, proposing ESG management initiatives to suppliers, and working with partners to build a transparent, collaborative, and win-win responsible supply chain system.

Supply Chain Management

CanSinoBIO strictly complies with the *Civil Code of the People's Republic of China*, the *Bidding Law of the People's Republic of China*, and other laws and regulations, establishing the *Supplier Management Regulations*, and adding and improving the *Supplier Evaluation Program*, *Supplier Performance Management*, *Supplier Development and Access Management*, *Management Procedures for Supplier Blocking, Unblocking and Withdrawal,* and *Procurement Application Management*, to clarify the management requirements, standards, and processes for the entire supply chain, and implement high-standard supplier management measures.

Supplier Management Flowchart



Supplier Entry

- The Company strictly reviews the completeness and authenticity of suppliers' licenses and admission materials during the supplier admission process and assesses the suppliers' corporate reputation, nature of legal disputes, and potential risks through third-party platforms.

Supplier Classification

- The Company categorizes suppliers into excellent, good, average, corrective, and unqualified suppliers based on supply risks and expenditure proportions, implementing differentiated management.
- The Company classifies suppliers into levels A, B, C, D, and E based on performance evaluation results, implementing tiered management, while further refining the classification of suppliers for key categories.

Supplier Audit

- The Company's daily assessments focus on suppliers' daily performance, the quality and usage of delivered materials, timeliness of delivery, and service performance, ensuring that suppliers meet the requirements in daily cooperation.
- For key raw material and consumable suppliers, on-site factory inspections will be conducted to gain a deeper understanding of their production and management capabilities.
- In the annual assessment, the Company conducts a comprehensive evaluation of suppliers based on multiple dimensions such as delivery, quality, service, and price, categorized by material type, to fully assess their annual performance.

Supplier Withdrawal

- The Company will directly eliminate suppliers that fail the audit. Suppliers that receive unsatisfactory annual evaluations and do not cooperate with rectification will also be eliminated.
- The Company will close suppliers with low annual cooperation amounts and purchasing frequencies after confirmation and review by procurement personnel, in accordance with relevant regulations.
- The Company closely monitors suppliers' internal risk assessment reports, and if serious risks are identified, cooperation will be terminated.

The Company implements a localized procurement strategy, prioritizing local enterprises in the selection and development of suppliers to deepen collaborative development with the regional economy and achieve mutual benefits. In 2024, the Company newly signed six framework agreements with R&D material suppliers, all of which were local distributors.

In 2024, CanSinoBIO Suppliers

Suppliers from the Chinese mainland	Suppliers from Hong Kong, Macao, and Taiwan	Overseas suppliers
1,098	8	89

In 2024, CanSinoBIO's Supplier Management System Certification

By the end of the reporting period, the number of suppliers that have obtained the quality management system certification (such as ISO 9001 certification, etc.) **135**

By the end of the reporting period, the number of suppliers that have obtained the health and safety management system certification (such as ISO 45001 certification, etc.) **46**

By the end of the reporting period, the number of suppliers that have obtained the environmental management system certification (such as ISO 14001 certification, ISO 14064 certification, etc.) **33**

Supply Chain ESG Management

CanSinoBIO places great importance on the ESG performance of its suppliers, aiming to build a green and sustainable responsible supply chain, and actively guides suppliers to practice sustainable development concepts. In 2024, the Company integrated core requirements such as environmental protection, health and safety, and business ethics into the *Supplier Code of Conduct*, prioritizing the procurement of low-carbon and environmentally friendly products and services, and has developed targeted measures to address environmental and social risks in supplier operations to ensure comprehensive optimization and risk control in supply chain management.

Basic requirements

- 100% of domestic suppliers must sign the *Supplier Code of Conduct*.

Certification requirements

- Under equal conditions, suppliers certified to ISO 9001, ISO 14001, ISO 45001, and OHSAS 18000 will be prioritized.

Health and safety requirements

- Suppliers are required to establish internal procedures for the prevention, management, tracking, and reporting of occupational injuries and diseases, and encourage the implementation of corrective actions.
- Suppliers are required to provide comprehensive health and safety training for employees to eliminate potential health and safety hazards from the source.
- Suppliers are required to strictly ensure employees' statutory benefits, implement rights such as paid leave, and ensure that employees' legal rights are fully protected.

Employee rights and interests requirements

- Suppliers are required to strictly comply with laws and regulations related to employee rights protection, prohibition of child labor and forced labor, and anti-discrimination to ensure compliant operations.
- Suppliers are required to fully respect employees' rights to freely associate and collectively bargain, ensuring the protection of employees' legitimate rights and interests.
- Suppliers are required to resolutely eliminate workplace discrimination caused by factors such as race, gender, age, and religious beliefs, creating a fair and inclusive work environment.

Environmental protection requirements

- Suppliers are required to conduct business in a responsible and proactive manner with the goal of minimizing environmental impact and protecting natural resources.
- Suppliers are required to minimize energy consumption in their production operations, prioritize reuse and recycling concepts, optimize product packaging design, reduce fuel and water usage, decrease greenhouse gas emissions, and strictly avoid the use of harmful materials.
- Suppliers are required to measure and control business activities that pose environmental risks, achieving standards recognized by national or international environmental management systems.

Business ethics requirements

- Suppliers are required to sign the Company's *Integrity Agreement* to avoid corruption incidents during cooperation. In 2024, 100% of domestic suppliers signed the *Integrity Agreement*.
- Suppliers are required to sign the Company's *Confidentiality Agreement* to strictly protect the Company's technical materials, intellectual property, and other information. In 2024, 100% of domestic suppliers signed the *Confidentiality Agreement*.
- The Company is required to actively create a fair business environment, strictly prohibiting unfair competition, fraud, money laundering, and other behaviors.

Supplier Training

CanSinoBIO has adopted a multi-level, targeted supplier training strategy. We conduct centralized training for suppliers, providing compliance training through online meetings to communicate basic requirements and ensure strict adherence to standards during cooperation. Regarding product quality, the Company organizes specialized quality training to help suppliers enhance their focus on product quality and control capabilities, ensuring the stability of the supply chain's quality. In addition, for specific issues faced by some suppliers, the Company arranges point-to-point communication to resolve practical difficulties encountered during cooperation through one-on-one discussions, assisting suppliers in better meeting corporate requirements.

Supply Chain Risk Management

CanSinoBIO places great importance on supply chain risk management, timely predicting and identifying potential risks, and formulating comprehensive response strategies to enhance the resilience and stability of the supply chain, deeply integrating quality management into every aspect of the supply chain.

Access Assessment

We sign quality agreements with suppliers, delineating the quality responsibilities and standards of both parties to ensure that suppliers can consistently and stably provide high-quality production materials that meet high standards.

Risk Assessment

The Company regularly checks the inventory and usage of production materials, conducts risk assessments to identify risks of stagnation and material shortages, and promptly issues warnings to coordinate with suppliers and user departments to resolve issues.

Emergency Management

To respond to emergencies, the Company has established emergency procurement processes and detailed regulations for urgent procurement based on different levels of urgency and amounts, aiming to comprehensively enhance the supply chain's risk response capabilities.

Regular Inspections

During the collaboration with suppliers, the Company uses supplier surveys to investigate various aspects of supplier performance, thoroughly identifying potential risk points.

To ensure that suppliers strictly comply with GMP and related quality standards, we regularly conduct on-site audits covering various aspects such as product quality, storage compliance, and logistics support. In response to issues identified during the audits, the Company provides practical improvement suggestions to help suppliers continuously enhance their quality management capabilities. In 2024, the Company conducted a total of 30 supplier quality audits, and all identified issues have been rectified.

Information Security

CanSinoBIO strictly adheres to the *Cybersecurity Law of the People's Republic of China*, the Data Security Law of the People's Republic of China, and other laws and regulations, and has added and improved internal systems such as the *Information Security Incident Management Regulations* and the *Data Security Management Regulations*, clarifying information processing principles, data transmission standards, and the protection of personal information rights, ensuring data security and compliant operations.

The Company has improved its information security organizational system, establishing a five-tier structure of "decision-making tier - management tier - executive tier - employees and partners - supervision tier", creating a clear and hierarchical management model. Based on the existing functions of the security team and related departments, the Company has introduced third-party professional institutions for collaborative cooperation, ensuring that security responsibilities are implemented step by step from the inside out.

Decision-making Level

- Formulate information security management objectives and policies
- Coordinate decision-making on key information security incidents

Management Level

- Develop a comprehensive information security plan based on compliance standards and business needs, standardizing operations at all levels

Executive Level

- Implement specific information security measures, including access control management and threat monitoring
- Be responsible for information security risk assessment and continuous improvement

Employees and Partners

- Strictly comply with and implement the Company's information security requirements
- Promptly report various information security risks and collaborate with the management team to enhance protection

Supervision Tier

- Supervise the actual implementation of information security policies and the effectiveness of information security management
- Monitor information security risks
- Conduct information security audits

In terms of ensuring network security, we monitor the overall security situation in real time through an intelligent regulatory security dashboard, including asset status, vulnerabilities, attack trends, and security incidents. Comprehensive security monitoring enables the Company to quickly perceive and respond to internal network security threats, protecting the Company's information assets and providing a solid security guarantee for digital transformation.

To ensure data security, the Company has established a data operation record and custody system to ensure that all operational behaviors are traceable. We adhere to the principle of "least privilege" when assigning data access rights to prevent unauthorized access. Meanwhile, we implement an identity authentication mechanism for database access and conduct real-time monitoring and auditing to ensure compliance with operations. In addition, the Company has masked or de-identified sensitive data to minimize the risk of data leakage. In 2024, the Company conducted two internal special audits on information security to ensure that all information security risks are rectified in a timely manner. The Company has successfully passed the Level 3 Cybersecurity Protection Certification of Information Systems of the People's Republic of China.

To enhance employees' awareness and response capabilities in information security and privacy protection, the Company organized and implemented information security training and assessments for all employees through the E-Learning platform, covering basic knowledge of information security, cybersecurity protection strategies, among others. In addition, the Company effectively improved employees' ability to identify and prevent phishing attacks by conducting phishing email drills and simulated red-blue team exercises, strengthening the emergency response level for information security incidents. In 2024, the Company organized a total of 4 training sessions on information security and privacy protection, achieving coverage for all employees.

Innovative Practices in the Intelligent Transformation of CanSinoBIO Factory

In 2024, the Company's factory achieved intelligent business processes through digital transformation, effectively enhancing operational efficiency and collaborative work capabilities. The smart factory integrates different core business systems, optimizes the data center and automation systems, and realizes the visualization and intelligent control of production processes, logistics processes, and financial management, improving overall work efficiency. With outstanding work in digital and intelligent transformation, the Company was awarded the title of "2024 Tianjin Intelligent Factory".


荣誉证书

Honor Certificate of CanSinoBIO Intelligent Factory

Content Index of ESG Reporting Code of Hong Kong Stock Exchange

Subject Area	Aspect	KPIs	Corresponding Chapters
Environmental	A1 Emissions	General Disclosure Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air and greenhouse gas emissions, discharges into water and land, and generation of hazardous and non-hazardous waste.	Management of Waste Gas, Wastewater, and Solid Waste
		A1.1 The types of emissions and respective emissions data.	Management of Waste Gas, Wastewater, and Solid Waste ESG Data list
		A1.2 Direct (Scope 1) and energy indirect (Scope 2) greenhouse gas emissions (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Management of Waste Gas, Wastewater, and Solid Waste ESG Data list
		A1.3 Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Management of Waste Gas, Wastewater, and Solid WasteESG Data list
		A1.4 Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Management of Waste Gas, Wastewater, and Solid Waste
		A1.5 Description of emission target(s) set and steps taken to achieve them.	Management of Waste Gas, Wastewater, and Solid Waste
	A2 Use of Resources	General Disclosure Policies on the efficient use of resources, including energy, water and other raw materials.	Use of Resources
		A2.1 Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in' 000s) and intensity (e.g. per unit of production volume, per facility).	Use of Resources ESG Data list
		A2.2 Water consumption in total and intensity (e.g. per unit of production volume, per facility).	Use of Resources ESG Data list
		A2.3 Description of energy use efficiency target(s) set and steps taken to achieve them.	Use of Resources
Environmental	A2 Use of Resources	A2.4 Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	Use of Resources
		A2.5 Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	Use of Resources ESG Data list
	A3 The Environment and Natural Resources	General Disclosure Policies on minimising the issuer's significant impacts on the environment and natural resources.	Environmental Management
		A3.1 Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	Environmental Management
Social	B1 Employment	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.	Employee Employment and Rights and Interests Employee Remuneration and Benefits Employee Training and Development
		B1.1 Total workforce by gender, employment type (for example, full or part-time), age group and geographical region.	Employee Employment and Rights and Interests
		B1.2 Employee turnover rate by gender, age group and geographical region.	Employee Employment and Rights and Interests
	B2 Health and Safety	General Disclosure Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards.	Occupational Health and Safety
		B2.1 Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	Occupational Health and Safety

Subject Area	Aspect	KPIs	Corresponding Chapters
Social	B2 Health and Safety	B2.2 Lost days due to work injury.	Occupational Health and Safety
		B2.3 Description of occupational health and safety measures adopted, how they are implemented and monitored. General Disclosure Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities.	Occupational Health and Safety
	B3 Development and Training	General Disclosure Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities.	Employee Training and Development
		B3.1 The percentage of employees trained by gender and employee category (e.g., senior management, middle management).	Talent Cultivation
		B3.2 The average training hours completed per employee by gender and employee category.	Talent Cultivation
	B4 Labour Standards	General Disclosure Information on: the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labour.	Employee Rights and Rights Protection
		B4.1 Description of measures to review employment practices to avoid child and forced labour.	Employee Rights and Rights Protection
		B4.2 Description of steps taken to eliminate such practices when discovered.	Employee Rights and Rights Protection
	B5 Supply Chain Management	General Disclosure Policies on managing environmental and social risks of the supply chain.	Responsible Supply Chain
		B5.1 Number of suppliers by geographical region.	Responsible Supply Chain
		B5.2 Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.	Responsible Supply Chain
		B5.3 Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	Responsible Supply Chain
		B5.4 Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	Responsible Supply Chain

Subject Area	Aspect	KPIs	Corresponding Chapters
Social	B6 Product Responsibility	General Disclosure Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labeling and privacy matters relating to products and services provided and methods of redress.	Product Safety and Quality Customer Service and Pharmacovigilance Responsible Marketing
		B6.1 Percentage of total products sold or shipped subject to recalls for safety and health reasons.	Product Safety and Quality
		B6.2 Number of products and service-related complaints received and how they are dealt with.	Product Safety and Quality
		B6.3 Description of practices relating to observing and protecting intellectual property rights.	Product Innovation and Research
		B6.4 Description of quality assurance process and recall procedures.	Product Safety and Quality
		B6.5 Description of consumer data protection and privacy policies and how they are implemented and monitored.	Information Security
	B7 Anti-corruption	General Disclosure Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.	Business Ethics
		B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	Business Ethics
		B7.2 Description of preventive measures and whistle-blowing procedures, how they are implemented and monitored.	Business Ethics
		B7.3 Description of anti-corruption training provided to directors and staff.	Business Ethics
	B8 Community investment	General Disclosure Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	Community Development and Public Welfare
		B8.1 Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).	Community Development and Public Welfare
		B8.2 Resources contributed (e.g. money or time) to the focus area	Community Development and Public Welfare

Climate-related disclosures

Climate-related disclosures	**Governance**	Governance	Response to Climate Change
	Strategy	Climate-related risks and opportunities	Response to Climate Change
		Business model and value chain	Response to Climate Change
		Strategy and decision-making	Response to Climate Change
		Financial position, financial performance and cash flows	Response to Climate Change
		Climate resilience	Response to Climate Change
		Financial impacts of climate-related risks and opportunities	Response to Climate Change
	Risk Management	Risk management	Response to Climate Change
	Metrics and Targets	Greenhouse gas emissions	Response to Climate Change ESG Data list
		Climate-related transition risks	Response to Climate Change
		Climate-related physical risks	Response to Climate Change
		Climate-related opportunities	Response to Climate Change
		Capital deployment	Response to Climate Change
		Internal carbon prices	Response to Climate Change
		Remuneration	Response to Climate Change
		Industry-based metrics	Response to Climate Change
		Climate-related targets	Response to Climate Change
		Cross-industry metrics and applicability of cross-industry metrics	Response to Climate Change

Shanghai Stock Exchange Index

Dimension	Number	Topic	Topics	Corresponding Chapters
Environment	1	Climate change tackling	Article 21-28	Response to Climate Change
	2	Pollutant discharge	Article 30	Management of Waste Gas, Wastewater, and Solid Waste
	3	Waste disposal	Article 31	Management of Waste Gas, Wastewater, and Solid Waste
	4	Ecosystem and biodiversity protection	Article 32	Environmental Management
	5	Environmental compliance management	Article 33	Environmental Management
	6	Energy usage	Article 35	Use of Resources
	7	Usage of water resources	Article 36	Use of Resources
	8	Circular economy	Article 37	Use of Resources
Social	9	Rural revitalization	Article 39	Community Development and Public Welfare
	10	Contributions to the society	Article 40	Community Development and Public Welfare
	11	Innovation-driven	Article 42	Product Innovation and Development
	12	Ethics of science and technology	Article 43	Clinical Trial Ethics
	13	Supply chain security	Article 45	Responsible Supply Chain
	14	Equal treatment to small and medium-sized enterprises	Article 46	Responsible Supply Chain
	15	Safety and quality of products and services	Article 47	Product Safety and Quality
	16	Data security and customer privacy protection	Article 48	Information Security
	17	Employees	Article 50	Employee Employment and Rights and Interests Employee Remuneration and Benefits Employee Training and Development
Sustainability-related governance	18	Due diligence	Article 52	Stakeholder Communication
	19	Communications with stakeholders	Article 53	Stakeholder Communication
	20	Anti-commercial bribery and anti-corruption	Article 55	Business Ethics
	21	Anti- unfair competition	Article 56	Business Ethics

GRI Content Index

Statement of use CanSinoBIO has reported in accordance with the GRI Standards for the period [January 1, 2024 to December 31, 2024].

GRI 1 used GRI 1: Foundation 2021

Disclosure issue/ disclosure item	Disclosure	Page
GRI 2: General Disclosures 2021		P01
The organization and its reporting practices		
2-1	Organizational details	P01
2-2	Entities included in the organization's sustainability reporting	P01
2-3	Reporting period, frequency and contact point	P01, P113
2-4	Restatements of information	P107-P108
Activities and workers		
2-6	Activities, value chain and other business relationships	P01-03, P93-96, P60-62
2-7	Employees	P68-80
2-8	Workers who are not employees	P93-96
Governance		
2-9	Governance structure and composition	P08-10, P86-87
2-10	Nomination and selection of the highest governance body	P86-87
2-11	Chair of the highest governance body.	P86-87
2-12	Role of the highest governance body in overseeing the management of impacts	P08-10, P86-87
2-13	Delegation of responsibility for managing impacts	P08-10, P86-87
2-14	Role of the highest governance body in sustainability reporting	P08-10, P86-87
2-15	Conflicts of interest	P89, P91-92
2-16	Communication of critical concerns	P12-13
2-17	Collective knowledge of the highest governance body	P86
2-19	Evaluation of the performance of the highest governance body	P73, P86
2-20	Remuneration policies	P73, P86
Strategy, policies and practices		
2-22	Statement on Sustainable Development Strategy	P09
2-23	Policy commitments	P09
2-25	Processes to remediate negative impacts	P09

Disclosure issue/ disclosure item	Disclosure	Page
2-26	Mechanisms for seeking advice and raising concerns	P09
2-27	Compliance with laws and regulations	P104-106
Stakeholder engagement		
2-29	Approach to stakeholder engagement	P12-13
GRI 3: Material Topics 2021		
3-1	Process to determine material topics	P12-13
3-2	List of material topics	P13
3-3	Management of material topics	P13
Economic		
GRI 201: Economic Performance		
201-2	Financial implications and other risks and opportunities due to climate change	P25-P29
201-3	Defined benefit plan obligations and other retirement plans	P73-74
GRI 205: Anti-corruption		
205-1	Operations assessed for risks related to corruption	P91-92
205-2	Communication and training about anti-corruption policies and procedures	P91-92
205-3	Confirmed incidents of corruption and actions taken	P91-92
GRI 206: Anti-competitive Behavior		
206-1	Legal actions for anticompetitive behavior, anti-trust, and monopoly practices	P92

Disclosure issue/ disclosure item	Disclosure	Page
Environmental		
GRI 302: Energy 2016		
302-1	Energy consumption within the organization	P108
302-2	Energy consumption outside of the organization	P108
302-3	Energy intensity	P108
302-4	Reduction of energy consumption	P108
302-5	Reductions in energy requirements of products and services	P35-P36
GRI 303: Water and Effluents 2018		
303-1	Interactions with water as a shared resource	P35-P36
303-2	Management of water discharge-related impacts	P35-P36
303-3	Water withdrawal	P108
303-4	Water discharge	P107
303-5	Water consumption	P108
GRI 305: Emissions 2016		
305-1	Direct (Scope 1) GHG emissions	P31
305-2	Energy indirect (Scope 2) GHG emissions	P31
305-4	GHG emissions intensity	P107
305-5	Reduction of GHG emissions	P107

Disclosure issue/ disclosure item	Disclosure	Page
305-7	Nitrogen oxides (NOx), sulfur oxides (SOx), and other significant air emissions	P107
GRI 306: Waste 2020		
306-1	Waste generation and significant waste-related impacts	P37-P38
306-2	Management of significant waste-related impacts	P37-P38
306-3	Waste generated	P107
GRI 308: Supplier Environmental Assessment 2016		
308-1	New suppliers that were screened using environmental criteria	P93-96
308-2	Negative environmental impacts in the supply chain and actions taken	P93-96
Social		
GRI 401: Employment		
401-1	New employee hires and employee turnover	P70-71
401-2	Benefits provided to full-time employees that are not provided to temporary or part-time employees	P74
401-3	Parental leave	P72
GRI 403: Occupational Health and Safety		
403-1	Occupational health and safety management system	P80
403-2	Hazard identification, risk assessment, and incident investigation	P80-81
403-3	Occupational health services	P80-81
403-5	Worker training on occupational health and safety	P82

Disclosure issue/ disclosure item	Disclosure	Page
403-6	Promotion of worker health	P80-82
403-7	Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	P80
403-9	Work-related injuries	/
GRI 404: Training and Education 2016		
404-1	Average hours of training per year per employee	P79
404-2	Programs for upgrading employee skills and transition assistance programs	P77-78
GRI 405: Diversity and Equal Opportunity		
405-1	Diversity of governance bodies and employees	P87
GRI 406: Non-discrimination		
406-1	Incidents of discrimination and corrective actions taken	P72
GRI 408: Child Labor		
408-1	Operations and suppliers at significant risk for incidents of child labor	/
GRI 409: Forced or Compulsory Labor		
409-1	Operations and suppliers at significant risk for incidents of forced or compulsory labor	/
GRI 413: Local Communities		
413-1	Operations with local community engagement, impact assessments, and development programs	P83-84
GRI 414: Supplier Social Assessment		
414-1	New suppliers that were screened using social criteria	P93-96

Disclosure issue/ disclosure item	Disclosure	Page
GRI 416: Customer Health and Safety 2016		
416-1	Assessment of the health and safety impacts of product and service categories	P49
416-2	Incidents of non-compliance concerning the health and safety impacts of products and services	/
GRI 417: Marketing and Labeling 2016		
417-1	Requirements for product and service information and labeling	P65
417-2	Incidents of non-compliance concerning product and service information and labeling	/
417-3	Incidents of non-compliance concerning marketing communications	/
GRI 418: Customer Privacy		
418-1	Substantiated complaints concerning breaches of customer privacy and losses of customer data	/

List of Internal Systems[17]

System	ESG Reporting Guide by HKEX
Environmental Management System	A1 Emissions, A2 Use of Resources, A3 the Environment and Natural Resources
Management System for Environmental Protection Equipment and Facilities	A1 Emissions, A3 the Environment and Natural Resources
EHS Targets and Responsibility Management System	A1 Emissions, A3 the Environment and Natural Resources
EHS Reward and Punishment Management System	A1 Emissions, A3 the Environment and Natural Resources
Wastewater Management Regulations	A1 Emissions
Exhaust Management Regulations	A1 Emissions
Regulations of Energy Management	A2 Use of Resources
Energy Management Guidelines	A2 Use of Resources
Regulations of Gas Fired Boiler Production and Operation	A2 Use of Resources
Emergency Response Plan for Heavy Pollution Weather	Climate-related disclosures, B2 Health and Safety
Emergency Management Procedures on Water Cut-offs, Water Leaks and Industrial Steam Shutdown	Climate-related disclosures, B2 Health and Safety
Board Member Diversity Policy	B1 Employment
Employee Handbook	B1 Employment, B4 Labor Standards
Statement of Employee Rights and Interests	B1 Employment
Attendance, Overtime, and Leave Management System	B1 Employment

[17] This table only includes internal systems and key systems relating to each ESG topic disclosed in the Report as the part of the Company's all internal system lists.

System	ESG Reporting Guide by HKEX
CanSinoBIO Occupational Health Management System	B2 Health and Safety
Worker Protection Materials Management System	B2 Health and Safety
EHS Goals and Responsibility Management System	B2 Health and Safety
EHS Rewards and Punishment System	B2 Health and Safety
Safety Management System of Special Equipment	B2 Health and Safety
Hazardous Chemical Safety Management System	B2 Health and Safety
SOP-SFY-032 Hazardous Chemicals Management System	B2 Health and Safety
Training Management System	B3 Development and Training
Contractor Safety Management System	B5 Supply Chain Management
Supplier Management Regulations	B5 Supply Chain Management
Supplier Evaluation Program	B5 Supply Chain Management
Supplier Performance Management	B5 Supply Chain Management
Supplier Blocking, Unblocking and Withdrawal Management	B5 Supply Chain Management
Supplier Development and Registration Management	B5 Supply Chain Management
Supplier Code of Conduct	B5 Supply Chain Management
Procurement Application Management	B5 Supply Chain Management
Regulations for the Administration of Affairs Concerning Laboratory Animals	B6 Product Responsibility
Feed and Padding Management Regulations	B6 Product Responsibility
Management Regulations for Employee Dress Changing in Animal Quarters	B6 Product Responsibility
Standard Operating Procedures for Environmental Management of Animal Quarters	B6 Product Responsibility

System	ESG Reporting Guide by HKEX
Standard Operating Procedures for Goods in and out of Animal Quarters	B6 Product Responsibility
Standard Operating Procedures for Quarantine of Laboratory Animals	B6 Product Responsibility
Animal Quarters Management Regulations	B6 Product Responsibility
Disinfectant Preparation and Usage Operating Procedure	B6 Product Responsibility
Deviation Management Regulations	B6 Product Responsibility
Change Management Regulations	B6 Product Responsibility
Management Procedures for OOS/OOT/AD	B6 Product Responsibility
Constitution of the Drug Safety Committee	B6 Product Responsibility
Safety Signal Management Process	B6 Product Responsibility
Pharmacovigilance Management System	B6 Product Responsibility
Regulation for Pharmacovigilance Management during Clinical Trials	B6 Product Responsibility
Major Safety Incident Handling Process	B6 Product Responsibility
Management Procedures for Non-conforming Products	B6 Product Responsibility
Procedures for the Management of the Vaccine Traceability System	B6 Product Responsibility
Recall Management Procedures for Marketed Products	B6 Product Responsibility
Management Procedures for Acquisition and Implementation of Domestic and Foreign New Regulations	B6 Product Responsibility
Quality Manual	B6 Product Responsibility
Responsibilities of Quality Management Person	B6 Product Responsibility
Responsibilities of Quality Authorized Person	B6 Product Responsibility
Regulations on the Management of Employee GMP Training	B6 Product Responsibility

System	ESG Reporting Guide by HKEX
Regulations on the Management of Sampling Personnel Training	B6 Product Responsibility
Naming System for R&D Products	B6 Product Responsibility
Intellectual Property Management System	B6 Product Responsibility
Intellectual Property Contingency Plan	B6 Product Responsibility
Copyright Management Regulations	B6 Product Responsibility
Trademark Management Regulations	B6 Product Responsibility
Patent Management Regulations	B6 Product Responsibility
Technical Secrets Management Procedure	B6 Product Responsibility
Patent and Invention Creation Reward Regulations	B6 Product Responsibility
Management Procedures for Complaints of Marketed Products	B6 Product Responsibility
Compensation Procedure for Adverse Reactions to Vaccination	B6 Product Responsibility
Responsible Commercial Statement	B6 Product Responsibility
Compliance Operation Standard Manual	B6 Product Responsibility
CanSinoBIO Compliance Manual	B7 Anti-Corruption
Compliance Obligations and Risk Assessment Procedures	B7 Anti-Corruption
Project Compliance Management System	B7 Anti-Corruption
Procurement Compliance Management System	B7 Anti-Corruption
Compliance Performance Management System	B7 Anti-Corruption
Internal Control Manual	B7 Anti-Corruption
Internal Audit Management System	B7 Anti-Corruption

System	ESG Reporting Guide by HKEX
Audit Rectification Implementation Supervision System	B7 Anti-Corruption
Anti-corruption and Anti-fraud Management System	B7 Anti-Corruption
Punishment Regulations for Dereliction of Duty in Anti-Bribery and Anti-Fraud Management	B7 Anti-Corruption
Compliance Management System for Business Partners	B7 Anti-Corruption
System of Conflicts of Interest	B7 Anti-Corruption
Employee Receiving Gift Management Process	B7 Anti-Corruption
Reward Process for Non-compliance Reporting	B7 Anti-Corruption
Procedures for Compliance Whistleblowing, Reporting and Internal Compliance Investigation	B7 Anti-Corruption
Donation Management System	B8 Community Investment
Information Security Incident Management Regulations	/
Data Security Management Regulations	/

ESG Data List

Environmental[18]

Indicator	Unit	2024	2023	2022
GHG Emission				
Total GHG emissions (Scopes 1 and 2)	tCO_2e	31,075.31	31,726.94	30,517.25
Total GHG emissions per unit floor area of production and auxiliary facilities[19]	tCO_2e per square meter	0.46	0.46	0.35
Natural gas	tCO_2e	1,176.73	3,140.18	5,779.84
Gasoline	tCO_2e	13.46	166.11	129.36
Diesel fuel	tCO_2e	5.30	3.98	7.25
Refrigerant	tCO_2e	668.61	1,035.19	123.93
Purchased power	tCO_2e	17,485.91	17,196.19	18,030.93
Purchased stream	tCO_2e	11,725.30	10,185.30	6,445.94
Discharge and Emission				
Total wastewater emissions	tons	221,776.80	293,485.00	238,153.00
Suspended solids	tons	3.60	1.43	3.57
Chemical oxygen demand	tons	10.05	15.82	8.10
Ammonia nitrogen	tons	1.09	1.76	0.56
Discharge of wastewater pollutants per unit building area at drainage sites[20]	tons per cubic meter	0.00017	0.00021	0.00014
Total waste gas emissions	cubic meter	462,312,072.00	486,347,470.00	407,700,000.00
Oxynitride	tons	1.48	1.97	1.57
Non-methane hydrocarbon	tons	2.66	2.30	0.50
PM (particulate matter)	tons	0.13	0.02	0.18
Waste gas pollutants emission during product production of a single batch	tons/batch	0.0118	0.0077	0.0029
Total non-hazardous waste	tons	84.89	180.24	158.53
Non-hazardous waste emissions per unit area of production and auxiliary facilities[21]	$tons/m^2$	0.0013	0.0026	0.0018
Total emission of hazardous waste	tons	216.42	573.43	307.15

[18] In light of the changes in the 2024 reporting criteria and to ensure data comparability and traceability, we have comprehensively updated the 2023 data. Additionally, we have adjusted certain indicators in accordance with the updated environmental targets for 2024.

[19] Floor areas of the Company's projects under construction and R&D projects not included.

[20] All wastewater from the company's various plant sites is centrally collected and treated at a single sewage treatment station, with discharge density calculated based on the drainage plant area.

[21] 2021 data includes the area of construction and R&D projects.

Indicator	Unit	2024	2023	2022
Hazardous waste generation during product production of a single batch	tons/batch	0.60	1.03	0.40
Resource and Energy Use				
Natural gas	cubic meter	537,603.00	1,434,630.00	2,640,585.26
Gasline	liter	6,191.61	76,397.60	59,495.58
Diesel fuel	liter	2,000.00	1,500.00	2,736.00
Refrigerant	kg	437.00	464.50	81.00
Purchased power	kWh	28,180,350.00	30,152,880.00	31,616,569.00
Purchased stream	tons	40,224.00	34,941.00	22,113.00
Comprehensive	MWh	76,161.28	82,917.68	83,874.56
Energy consumption per floor area of production and auxiliary facilities	MWh per square meter	1.13	1.20	0.95
Municipal water supply	tons	210,136.00	341,713.00	391,308.00
Water consumption per floor area of production and auxiliary facilities	tons per square meter	3.12	4.93	4.42
Package	tons	296.77	220.86	391.00

Social

Indicator	Unit	2024	2023	2022
Employment				
Number of employees	employee	1,105	1,494	2,291
Number of new salaried employees this year (including those who have left)	employee	91	214	948
Number of employees by gender				
Male	employee	537	735	1,232
Female	employee	568	759	1,059
Proportion of employees by gender				
Male	%	48.60	49.20	53.78
Female	%	51.40	50.80	46.22
Number of employees by employment type				
Senior managers	employee	17	30	30
Middle managers	employee	182	248	264
Junior employees	employee	906	1,216	1,997
Proportion of employees by employment type				
Senior managers	%	1.54	2.01	1.31
Middle managers	%	16.47	16.60	11.52
Junior employees	%	81.99	81.39	87.17

Indicator	Unit	2024	2023	2022
Number of employees by age				
30 below	employee	216	380	803
30 to 49	employee	871	1,084	1,458
50 and above	employee	18	30	30
Proportion of employees by age				
30 below	%	19.55	25.44	35.05
30 to 49	%	78.82	72.55	63.64
50 and above	%	1.63	2.01	1.31
Number of employees by nationality				
Chinese	employee	1,095	1,476	2,279
Overseas	employee	10	18	12
Proportion of employees by nationality				
Chinese	%	99.10	98.80	99.48
Overseas	%	0.90	1.20	0.52
Employee Turnover [22]				
Overall employee turnover rate	%	7.53	13.14	17.32
Turnover rate by gender				
Male	%	8.36	14.83	20.52
Female	%	6.73	11.44	13.27
Turnover rate by age				
30 below	%	11.84	18.80	20.34
30 to 49	%	6.44	11.22	15.82
50 and above	%	5.26	3.23	3.23
Turnover rate by region				
Chinese	%	7.53	13.28	17.32
Overseas	%	0	0	0
Turnover rate by job type				
Commercial plate	%	12.68	15.42	32.41
R&D plate	%	3.93	7.74	7.59
Functional plate	%	15.07	11.11	11.31
Technology operations and products supply plate	%	1.95	16.97	16.01
Employee Health and Safety				
Number of work-related injuries	employee	0	0	0
Proportion of work-related injuries	%	0	0	0
Lost work hours	hour	0	1,120	24
Employee Development and Training				
Average training hours for all employees	hour	37.8	72.70	149.2

[22] Data includes only employees who left voluntarily.

Indicator	Unit	2024	2023	2022
Percentage of employees trained by gender				
Male	%	48.60	49.20	48.4
Female	%	51.40	50.80	51.6
Average training hours per employee by gender				
Male	hour	39.19	76.33	65.1
Female	hour	36.48	69.18	68.0
Percentage of employees trained by employment type				
Senior managers	%	1.54	2.01	1.28
Middle managers	%	16.47	16.60	12.31
Junior employees	%	81.99	81.39	86.41
Average training hours per employee by employment type				
Senior and middle managers	hour	33.92	79.20	51.5
Junior employees	hour	38.65	71.21	69.0
Supplier Management				
Number of suppliers by region				
Chinese Mainland	supplier	1,089	1,148	1,191
Hong Kong, Macao, Taiwan	supplier	8	10	10
Overseas	supplier	89	71	62
Supplier's certification				
Supplier with quality management system certification (ISO 9001, etc.)	supplier	135	150	150
Supplier with environmental management system certification (ISO 14001, ISO 14064, etc.)	supplier	46	55	55
Supplier with health and safety management system certification (ISO 45001, etc.)	supplier	33	55	54
R&D and Innovation				
Investment in R&D	RMB '00 million	5.11	6.62	7.90
Patents granted	item	70	61	37
Anti-Corruption				
Anti-corruption training hours for all employees	hour per person	4.5	4.69	3.5
Anti-corruption training hour for board members and senior management	hour per person	1	1	1
Participation rate of anti-corruption training for board members	%	100	100	100
Cases of corruption-related litigation	case	0	0	0
Community Welfare				
Total amount of charitable donations	RMB 10,000	44.77	41.30	131
Participating hours in public welfare and charity	hour	311	/	/

Definition

Term	Definition
HKEX	The Stock Exchange of Hong Kong Limited
NMPA	The National Medical Products Administration of China or, where the context so requires, its predecessor, the China Food and Drug Administration or CFDA
Vaccine	An active immunity preparation for the prevention of infectious diseases, which is made of pathogenic microbes (such as bacteria, rickettsia, viruses, etc.) and their metabolites through detoxification, inactivation, or genetic engineering
Antigen	Substances that can cause immune responses in humans and animals, can not only produce antibodies and primed lymphocytes by stimulating the immune system to have specific immune responses but also combine and react with antibodies and primed lymphocytes. It is usually a protein, but polysaccharides and nucleic acids can also be used as antigens
Conjugate vaccines	The polysaccharide-protein conjugate vaccine was prepared by containing polysaccharides conjugated to the carrier protein by chemicals
mRNA	Messenger RNA
mRNA vaccine	A vaccine which is based on the mRNA structure corresponding to antigen protein in the pathogen, transmitted to human cells through different transmission approaches and after translation, which can stimulate cells to produce antigen protein and produce specific immune responses
Ad5-nCoV	Ad5-nCoV Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), including two types of products, Convidecia® and Ad5-nCoV for inhalation

Term	Definition
Convidecia®	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for intramuscular injection, whose trade name is Convidecia®
Convidecia® Air® or "Ad5-nCoV for Inhalation"	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for inhalation
COVID-19	The disease caused by a new coronavirus called SARS-CoV-2
PCV13	13-Valent pneumococcal conjugate vaccine, 13-valent vaccine primarily used for the prevention of invasive pneumococcal diseases
PCV13*i*	An improved pneumococcal polysaccharide conjugate vaccine being developed by us
PBPV	A globally innovative, serotype-independent protein-based pneumococcal vaccine being developed by us
PPV23	23-valent pneumococcal polysaccharide vaccine, used for the prevention of invasive pneumococcal disease in children aged above two years of old and adults
Recombinant Poliomyelitis Vaccine	A VLP-based poliomyelitis vaccine developed by the Company
Recombinant Zoster Vaccine	The Recombinant Zoster Vaccine (Adenovirus Vector) developed by the Group in cooperation with Barinthus Biotherapeutics (UK) Limited (formerly known as Vaccitech (UK) Limited)
MCV	Meningococcal conjugate vaccine, used to prevent infection caused by meningococcal bacteria

Term	Definition
MCV2	Groups A and C MCV, a vaccine used for the prevention of N. meningitides (Lta)
MCV4	Groups A, C, Y and W135 MCV, a vaccine used for the prevention of N. meningitides (Lta)
Menhycia®	Trade name of Groups A, C, Y and W135 MCV, a vaccine used for the prevention of N. meningitides (Lta)
Menphecia®	Trade name of Groups A and C MCV, a vaccine used for the prevention of N. meningitides (Lta)
DPT	Diphtheria, Pertussis, Tetanus
Pertussis	Commonly known as whooping cough, a respiratory tract infection characterized by a paroxysmal cough
DTcP	Diphtheria, tetanus and acellular pertussis (components) combined vaccine, each pertussis antigen of DTcP vaccines is purified individually and are subsequently combined in a defined ratio, hence ensuring a fixed and consistent composition
DTcP Infant	DTcP vaccine for infants and toddlers (under 2 years old)
DTcP-Hib-MCV4 Combined Vaccine	Absorbed diphtheria, tetanus and acellular pertussis (components) Haemophilus Influenzae Type b (Conjugate) – Group ACYW135 Meningococcal (Conjugate) combined vaccine
Tdcp Adolescent and Adult	A vaccine being developed by us for adolescents and adults (above 6 years old) that protects against pertussis, containing slightly increased amount of TT antigen to DTcP vaccine candidate for infants, but reduced amounts of pertussis and DT antigens

Term	Definition
Hib	Haemophilus Influenzae Type b Conjugate Vaccine, Freeze-dried
Tetanus Vaccine	Adsorbed Tetanus Vaccine
GMP	Good Manufacturing Practice, guidelines and regulations from time to time issued pursuant to the *People's Republic of China Drug Administration Law* as part of quality assurance which aims to minimize the risks of contamination, cross contamination, confusion and errors during the manufacture process of pharmaceutical products and to ensure that pharmaceutical products subject to these guidelines and regulations are consistently produced and controlled in conformity to quality and standards appropriate for their intended use
EHS	Environment, Health, and Safety for short
CRM197	A well-defined diphtheria toxin mutant protein, in which one of its amino acids is mutated from glutamic acid to glycine
Clinical trial	Systematic research on drugs in the human body, for example, patients or healthy volunteers, to confirm or reveal the effects, adverse reactions and/or absorption, distribution, metabolism, and excretion of experimental drugs, aiming to determine the effectiveness and safety of experimental drugs
ICH	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
Adjuvant	Substances that can assist antigen response and modulate immune reactions
Immunogenicity	The ability of a particular substance, such as an antigen, to provoke an immune response in the body of a human and other animal

Reader's Feedback

Thank you for reading the *2024 Environmental, Social and Governance (ESG) & Sustainability Report of CanSino Biologics Inc.*. We highly value your opinion of the Report. To improve the Company's performance in the environment, society, and governance, we welcome your opinions and suggestions on the Report, so that we can further improve the Report.

Feedback Table of the *2024 Environmental, Social and Governance (ESG) & Sustainability Report of CanSino Biologics Inc.*

Your Name: Your Tel.:

Your Company: Your Email:

Your Address:

Address: 401-420, 4th floor, West District Biomedical Park, 185 South Street, West District, Economic and Technological Development Zone, Tianjin, China

Fax:022-58213677

Website: https://www.cansinotech.com.cn/

Tel: 022-58213766

1. Your overall comment on the Report

☐ Excellent ☐ Good ☐ Ordinary ☐ Not Good ☐ Bad

2. Your comment on the readability of the Report

☐ Excellent ☐ Good ☐ Ordinary ☐ Not Good ☐ Bad

3. Your comment on the structural arrangement of the Report

☐ Excellent ☐ Good ☐ Ordinary ☐ Not Good ☐ Bad

4. Does the content disclosed in the Report fulfill your expectations?

☐ Yes ☐ No ☐ Not clear

5. Are CanSinoBIO's ESG performances fully reflected in the Report?

☐ Fully reflected ☐ Partially reflected ☐ Not reflected

6. If you have other opinions and suggestions on the *2024 Environmental, Social and Governance (ESG) & Sustainability Report of CanSino Biologics Inc.*, please kindly write them down below.

Address: 401-420, 4th floor, West District Biomedical Park, 185 South Street, West District, Economic and Technological Development Zone, Tianjin, China

Tel: 022-58213766

Fax:022-58213677

Email: ir@cansinotech.com